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ABSTRACT

THE PRODUCTION AND CHARACTERIZATION OF A MONOCLONAL ANTIBODY TO
A NATURALLY OCCURRING AMINOMALONIC ACID EPITOPE AND A
COMPARISON WITH AN ANTIBODY TO A SYNTHETICALLY DERIVED
AMINOMALONIC ACID EPITOPE

by
James Gulley

The goal for this project is to undertake the first step in the study of blocking
metastasis by a monoclonal antibody. The long range goal of this line of research is
to study a novel mechanism for the blocking of tumor metastasis in general and
prostatic cancer metastasis in particular. The problem that this addresses is the
growing number of cases of prostatic cancer in the increasingly aging male
population. This cancer is not lethal unless it metastasizes, yet there is no cure for
the metastatic disease. The inherent specificity of a monoclonal antibody combined
with the uniqueness of the epitope and its presumed importance as an adhesion
molecule vital for metastasis make this an interesting approach to cancer treatment.
The mAb-Amasyn antibody (Ortho Diagnostic Systems Clone
#57D4B6G2B11), developed by immunizing mice with a synthetic aminomalonic acid
(Ama) epitope made by the conjugation of N-acetyl Ama ethyl amide to BSA (Koch et
al.), was used to identify a source (human prostate cancer cell line, DU-145) of
naturally occurring anti-AmaSyn antibody-reactive protein (DU-145 Ag). A
monoclonal antibody, anti-Amanat (IgGi kappa), to this antigen was produced which
binds specifically to synthetic Ama epitopes and when tested with the anti-AmaSyn

antibody, binds with partial additivity to synthetic and naturally occurring Ama
epitopes. This antibody does not cross-react with fresh frozen normal human
prostate or any other normal tissues tested. This antibody may be more specific for
the DU-145 antigen than the anti-AmaSyn antibody.
The DU-145 Ag contains an acid-labile antibody binding site, possibly
indicating the presence of Ama, and is upregulated on cells associated with a more
metastatic phenotype. This antigen is a 200 kD glycoprotein containing GlcNAc with
a pi of 4.7. This antigen may be part of a metastasis-associated adhesion molecule.
The results indicate that the anti-Amanat antibody may be able to play a role
in histological diagnosis, in vivo detection, and eventual therapy of prostatic cancer.
They also affirm the importance of deriving an antibody from a naturally occurring
protein.
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I. LITERATURE REVIEW

A. Aminomalonic Acid

The history of the discovery of aminomalonic acid (Ama) in naturally
occurring proteins starts with an unusual case of cancer (Kirsch personal
communication 1990). A patient, who was undergoing therapy with warfarin for
treatment of myrantic thrombophlebitis, was diagnosed with pancreatic cancer. The
patient, under the care of William Waddell, was started on fluorouracil (5-FU)
chemotherapy and survived for two years. This survival time was of great interest
to the examining physicians since half of the people inflicted with pancreatic cancer
die within a few months of the onset of symptoms (Scarpelli 1988). The physicians
postulated that the longer survival time might be due to the combination of 5-FU
and warfarin (Kirsch et al. 1974). It was brought to the attention of the attending
doctors that warfarin, used as a rat poison, produced a negative nitrogen balance in
rats, causing the rats to undergo wasting and die as if starved. Armed with these
facts, Wolff Kirsch, a colleague of Waddell and a neurosurgeon with a background in
biochemistry research, investigated whether the decrease in protein synthesis with
therapeutic levels of warfarin might be tumor specific (Van Buskirk and Kirsch
1973).
BW7756 hepatomas and sodium warfarin were given to C57L/J mice. In the
control group (given no warfarin) the ratio of RNA to protein in the hepatoma was
about twice that found in the normal liver, whereas in the experimental group
(warfarin treated) the ratio was about the same for both tumor and normal liver.
The absolute value of RNA/protein in the normal liver was unaffected by warfarin.
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These results indicated that warfarin, in the therapeutic range, seemed to cause a
decrease in ribosomal RNA (with an overall concomitant drop in protein synthesis)
specifically in tumor cells. Indeed, other experiments confirmed that warfarin did
interact with the ribosomes by actually binding to them (Thierry et al. 1970).
While Kirsch was studying ribosomes, another finding came to light that
would alter the direction of his research. Scientists had determined that vitamin K
was necessary for the biosynthesis of active prothrombin. It was also known that
warfarin, a vitamin K antagonist, blocked the modification of prothrombin, making
it unable to bind Ca++ and thus unable to become activated in the final common
pathway of blood clot formation. The finding of significance was that vitamin K
catalyzed a carboxylation of the first ten glutamic acid residues of prothrombin to
form y-carboxyglutamic acid (Gla) (Figure 1.1) (Fernlund et al. 1975).
This finding spurred Kirsch to see if Gla could be detected in ribosomes. He
reasoned that if the production of Gla is warfarin sensitive and ribosomal RNA
synthesis is also warfarin sensitive, then there was reason to suspect the
participation of a Gla-containing protein in ribosomal RNA metabolism. Mammalian
ribosomal proteins were isolated, assayed and found to contain Gla (Van Buskirk and
Kirsch 1978). Further work identified Gla in prokaryotic ribosomes (Christy et al.
1981). This latter work also identified p-carboxy aspartic acid (Asa), a congener of
Gla (Figure 1.2) in prokaryotic ribosomes. This finding encouraged Kirsch to look
for other minor percarboxylated amino acids in ribosomes. In 1983 he and his
colleagues found alpha-carboxy glycine or aminomalonic acid (Ama, Figure 1.3) in
Escherichia coli ribosomes and human atherosclerotic plaque (Van Buskirk et al.
1984). The exciting aspect of this discovery was the relatively large quantities of
Ama found in atherosclerotic plaque and the implications for not only understanding

3

Figure 1.1. Vitamin K dependent carboxylation of Glu in prothrombin to form Gla.

Figure 1.2. Beta-car boxy aspartic acid (Asa).

Figure 1.3. Aminomalonic acid (Ama).
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plaque formation but developing new methods of diagnosis and treatment.
Furthermore, this was the first time that Ama was proven to be a naturally
occurring constituent of proteins. (That this minor amino acid had not been
identified in nature until 1983 may precipitate a re-evaluation of the amino acid
sequences of many proteins which may not have been fully and accurately
characterized. Because the percarboxyl group of Ama is acid labile, traditional acid
degradation of proteins decarboxylate this molecule and may yield erroneous
sequences for proteins containing Ama.) Mass spectometry coupled with gas
chromatography provided amino acid analysis oi Escherichia coli alkaline
hydrolysates. This method was employed to preserve any acid labile
percarboxylations which might exist. The analysis revealed high levels of Ama and
Asa. As an indication of the acid lability of Ama, the Ama-containing acid-treated
fractions revealed Gly and no Ama, whereas the untreated portions of the same
fraction contained only Ama (Van Buskirk et al. 1984).
The association of Ama with dystrophically-calcified tissues (e.g.,
atherosclerotic plaque) led L. Sillerud, a colleague of Kirsch, to study the calcium
binding properties of this novel amino acid (Sillerud et al. unpublished data). He
found that the calcium binding constant for Ama was comparable with that found for
Gla. The stoichiometry of this binding was determined to be CaAma2. This can be
understood in terms of charge neutralization. At neutral pH, Ama has a single
negative charge while calcium is a divalent cation; therefore two Ama molecules are
needed to neutralize one calcium. In Gla-containing calcium binding proteins,
several closely spaced Gla residues cooperate to increase the affinity of these
proteins for calcium. Sillerud proposed that in proteins, Ama may act in a similar
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manner, associating with a spatially near residue of Ama, Asp or Glu to create a
calcium binding site.
The question of how the cell makes Ama-containing proteins has not been
fully answered. To rule out the possibility that Ama is an artifact of protein
hydrolysis, gas chromatography combined with mass spectometry was used to
unambiguously confirm the presence of Ama in E. coli cytosol hydrolysate and
atherosclerotic plaque hydrolysates (Van Buskirk et al. 1984).
One possible mechanism of Ama production is that this minor amino acid
could be synthesized in the cell by one of a number of pathways (Figure 1.4) and
then incorporated (during translation) into proteins. However, this is not likely as it
would require not only tRNA recognition of Ama and an altered proofreading
mechanism, but also a sufficient concentration of free Ama in the cell.
The most plausible method of Ama incorporation into proteins is posttranslational modification of the protein. As shown in Figure 1.4, this could
theoretically be the result of an amino acid modification. For instance, glycine could
be carboxylated, serine oxidized, or cysteine oxidized to form Ama. In fact, Koch
and colleagues at the University of Colorado originally concluded that Ama synthesis
was a non-enzymatic, free radical-mediated, post-translational modification of
peptide linked glycine (Kleyer et al. 1983). However, recent observations have called
into question the glycine carboxylation scenario. Since Ama has been found in
relatively large amounts in atherosclerotic plaque, and oxidative modification of low
density lipoprotein has been proposed as an important causative event in
atherosclerosis (Retsky et al. 1993), it is felt that oxidation might play a role in the
production of Ama. One piece of evidence pointing to serine as the most likely
precursor is that wild type Escherichia coli contains about 0.38 Ama molecules per
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Figure 1.4. Possible pathways of Ama production.
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1000 amino acids while another strain with a deficiency in the serine synthetic
pathway (JC-158) contains 0.04 Ama molecules per 1000 amino acids (Kirsch
personal communication 1990).
This post-translational modification yielding Ama may be physiological or
accidental. If it were an intentional, physiological effect in the cell, one would
expectAma containing proteins to be localized to an area where they could carry out
their function. If it were accidental, one would expect these proteins to be found
randomly in cells and associated with a triggering event. Preliminary electron
microscopy studies, as well as immunohistochemistry studies (described in Chapter
III) have found that an anti-Ama antibody-reactive epitope is found on cell and
microsomal membranes of DU-145 (human prostate carcinoma cell line) cells, but
not free in cytoplasm (unpublished). This lends credence to a physiological role for
Ama, such as being part of a binding protein.
To assess the possible physiological role of Ama, a look at the well-studied
congener of Ama, Gla, may be profitable. As was mentioned earlier, Gla found on
prothrombin is the result of an enzymatic post-translational carboxylation of
glutamate. Additionally, Gla is found on blood factors VII, IX and X which also play a
role in blood coagulation. Together these factors are called the vitamin K-dependent
serine protease factors. These serine proteases are activated by vitamin K in a
reaction that carboxylates certain of their glutamic acid residues to form Gla
(Figure 1.1). This carboxylation enables the factors to bind Ca++, which in turn
allows for binding to phospholipids found on platelets in the beginning of the
formation of a blood clot.
Blood clotting can be disrupted by warfarin, a vitamin K antagonist. The
coumarin anticoagulants, of which warfarin is a member, have long been shown to
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be the cause of hemorrhagic disease in cattle. Found in sweet clover, this
anticoagulant has been used as a rodentocide and also, clinically, to treat
hypercoagulable states. Its efficacy for tumor therapy has also been studied. High
concentrations of warfarin (1 mM) decrease tumor growth in vitro, but cause
exsanguination in vivo in rats (McCulloch and George 1988). These undesirable
anticoagulant effects of coumarins (particularly warfarin) limit their potential as
direct anti-tumor therapeutic agents. Coumarins have also been shown to inhibit
metastasis in several animal models (Brown 1973; Hilgard et al. 1977; Ryan et al.
1969; and Williamson et al. 1980). Indeed, the coagulation system seems to play an
important role in the pathogenesis of blood borne metastasis (Agostino et al. 1966;
Brown 1973; Dvorak et al. 1981; Hilgard et al. 1977; Koike 1964; O'Meara 1968; Poggi
et al. 1978; Wood 1958; Wood 1974; and Zacharski et al. 1979). Research has shown
that metastasis of a mammary carcinoma in rats can be promoted by the addition of
a specific complex of coagulation factors, namely the vitamin K-dependent serine
protease factors II, IX and X (McColloch and George 1988). Factor VII did not have an
effect on metastasis. Further research has shown that warfarin (a vitamin K
antagonist anticoagulant) significantly decreases metastasis in rats, yet Arvin (an
anticoagulant that cleaves fibrinogen) has no effect on metastasis (McColloch and
George 1988; and McColloch and George 1989). In fact, the inhibition of metastasis
was reversed by replenishment of the coagulation factors (II, VII, IX, and X) whose
actions warfarin suppresses (McColloch and George 1988). Another study showed
that warfarin (but not snake venom or heparin whose mechanisms of
anti coagulation do not include the blocking of carboxylation) had significant
antimetastatic activity (Hilgard 1981).
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Hauschka et al. (1986) provided evidence that vitamin K-dependent protein
carboxylation is a general property of tumor cells. Amino acid analysis of a variety of
tumor cell lines showed that they contained from 5 to 41 Gla residues per 106 amino
acids.
In related research, Berg (1991) inserted a vector for the Gla-containing
protein C into adenovirus-transformed and nontransformed cell lines. The secreted
protein C from the transformed and nontransformed cells displayed identical serine
protease function. However, the transformed cell lines secreted a protein C with a
70% increase in Gla-dependent coagulation and an approximately four-fold increase
in calcium dependent (high Gla) elution from anion exchange when compared with
the protein C secreted from the nontransformed cell lines. Thus, the oncogenic
viral transformation of these cells was associated with an increase in carboxylation.
These studies point toward the involvement of a carboxylation reaction of some
kind in the metastatic process.
Thus one possible physiological role for Ama may be its incorporation into an
adhesion molecule facilitating the binding of calcium in a manner similar to the
binding of calcium to Gla in prothrombin. A tumor cell containing this molecule
might use it to bind to the endothelium during metastasis. Perhaps warfarin is not
only inhibiting the y-carboxylation of Glu, but is also blocking a similar reaction
converting glycine to Ama, possibly in the RGD (Arg-Gly-Asp peptide thought to be
the binding site associated with some integrins) segment of the integrin binding
loop. Therefore, if Ama is needed for adhesion, then blocking this Ama epitope
(with a monoclonal antibody, for example) could have very similar actions to
warfarin in decreasing tumor metastasis without the traditional anticoagulant side
effects.

12
B. Adhesion Molecules

In tumor metastasis, adhesion molecules are necessary for tumor cell
binding to, and migration through, the endothelium as well as for binding together
(Vancy et al. 1990). Indeed, research has shown that some tumor cells have
increased amounts of integrins on their cell surface (Deodhar and Saulneir 1990;
Horst et al. 1990; Kuppner, Hamou and deTribolet 1990; and Lehmann et al. 1989).
In hairy cell leukemia, transformed lymphoid cells express a large amount of
pl50,95, an activation-associated adhesion molecule (Corbi et al. 1987). (For a recent
review on the role of cell adhesion molecules in cancer, see Fawcett and Harris
1992.)
The phenomenon of adhesion molecule-dependent metastasis can be shown
in the laboratory. In one study (Roosien et al. 1990), a highly metastatic T-cell line
(TAM2D2) was mutated; the three adhesion molecule deficient clones that were
obtained invaded very poorly compared to the original nondeficient strain. Another
research group (Kojima et al. 1992) showed that highly metastatic murine
melanoma cells, which carry a lactose binding lectin, will lose up to 50% of their
metastatic spread by the addition of lactose to the cells prior to injection into mice.
This group theorized that lactose would bind to lectins found on the tumor cell
surface, making those adhesion molecules unable to attach to lactose moieties found
on tissues to which the tumor might spread.
Cell adhesion proteins are also important in melanoma (Menrad and Herlyn
1992). One laboratory reported that the pa integrin subunit was expressed in
vertical-growth-phase and metastatic melanoma associated with a poor prognosis,
while benign melanocytes and radial-growth-phase melanomas associated with a
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good prognosis showed no such expression (Albelda et al. 1990). Another research
group demonstrated that by blocking a lung endothelial cell adhesion molecule (LuECAM-1) with monoclonal antibodies, a decrease in lung metastasis of melanoma in
mice was observed (Zhu et al. 1992). A human lung tumor-associated antigen,
recently identified as an adhesion molecule, has aroused suspicion that this molecule
might be involved in the metastatic potential of lung cancer (Chen et al. 1991).
Another example of an adhesion molecule used by tumor cells during
metastasis is CD44. This molecule is found on normal lymphocytes where it plays a
role in their extravasation to areas of inflammation (Bazil and Horejsi 1992). The
CD44 molecule is expressed in at least nine different variants of the so-called
standard form (Kahn 1992). The variant forms are transiently expressed and may
play a role in the activation and differentiation of immature lymphocytes into
mature immune cells in the lymph nodes (Arch et al. 1992). Variant forms have also
been linked to tumor metastasis. One study showed that not only was a variant of
CD44 found in metastasizing clones of a pancreatic cell line, but that overexpression
of the gene coding for this CD44 induced metastasis in a nonmetastasizing clone
(Gunthert et al. 1991). Later these same researchers showed that antibodies
directed to the conserved portions of the variant CD44 molecules blocked the spread
of the metastasizing pancreatic carcinoma (Arch et al. 1992). Not only does this
research suggest an alternative form of therapy for cancers dependent on CD44 for
metastasis, but it also suggests that these cells may elude the immune system by
using the CD44 as a molecular disguise (Kahn 1992). This may enable the tumor to
“hide” in the CD44 variant rich population found in the lymph nodes from whence it
can differentiate and spread. In fact, a recent review (Sharon and Lis 1993)
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concurred that some tumors might recruit adhesion molecules from the normal
immune system, possibly to promote their own metastasis.
Tumor-associated cytokines secreted by the immune system may also
increase metastasis. Taichman et al. (1991) recently showed that tumor necrosis
factor activated endothelial cells and increased the adhesion of tumor to them by as
much as 800%. It was further shown that this adhesion was mediated by the
binding of a tumor containing integrin (alpha-4 beta-1) to an endothelial cell protein
(inducible cell adhesion molecule 110 or INCAM-110). Another research group
demonstrated that pretreatment of murine endothelial cells with TNF, IL-1 or LPS
augmented the binding of tumor cells in vitro (Bereta et al. 1991).
Some adhesion molecules may indirectly play a part in the protection of the
tumor from the immune system. Tenascin is a matrix adhesion molecule that is
expressed during inflammation and tissue repair as well as with certain malignant
tumors. Tenascin apparently acts by inhibiting T-cell activation, and thus isolates
the tumor from the immune system (Pardi et al. 1992).
Integrin receptors have also been implicated with the development of tumor
associated angiogenesis (Ingber 1992). In vivo administration of RGD, a peptide
found in the binding site of many integrin molecules, has been shown to inhibit
experimental seeding of human ovarian cancer cells (Yamamoto et al. 1991).
Since tumors must promote capillary ingrowth if they are to form a solid
mass larger than one cubic millimeter (Ingber 1992), blocking angiogenesis by
targeting specific endothelial cell adhesion molecules may provide an important
therapeutic venue. And since normal endothelium grows quite slowly, this strategy
could be quite specific for the rapidly growing tumor vessels.
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As has been discussed, the evidence supporting the direct association of
adhesion molecules and cancer includes the finding of greater quantities of adhesion
molecules on many tumor cells and the apparent causative association of these
molecules with metastasis. In addition, the adhesion molecules may shelter the
tumor from immune system detection and cause neovascularization necessary for
tumor growth. These data indicate the elaborate role of adhesion molecules in
growth and metastasis of malignant tissue.
The investigation of these adhesion molecules may play a significant role in
our understanding of the metastasis in cancer. In the well-studied lymphocyte
system, it has been shown that adhesion molecules are not expressed in resting
cells (Pardi et al. 1992); however, in activated cells, which require an external
triggering stimulus, adhesion molecules are expressed (Hershkovitz et al. 1992,
Pardi et al. 1992). Thus cancers may display adhesion molecules due to activation--in
effect, metastasis may be a result of an outside stimulation. This stimulation could
come from a variety of sources including the immune system itself, which would be
in agreement with the recently proposed immunofacilitation theory of cancer
submitted by Prehn and Prehn (1989).
Adhesion molecules require Ca++ or Mg++ for ligand binding. Other Ca ++
binding proteins-calmodulin, troponin C and parvalbumin-contain putative
divalent cation binding sites in a structure called the "EF-hand loop." This loop is
thought to bind ions by a glutamic acid residue. Integrins possess a similar loop, but
the lack of any associated Glu has thwarted attempts at localizing the exact binding
site. However, in the integrin ligands, it has been proposed that the aspartic acid
residue of the Arg-Gly-Asp (RGD) sequence may coordinate with calcium to bind the
integrin (Larson and Springer 1990). This explanation is not entirely satisfactory,
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however, because Asp contains only one free carboxyl group, and two or more are
necessary for optimal calcium binding.
Perhaps the difficulty in localizing the divalent cation binding sites on the
integrins and their ligands lies in the misidentification of Ama (percarboxylated
glycine) as Gly. This may be due to Ama's lability resulting in its decarboxylation to
Gly under the conditions of 1) alkaline protein hydrolysis used in the analysis of
malonic acid bearing amino acids, as well as 2) acid hydrolysis (Van Buskirk et al.
1984). Reinforcing this postulate is the fact that free Ama (unlike Arg or Gly) can
and does bind Ca++ strongly (Sillerud et al. unpublished data) (Figure 1.5). The
binding of calcium in adhesion molecules could conceivably require two spatially
near negative charges. In the RGD sequence, if Gly is actually Ama, the free
carboxyl groups of the Ama and Asp could be utilized to bind the divalent cation.
(Figure 1.6). A similar divalent cation binding site could be could be created by the
positioning of Ama spatially near another amino acid with a free carboxyl group (i.e.,
Gla, Glu, Asp, Asa or Ama).

C. Tumor Metastasis

The degree of invasion and metastasis largely determines the clinical
outcome of a patient with cancer. Tumors can be categorized as benign or
malignant. Most normal cells respect discrete boundaries and do not travel to distant
sites. Likewise, benign tumors generally grow in a confined area and thus have
excellent cure rates with surgical resection (Mareel et al. 1991c). Malignant cells,
however, not only grow locally but spread to surrounding normal tissue and to
distant sites, a phenomenon called metastasis. If the tumor is not detected prior to
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Figure 1.5. Calcium binding of Ama. The two free carboxyl groups allow free Ama
to bind divalent cations, such as calcium, which in turn allows for binding to
negatively charged cell surfaces.

Figure 1.6. Possible adhesion role of Ama. In protein, Ama contains only one free
carboxyl group. In order for it to retain optimal calcium binding properties, it must
be spatially near another similarly charged amino acid to share in the binding of
calcium. This is depicted in this figure of a fictitious adhesion molecule divalent
cation binding site where Ama, in conjunction with aspartate, can bind calcium.
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metastasis, the cure rate of the disease decreases substantially. In general, the cure
rates of metastatic tumors have not significantly improved in decades (Liotta 1992;
Steeg 1992). Still, basic and clinical research is slowly improving the prognoses of
the thousands of cancer patients diagnosed each year.
To facilitate the development of therapeutic strategies to combat malignant
tumors, it is necessary to understand the process of metastasis. The most studied
type of cancers are the carcinomas (of epithelial origin) which make up about 90%
of all tumors. Metastasis can be divided into invasion of basement membrane,
transport through vessels, extravasation, and growth of the tumor. In carcinomas,
invasion involves three distinct steps (Kleinman and Kibbey 1991; Liotta 1992). The
first is binding of the tumor cell to basement membrane by adhesion molecules.
This binding, which may involve many of the different adhesion molecules
associated with cancer, is vital for the second step.
The second step involves an enzymatic breakdown of the extracellular
basement membrane to which the tumor cell is bound. This is accomplished with
the aid of any of several classes of proteases. Two of the more important, and better
studied, destruction-causing enzymes are type IV collagenase, a metalloproteinase
that degrades type IV collagen, and urokinase, a plasminogen activator which
converts plasminogen to plasmin (Steeg 1992). Plasmin degrades fibrin, type IV
collagen, fibronectin and laminin, and activates latent collagenase. Inhibitors of
metalloproteinases have been identified and found to decrease metastasis. (Alvarez
et al. 1990; Shultz et al. 1988).
The final step of invasion of the basement membrane is intravasation or
movement of the tumor cell into a capillary or lymphatic vessel. Capillaries contain
endothelium surrounded by a continuous basement membrane and pericytes,
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whereas the lymphatic vessels have no basement membrane, making them a
somewhat easier target for tumor spread.
Transport through the vessels from one part of the body to another, the
second major event in metastasis, is generally considered to be passive. There may
be, however, adhesion molecule or growth-factor-related targeting of specific organs
by tumor cells.
A tumor cell having progressed this far has escaped the primary immune
surveillance mechanism. But now it is in a body compartment inundated with
immune cells. It is within these immune cell-rich blood and lymph vessels that the
body has one of its best chances to defeat the tumor, in part due to the finding that
it requires 10-20 immune cells to kill a single tumor cell (Kleinerman 1991). After
the cell takes up residence in a host organ, it can again be the master of
manipulation and evade the immune system. But in the vessels, tumor cells come
in contact with various potentially tumoricidal serum factors and cellular
components. Another tumoricidal effect is the mechanical deformation of the
cancer cell in the microvasculature which results in surface membrane rupture
(Weiss et al. 1992). In fact it is estimated that fewer than one in 10,000 of the tumor
cells that leave the primary tumor survive to establish new tumor colonies (Liotta
1992). Thus, for the tumor cell, it is imperative to leave this environment as quickly
as possible.
Those cells making it through the vascular gauntlet generally extravasate
during their passage through the capillary beds of major organs. This third phase of
cancer metastasis takes place in the capillary beds because the rate of blood flow is
significantly decreased, providing a slower-moving tumor cell with more time to
adhere and, once bound, less of a shear force to dislodge the cell. The cell must then
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bind to and move through the vessel wall, in the reverse order of intravasation, to
take up residence in the tissue.
This is followed by the final phase of the successful metastasis-growth of the
tumor-which is dependent on angiogenesis (Steeg 1992). Often the tumor cell will
secrete factors promoting neovascularization of the growing cell mass. Its survival
tactics also may include secretion of immunosuppressants, down regulation or
modulation of surface antigens, and growth of a tumor core surrounded by dead
cells physically isolating it from the immune cells. The primary tumor may
continue to spew out seeds of metastasis as may the secondary tumor (Liotta 1992).
Eventually the tumor may compromise the function of the host organ, compress
some vital structure, or become such a metabolic burden that it kills the host.
The fact that some cancer cells metastasize while others do not has led
scientists to study the differences between these two categories of cells at the
molecular level. One interesting discovery is that the metastatic phenotype may be
related to the expression of MHC class I molecules. In the mouse, the two genes
and their products which constitute class I MHC are called H-2D and H-2K. A
murine 3LL carcinoma metastasis was dependent on a high ratio of H-2D to H-2K
surface density (Feldman and Eisenbach 1988). It was further found that the
expression of this metastatic phenotype was linked to the fos oncogene. The
surprising fact was that the fos gene was found in non-metastatic cells and its
insertion into metastatic cells decreased their ability to metastasize.
Other genes have been identified which seem to be able to block cancer
metastasis. These tumor suppressor genes have been found to be altered or absent
in a variety of different cancers (Cowell 1990). Two of these genes which have been
extensively studied are the retinoblastoma gene (RBI) and the p53 gene. Both the
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RBI and p53 gene products are bound by various transforming early proteins
encoded by several DNA tumor viruses (Cowell 1990). It is thought that this binding
renders the suppressor proteins inactive and thus may contribute to cancer
formation. While not all of the mechanisms have been defined, it is believed that
the gene products of the tumor suppressor genes act in a way that promotes
controlled growth.
Therapeutic strategies against malignant tumors traditionally have relied on
early detection for cure. Once detected, primary tumors may be successfully
treated with radiation, chemotherapy, surgery, or a combination of any or all of
these modalities. However, after a tumor has metastasized, the treatments available
are less effective and more destructive, and there is a significant decrease in cure
rate. Radiation and chemotherapy often prolong survival, and surgery may
temporarily decrease the tumor burden. The real key, however, is to prevent the
tumor from metastasizing.
One relatively untested strategy is the blocking of tumor cell/substrate
adhesion. This adhesion presumably takes place early in invasion when the cells
interact with the basement membrane and connective tissue, as well as later during
the extravasation process (Liotta 1986). Theoretically such a strategy could block
intravasation and thus confine the tumor for a more prognostically favorable
resection. Any tumor cell defeating this first level of blockade may be caught by
blocking its binding during extravasation. This would force the tumor cell to be in
circulation for an extended period during which time immune cells and products
would have direct access to it, not only isolating the cell for easy killing, but also
priming or further stimulating the immune response against the tumor (and in
particular the clone that has developed the capability to intravasate).
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While this strategy may never take the place of other therapeutic modalities,
it promises to be a positive adjunctive therapy. It may be especially useful for a
disease such as primary prostate cancer where the malignancy is often dormant and
generally has an onset late in life. Rather than undergoing surgery, chemotherapy
or radiation with their concomitant side-effects, the prevention of metastasis by
blocking the adhesion capabilities of the tumor cells in theory would allow a better
quality and length of life for the patient. Additionally, regular screening tests could
parallel this treatment to catch any exacerbation of the disease. Currently prostate
cancer therapy is often avoided if the life expectancy of the individual is less than
10 years, since there is a good chance that the tumor will remain quiescent for the
life span of the individual. Adhesion blocking therapy for prostate cancer may help
keep secure clinical quiescence for a long period.

D. Prostate Cancer

Prostate cancer is the most frequently diagnosed cancer in men; it is the
leading cause of cancer death in men over 75, and the second leading cause in men
under 75 in the United States (Breau 1992; Mcleod et al. 1992; and Moon 1992). The
rate of incidence is the third fastest rising of all major cancers, with a 45.9% increase
from 1973-1978; it is among the top 10 cancers, showing the largest increase in
mortality rate (out of 25) over the same time period (Stephens 1991). In the United
States, a man has a 1 in 11 lifetime risk of developing prostate cancer, but his risk of
dying from the disease is 1 in 22-33 (Fair 1992). The direct costs are over $1 billion
with 250,000 hospitalizations and 30,000 deaths annually (National Cancer Institute
1991). Autopsy data indicates that 30%-50% of American males over the age of 50
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have at least one focus of prostatic adenocarcinoma (Messing 1991). This cancer is
twice as common in African Americans as Caucasian Americans (Centers of Disease
Control 1992), but is less common in Asian Americans than either group. American
Asians are more likely than their Asian counterparts to develop this cancer, showing
an environmental as well as genetic basis for this disease (Ross et al. 1992). Age also
is a risk factor; the rule-of-thumb is that 90% of men over the age of 90 have
prostate cancer (Janssen 1990). While these risk factors are clear, the etiology is
unknown, although some studies provide inconclusive evidence that cadmium or
viruses may play a role (Garcia-Sanchez et al. 1992; Peterson 1988). There are still
no effective screening procedures for this disease. Seventy percent of all cases go
undetected until they have spread (Walker 1991), and 15%-20% already have
symptoms of metastasis on presentation (Messing 1991). Prostatic adenocarcinoma
accounts for 98% of all primary prostatic tumors (Peterson 1988) and is referred to
in this section as "prostate cancer."
The prostate gland surrounds the urethra immediately below the bladder, is
about the size and shape of a horse chestnut, and weighs about 25 grams
(Figure 1.7; Peterson 1988). A thin muscular capsule surrounds the prostate, which
is made up of numerous individual glands. These glands open into ducts in the
prostatic urethra and secrete fluid during ejaculation which helps liquefy the semen
and facilitate the journey of sperm to the ova (Cormack 1987; Genuth 1988). The
prostate can be divided functionally into glandular and nonglandular portions. The
anterior nonglandular portion is fibromuscular and quite resistant to cancer. The
glandular portion can be subdivided into four zones based on the origin of the ducts.
The peripheral zone (PZ) comprises about 70% of the glandular portion; 70% of all
primary cancers of the prostate occur in this zone. Most tumors found here are of a
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Figure 1.7. Prostate cross-sections. The cross-sections of normal and diseased
prostates are shown (A) to portray the usual sites of disease and its physiologic
consequences. The sagittal sections (B) show the relation of the prostate to the
surrounding organs as well as stages of cancer spread.
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high grade; however, the anatomy of the PZ allows early detection (about stage B) of
cancers by digital rectal exam (Peterson 1988). The central zone (CZ) contains an
additional 25% of the glandular tissue but is quite resistant to both cancer and
inflammation. The transitional zone (TZ) has 5%-10% of the glandular portion and,
like the PZ, is susceptible to cancer. However, unlike the PZ, the tumors arising in
the TZ are low grade and have a low probability of spread. The periurethral zone is
very small and relatively few cancers arise here.
The prostatic capsule provides a boundary for metastasizing cells; however,
the apex contains no capsule and is therefore important in metastasis. The
neurovascular bundles come into the lateral surface of the prostate through the
capsule and thus may provide another avenue of cancer spread (Olsen 1993).
A common problem occurs when the inner glands of the TZ hypertrophy (in
benign prostatic hyperplasia), causing obstruction of the bladder outlet with
symptoms including frequency and urgency of urination with only incomplete
emptying of the bladder. Prostate cancer, on the other hand, generally arises in the
outer main prostatic gland or subcapsular tissue (Janssen 1990). This usually
provides no physical warning (i.e., urination problems) as would occur if cancer
were located in the periurethral zone or TZ.
While there are usually no warning signs in early prostate cancer which are
obvious to the patient, there are screening tests. As imperfect and under-utilized as
the available screening tests are, they offer the only available means of early cancer
detection. One such test in wide use is the uncomfortable and subjective digital
rectal exam (DRE). The utility of this test is based on the fact that a cancerous
prostate feels harder than normal prostate. However it is only useful for detecting
cancer residing in the zones of the prostate next to the rectal wall.
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Another test is based on the fact that the prostate leaks prostate-specific
antigen (PSA) into the blood. PSA, a 34 kD, 240 amino acid glycoprotein, is produced
by the epithelial cells and enters into the prostatic ducts (Bilhartz et al. 1991). Its
function is to degrade seminal vesicle proteins, thus playing an important role in
semen liquefaction. In the normal prostate, a very small amount of this serine
protease leaks into the blood. However, when there is a significant breakdown in
the architecture of the gland as occurs with tumor growth, relatively large amounts
of PSA leak into capillaries and lymphatics. Thus, serum PSA levels roughly
correlate with the degree of destruction of the normal prostate. In fact one study
showed that the PSA test correctly identified 30% more prostate cancer cases than
DRE and 40% more than an ultrasound scope (Catalona et al. 1991). However, 38%48% of patients with organ-confined prostatic cancer have a PSA level within the
“normal” reference range (Oesterling 1992), rendering this screening test
ineffective in identifying up to half of those men who could be most easily and
effectively treated.
Unfortunately, blood PSA values can also be elevated in benign prostatic
hyperplasia (BPH) which is a common disorder in older men and does not lead to
tumor growth (Messing 1991). The rate of change in serum PSA values is a more
specific detector of prostatic cancer than absolute PSA values (specificity of 90% vs.
60% respectively) (Carter et al. 1992). Another technique for improving the
usefulness of testing PSA levels in prostatic cancer screening is to measure "PSA
density," a quotient determined by dividing the serum PSA value by the volume of
the prostate. Thus a moderately elevated PSA value and a significantly increased size
of the gland would result in a decreased PSA density indicative of BPH, whereas an
increased PSA with a "normal" gland size predicts cancer (Oesterling 1992). On the
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other hand, although PSA can identify more cancers sooner than DRE, DRE picks up
about 20% of PSA false negatives. The specificity and sensitivity of PSA tests are not
ideal, but in conjunction with DRE allow the best screening currently available
(Oesterling 1992).
Another, more expensive, screening test is the trans-rectal ultrasound. This
ultrasound test can delineate between normal and cancerous (hypoechoic) glands
and can be useful for determining the volume of the gland for a PSA density
measurement. This test is indicated in conjunction with a normal DRE and a slightly
elevated PSA value (Lee et al. 1991).
If abnormal results are obtained with these screening tests, diagnostic tests
can be done to determine the presence and severity of prostatic cancer. These tests
include biopsy, analysis of blood levels of prostatic acid phosphatase (PAP),
computer enhanced tomography (CT), bone scan, and blood tests for hepatic and
renal function. A biopsy can show histologic evidence of malignancy and spread, and
a PAP level of greater than 1.5 ng/ml indicates extraprostatic malignancy (Messing
1991). The remaining tests are used to locate cancer spread. Seventy-percent of all
patients with metastatic disease have bone involvement, with 63% having both
regional lymph node and lung involvement (Janssen 1990; Mareel et al. 1991a). [The
only other cancer approaching this unusually high rate of metastasis to the bones is
breast cancer (Mareel et al. 1991a).]
Prognosis of the patient is dictated by the grade and stage of the tumor. The
grading (histology) of prostatic tumors generally involves the use of the Gleason
Grading Scale (Janssen 1990) from 1-5, with 1 having well-differentiated tumor cells
and a relatively good prognosis, and 5 having poorly differentiated tumor cells and a
bad prognosis. Furthermore, an overall grade is assigned which is the sum of the
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score of the most common tissue type (1-5) and the worst grade (1-5), for a total
score within a possible grade of 10. The stages of the cancer range from A to D with
stage A having no spread and D having metastasis to distant sites (Figure 1.7).
Together, the stage and grade indicate prognosis.
The therapies available to the patients with prostate cancer include surgery,
radiation therapy and steroid therapy. For stage A or B tumors, a partial or radical
prostatectomy is generally the treatment of choice. Five-year survival is around
80%-90% and ten-year is 35%-70%. Radiation therapy is also a choice with five-year
survivals ranging from 60%-80% (Messing 1991).
For stage C tumors, radiation and hormone therapy appear to be effective.
Patients in this category have a five year survival rate of 50%-60% with radiation
therapy and 60% with hormone therapy, and a ten-year survival rate of 20%-35%
with radiation therapy (Messing 1991). Radiation treatments include conventional
x-ray beam, mixed beam (neutron and photon), and implantation of radioactive
seeds (1251, 198Au). Proton beam therapy has properties which could make it a
therapy option as well. The traditional steroid therapy includes diethylstilbestrol
(DES) or leuprolide. (The actions of these drugs are discussed below.) Sometimes
an orchiectomy is performed in conjunction with the hormone therapy.
For stage D tumors, the only therapy recommended is palliative therapy,
including pain medication (morphine) and steroid therapy or radiation (Yamanaka et
al. 1991). All of these therapies can provide immediate relief from pain. These
patients live an average of 2.5 years (Janssen 1990).
To understand the rationale behind the use of hormone therapy, one must
understand the effects of hormones on the prostate gland (Figure 1.8). Normal
development of the prostate is dependent on endocrine stimulation, with
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Figure 1.8. Endocrine loop and hormonal therapy in prostate cancer. Leuteinizing
hormone-releasing hormone (LH-RH) is produced in the hypothalamus and acts on
the anterior pituitary to secrete leuteinizing hormone (LH). This promotes the
testicular synthesis of testosterone (T) which becomes converted into
dihydroxytestosterone (DHT) in the prostate. The negative feedback loop (dotted
line) involves the action of testosterone and estradiol (E). This can be mimicked by
synthetic estrogens such as diethylstilbestrol (DES). Leuprolide, also used in
hormonal therapy, acts by decreasing the amount of LH-RH secreted. (For
additional details, see text.)
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testosterone being necessary for the prostate to develop into and remain a
functional gland (Cormack 1987). Leuteinizing hormone-releasing hormone
(LH-RH) is made in neurosecretory neurons in the hypothalmus. These neurons
terminate in the hypothalamic-hypophysial portal system. This unique vascular
bedshuttles the peptide LH-RH directly to the anterior lobe of the pituitary (which
incidentally gets 90% of its blood from this venous plexus). Leuteinizing hormone
(LH), produced in the anterior lobe of the pituitary, enters the circulation and
subsequently binds to a specific high affinity receptor on the plasma membrane of
the testicular interstitial cells of Leydig. This receptor is associated with a G protein
which activates adenylate cyclase, triggering an increase in cAMP which acts through
calmodulin to increase the production of testosterone mRNA and thus testosterone
(American Medical Association 1989a; Neuman et al. 1991).
This testosterone enters the blood stream and performs two actions
pertinent to this discussion. Its direct action involves its diffusion into the glandular
cells of the prostate where it is reduced by the enzyme 5-alpha reductase which, in
turn, converts it to its active form, dihydroxytestosterone (DHT) or to 5 alphaandrostanediol (inactive). DHT is directly responsible for growth in the prostate. It
binds to a cytoplasmic androgen receptor and the steroid receptor complex moves
into the nucleus where it interacts with chromosomal DNA and nuclear proteins
(Genuth 1988). In the nucleus, subsequent activation of RNA polymerase is
followed by mRNA synthesis and resultant cell (and organ) growth. DHT eventually
becomes metabolized into testosterone glucuronide, a 17-ketosteroid, which is
conjugated in the liver and excreted in the urine.
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The second action of testosterone is more circuitous. It acts in a negative
control feedback loop to decrease the production of both LH-RH and LH, indirectly
leading to reduced production of testosterone.
There seems to be two different pathways of regulating human prostate
growth (Fiorelli et al. 1991; Schuurmans et al. 1991). The first is the androgendependent pathway described above. The second is an androgen-independent
pathway mediated by other growth factors, including epidermal growth factor
(EGF). In the normal human male, an increase in testosterone will decrease the
number of prostatic EGF receptors, while a decrease in testosterone will increase
the number of prostatic EGF receptors (Fiorelli et al. 1991). In a cancerous prostate,
however, there is a constituatively high expression of EGF receptors. And many
prostate cancers and cell lines studied to date secrete EGF and other growth factors
which act in an autocrine or "juxtacrine" manner (Schuurmans et al. 1991; Steiner
and Barrack 1992). Transforming growth factor-P is thought to be an inhibitory
hormone for EGF stimulation (Schuurmans et al. 1991). In cancers it appears that
the DHT and EGF act synergistically to promote cell growth (Schuurmans et al.
1991).
In a person with prostatic cancer, testosterone may act as the driving force in
the growth of that cancer. The cancerous cell receives the message to grow from
testosterone but never balances this message with a down-regulation of growth
factor receptors. Thus, although an increase in serum testosterone level cannot be
consistently shown in patients with prostatic cancer (Peterson 1988), the cancer can
grow unchecked. This gives rise to the strategy of hormone therapy.
DES is a synthetic estrogen which acts much like testosterone in the
negative feedback loop. It has been used successfully to decrease testosterone
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levels and rate of tumor growth. However, it has side effects from unpleasant
gynecomastia and impotence to potentially lethal thromboembolic episodes
(American Medical Association 1989b). Leuprolide is a nonapeptide agonist of
LH-RH with more potency than the natural hormone. However its action, while
originally increasing LH levels, eventually leads to decreased levels of LH and
testosterone (American Medical Association 1989c). Testosterone is synthesized
mostly in the testes in the male; however castration may not delete all of the
testosterone synthesis in the body and should be thought of as an adjunctive
therapy if it is used at all. Non-surgical castration (steroid therapy) can have less
damaging psychological effects while achieving similar results. Androgen ablation
therapy is initially profoundly effective in 70%-80% of prostatic cancers (Turkes et
al. 1987).
Drugs are being designed to take advantage of the pathway of testosterone
stimulation. One such drug is finasteride, which inhibits 5-alpha reductase
(Fackelmann 1991; Imperato-McGinley et al. 1992; and Rittmaster et al. 1991). This
drug only recently became the first FDA approved drug for the treatment of benign
prostatic hypertrophy (Gelb 1992). Flutamide, an anti-androgen also shows
promise, but remains very expensive (Imperato-McGinley et al. 1992; Labrie et al.
1991). 4-MAPC (4-methyl-3-oxo-4-aza-5-alpha-pregnane-20-caroxylate) is another
5 alpha-reductase inhibitor which is undergoing trials (Ghusn et al. 1991; Labrie et
al. 1991; and Rittmaster et al. 1991). It is conceivable that other drugs may be
developed which might increase testosterone conversion to inactive steroids, block
the cytoplasmic receptor to which DHT binds, block LH synthesis, or speed DHT
metabolism.

36

Once treated, the patient should be followed with periodic PSA tests. The
PSA levels fall dramatically after successful treatment and any significant rise in level
indicates a resurgence of prostatic cancer (Messing 1991). Unfortunately, a large
number of patients develop tumors insensitive to endocrine therapy (Kumamoto et
al. 1991; Mahler and Denis 1992; and Yamanaka et al. 1991). In fact, the median
duration of the response to steroid therapy is only 2 years with an average survival
following relapse limited to only 6 months (Eaton et al. 1991). Therefore, patients
who are undergoing or have undergone therapy should be followed closely for PSA
serum levels. Upon recurrence, these androgen insensitive tumors can be
effectively treated with chemotherapy or radiation to decrease pain associated with
bone metastasis (Janknegt 1992; Mcleod et al. 1992; Mohler et al. 1992; and
Yamanaka et al. 1991).
All these therapies only buy time for the patient with metastatic prostatic
adenocarcinoma for they only slow the progression of this disease. Curative therapy
necessitates the identification and eradication of the tumor before it metastasizes.
While some inroads to early detection have been made (PSA screening tests), little
has been accomplished in finding a means of preventing metastasis--of preventing a
treatable disease with a relatively good prognosis from turning into a irremediable
sickness with no chance of a cure.

E. Antibody Therapy for Cancer

When people become ill, they often take medicine to augment their body's
response to disease. In fact the practice of modern medicine is in large part dictated
by drug actions. A theoretically ideal drug regimen acts only on targeted cell
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populations with no adverse effects on the rest of the organism. Monoclonal
antibodies, due to their inherent specificity, represent a class of drugs with potential
for approaching this ideal.
The production of a monoclonal antibody necessitates the prior selection of
antigen for immunization. The antigen may be pure or a crude extract, whole cells,
proteins, or small peptides. Smaller epitopes may require a hapten in order to elicit
an appropriate immune response. Once injected into an appropriate animal (e.g.,
mouse), the antigen is processed by the immune system, including B cells in the
germinal center of lymphoid tissue (Nossal 1992). B lymphocytes subsequently
internalize this antigen by specific uptake or nonspecific uptake. Nonspecific
uptake does not involve the B-cell receptor and is associated with T-cell but not
B-cell activation (Klein 1990). In specific uptake, the B-cell receptor binds the
antigen and this complex becomes endocytosed. The endocytotic vesicle fuses with
a lysosomal vesicle which contains proteases that cleave the antigen into peptides.
This peptide-bearing vesicle then fuses with a vesicle containing newly synthesized
MHC class II molecules. The peptides bind in the antigen cleft of the MHC
molecules, and the complex is then transported to the cell surface (Hoffman 1992;
and Klein 1990). This complex of peptide and MHC class II molecule is recognized
by the T-cell receptor. This recognition, especially by T helper cells, appears to be
crucial in the activation of B cells. The T helper cell is thought to trigger B-cell
activation by two mechanisms: cross-linking of the B-cell receptors and secretion of
lymphokines. The T-cell, in turn, can be activated by antigen-presenting cells to
produce more lymphokines. These growth and differentiation factors cause an
increase in the rate of somatic mutation of the B-cell immunoglobulin variable
region genes, especially in the complimentarity determining region, which leads to
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the production of an antibody with increased affinity. This hypermutation
dramatically increases in the second week after immunization (Nossal 1992).
Further injection of the antigen is given at two to four week intervals to maximize
this hypermutation.
The immunogenicity of the antigen as well as the class of antibody desired, in
part dictate the number of injections to be given. The less specific IgM is the first
antibody produced by the immunized host, followed by the more specific subclasses
of IgG. To ensure a maximal proliferation of antigen reactive plasma cells, the final
boost is given 3 to 5 days prior to harvesting the plasma cells.
The plasma cells, harvested from spleen, lymph nodes, or other lymphoid
tissue, are fused with non-secreting myeloma cells to produce immortal hybridomas
(see Figure 1.9). These hybrid cells can be cloned and screened for appropriate
antibody production and the monoclonal antibody purified preferably from the cell
culture conditioned-media, but also from peritoneal acites when the hybridoma is
grown in vivo.
While monoclonal antibodies are used routinely in clinical laboratory
medicine (for sensitive screening tests, etc.) with outstanding success, most clinical
trials involving the use of monoclonal antibodies to kill tumor cells have been rather
disappointing (Glassy and Dillman 1988). Several factors contribute to the mediocre
efficacy of monoclonal antibodies in treating patients. Since it is ethically ill-advised
to purposefully immunize humans with potentially tumorigenic, most antibodies
are made in lower mammals such as mice. However, the xenogeneic serum
proteins derived from such animals readily elicit an immune response in the human
host because they are strong antigens themselves, and if given more than once may
induce severe reactions [serum sickness and Arthus reaction (Benjamini and
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Figure 1.9. Hybridoma production. A schema of hybridoma production illustrating
basic steps including antigen immunization, serum antibody testing, plasma cell
harvesting, immortalization of immunized plasma cells, and selection of appropriate
antibody-producing clones.
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Leskowitz 1988)], or may be immediately neutralized by resulting anti-idiotypic
antibody formation. Independent of this problematic aspect, animal antibodies have
a shorter serum half-life in the human, thus failing to provide lasting anti-tumor
activity (Bookman 1990; Glassy and Dillman 1988; Houghton and Larson 1989;
Morrison 1992; and Waldman 1991). And finally, the effector functions of murine
antibodies (i.e., antibody dependent cellular cytotoxicity and complement fixation)
may not be physiologically compatible with the human host and therefore their
effectiveness is either greatly decreased or non existent in the human body. All of
these effects result in reducing the effectiveness of this potentially powerful
therapy.
There are several ways of maximizing the usefulness of monoclonal
antibodies. Various strategies are all based on decreasing the "foreignness" of the
monoclonal antibodies. While cyclosporine (Ledermann et al. 1987) and
deoxyspergualin (Pai et al. 1990) seem to block reaction to murine monoclonal
antibody, the use of immunosuppressive drugs in cancer patients may not be
advisable. A more useful method is to modify murine antibodies by "humanizing"
them (Glassy and Dillman 1988; Houghton and Larson 1989; Morrison 1992; and
Waldmann 1991). This can be accomplished by making a chimeric antibody
comprised of the Fc portion of a human antibody joined to the Fab portion of a
murine monoclonal source. This chimeric molecule has several advantages
including normal effector function and decreased, but still bothersome,
immunogenicity. To further deplete the foreignness of the chimera, antibodies
have been made which contain only the variable regions (or better yet just the
complimentarity determining regions) of a given murine monoclonal in the
framework of a human antibody (Houghton and Larson 1989; Morrison 1992; and
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Waldmann 1991). Yet with only tens of foreign amino acids per antibody, there is
still problematic immunogenicity (Morrison 1992).
To circumvent this, fully human monoclonal antibodies have been made.
The manufacture of human monoclonal antibodies may be accomplished by
isolating lymphocytes from human volunteers and performing in vitro
immunization. While this technique has much potential, the efficiency is poor due
to the brief antigen exposure in vitro of the relatively short lived B cells. {In vivo
immunizations, on the other hand, allow repeated injections of antigens over weeks
to months.) To maximize the efficiency oi in vitro immunization, several steps
may be undertaken. First, to increase the period of B-cell exposure to antigen,
lymphocytes can be used which have had in vivo antigen contact. That is, while
ethical problems prohibit injecting potential tumor-inducing antigens into humans,
cancer patients who have had exposure to tumor antigen may produce an antibody
response which can be used as the basis for making human monoclonal antibodies
to this cancer by further stimulating these cells in culture. This avenue should allow
the production of cancer-specific antibodies to many human cancers.
Second, using a specific source of lymphocytes can enhance successful
antibody production. Since memory B cells are normally found in the lymph nodes
or spleen, lymphocytes isolated from these sites are preferable to peripheral blood
lymphocytes because they will theoretically yield higher numbers of appropriate
antibody-producing cells from individuals with previous antigen exposure. While
these sources may require invasive procedures, cancer patients often have surgery
in which the draining lymph nodes, a valuable source of tumor-specific
lymphocytes, are removed. Quiescent B cells require contact with a T-cell for
activation and antibody production; however, once the B-cell is activated, T-cell
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produced lymphokines will cause a similar result (Klein 1990). Cancer patients
often display little antibody reactivity to their tumors, in spite of the fact that the B
cells are immunized to tumor antigens, because they may be suppressed by the
tumor or not activated (Mareel et al. 1991b). An efficient way of assuring activation
in vitro is to provide autologous T cells in a culture of these B cells.
Third, this in vitro procedure may be maximized by the addition of various
immunoactivators, substances reported to increase the number of relevant antibody
producing cells, including IL-2 and IL-6, which play a role in the differentiation of
B-cells, and muramyl dipeptide and OK-432, which seem to sensitize lymphocytes to
antigens (Kawahara et al. 1992).
Once the problem of immunogenicity has been addressed, the issue of
decreased effector function should be considered. One way to accomplish this is to
conjugate molecules to the antibodies, enabling them to have altered effector
functions. These molecules can be toxins (ricin, exotoxin etc.) or radioisotopes to
kill or image targeted cells (Bookman 1990; Brinkmann et al. 1991; Mejer et al. 1991;
Pai et al. 1991; Waldmann 1991; and Woo et al. 1989), growth factors for certain cells
(e.g., immune cells) (Houghton and Larson 1989; Morrison 1992; and Pai et al. 1991),
drugs or prodrugs for action at a limited site (low toxicity) (Houghton and Larson
1989) or for passage through the blood brain barrier (Morrison 1992), liposomes
containing drugs or genes to be targeted to a certain site, or even small molecules
which, when conjugated to antibody, enjoy a longer serum half-life (e.g., CD4
conjugated to monoclonal antibody may provide therapy for HIV infected
individuals) (Morrison 1992). The conjugated molecule may also be used instead of
the complimentarity determining region of the antibody as the targeting device
(e.g., targeting of tumor cells with high levels of growth factor receptors on their
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surface). Heterobifunctional monoclonal antibodies can be made which enable the
antibody to bind the target of interest and then also bind a second target such as an
effector cell or drug (Houghton and Larson 1989; Kostelny, Cole and Tso 1992;
Mezzanzanica et al. 1991; and Waldmann 1991).
To date, most of the clinical trials involving monoclonal antibodies have been
accomplished with murine antibodies designed to kill tumor cells (Glassy and
Dillman 1988; Pietersz and McKenzie 1992). If the antibodies were directed against a
tumor specific antigen, an epitope unique to cancer cells, and if the antigen were
vital for the disease process, then deletion of epitope-positive cells would be
curative. However, most tumor associated antigens do not meet both criteria. Since
the tumor cell is a normal cell that has become transformed, it carries out most of
its functions using the normal cellular processes. Because of this, most of the
functional proteins are the same as those found in the non-transformed cell. Tumor
specific antigens have remained elusive, yet there have been quantitative
differences in epitope density in transformed vs. non-transformed cells as well as an
association of fetal antigen expression. Yet, antibodies against these epitopes may
only lead to clonal selection of surface antigen-negative cells without significantly
altering progression of the disease. In fact, the clonal deletion of altered-self
antigens (e.g., viral antigens) may make it more difficult for the immune system to
recognize the tumor cell stripped of associated markers. Thus it seems that an
alternative to the strategy of immunotherapy, designed to kill tumors with resulting
clonal deletion, needs to be considered. While the use of cocktails of antibodies and
radionuclide-conjugated antibodies are a step in the right direction, they rely on the
same underlying strategy.
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A simpler approach might be to make an antibody designed to simply block a
given function. This approach theoretically will not lead to clonal deletion, but may,
in certain cases, block the growth or spread of the tumor. This has an added
advantage in that murine antibody therapy can be used in spite of the lack of specific
effector function in man because the blocking role will not require an effector
function of the antibody.
In vivo administration of antibodies directed against growth factors has been
used to show a decrease in growth rate for tumor cell lines (Houghton and Larson
1989; Morrison 1992; Pai et al. 1991). Several researchers have suggested that new
therapies could be based on blocking specific adhesion pathways (Duffy 1992;
Hakomori 1991; and Osborn 1990). In fact, a number of studies have demonstrated
the blocking of metastasis using therapies designed to prevent binding by adhesion
molecules. These successful therapies included inserting anti-sense RNA of an
adhesion molecule into a tumor cell line (Mafune and Ravikumar 1992), in vivo
administration of adhesion-related peptides (Iwamoto et al. 1992; Soszka et al. 1991;
and Yamamoto et al. 1991), and blocking metastasis with an antibody generated to an
adhesion molecule (Zhu et al. 1992). However, almost all of the work to date using
anti-metastatic agents has been carried out in vitro or in animal models (Duffy
1992).
There are several reasons that these murine antibodies have not seen greater
success in clinical trials. These include inaccessibility of the tumor site to antibodies,
heterogeneity of antigen expression by tumor cells, down-regulation of surface
antigens to which the antibody is directed, and production of inhibitors of cytolysis.
In addition, murine antibodies are immunogenic and may have little effector
function in humans. However, recent technology has become available which
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addresses many of these problems (Old 1991). Antibodies can be made with little or
no immunogenicity and armed with a variety of different effector functions,
including natural ones. Cocktails of antibodies directed to multiple tumor antigens
can be bound to radionuclides (preferably alpha-emitting radionuclides) capable of
killing cells within a zone of several cell diameters (Bookman 1990; Waldmann
1991), thus minimizing the tumor's ability to hide through modulation of surface
antigens. Molecules capable of various effector functions can be attached to the
antibody to thwart inhibition of complement activation. And these antibodies can be
used as markers to guide other therapeutic modalities to the tumor cell specifically.
Thus antibody therapy for cancer appears to be on the verge of a new and
promising era of safer, more effective treatment.

F. Previous Work by Collaborators in this Project

Sternberger (1986) has pointed out the methodological advantages of
developing monoclonal antibodies to synthetic peptides, which then permit
detection of naturally occurring antigenic determinants produced through posttranslational protein modifications. In collaboration with T. Koch, Ama-containing
molecules have been synthesized. Ama was synthesized and conjugated to albumin
and utilized to immunize mice, from which antibody-producing plasma cells were
taken for hybridization with myeloma cells. These hybridomas were used to
produce monoclonal antibodies (anti-AmaSyn) (W. Kirsch and R. Wellerson et al.
1989; Ortho Diagnostic Systems Clone #57D4B6G2B11).
Studies performed by L. Sillerud enabled nuclear magnetic resonance
determinations of Ca++ binding to free Ama as well as Ama in peptide linkage. In
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further collaboration with Sillerud, NMR studies were conducted of Wallerian
degeneration, a lipid degenerative process in nerves in which foam cells appear
during the course of monocyte activation and myelin breakdown. The foam cells of
Wallerian degeneration contain an anti-Ama antibody-reactive protein. A U.S. patent
application has been submitted (Kirsch) describing a method of treatment of a
glutaraldehyde fixed, collagen/elastin bioprosthesis (prior to its implantation in vivo)
with selected free-radicals to block macrophage mediated carboxylation of the
glycine alpha-carbon (when in peptide linkage).
In another area of work, Kirsch and his colleagues have been isolating antiAma antibody-reactive material from granulomatous lesions containing lipid-laden
macrophages, or foam cells. In those studies, normal monocytes were used as
control cells. Mass spectroscopy quantitation of Ama revealed that the
granulomatous cells contained 3.7 Ama molecules per 1,000 glycines in contrast to
no detectable Ama in normal peripheral blood monocytes (Copley et al. 1991). This
finding led to an investigation of leukocytes in general by Cannarella. After isolating
leukocytes on Histopaque 1119 (Sigma, St. Louis, MO), the cells were washed, lysed
and applied to the Ama affinity column. Eluates were then applied to a sizeexclusion chromatography column, from which we isolated seven separate entities
ranging between 6 Kd and 200 Kd. Each of these were reacted in ELISA with the
anti-AmaSyn; reactivity was less than that of the malignant cell material but still
significant. It is not known, at this time, which of the leukocyte populations are
contributing; this is currently under investigation. The eluate taken directly from
the Ama affinity column and studied in gel electrophoresis has revealed (on silver
stain) two bands of material, both falling between 15 Kd and 20 Kd.
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Cannarella et al. have also had some success in altering the course of
alloreactivity produced in mixed lymphocyte culture reactions by the addition of
anti-AmaSyn. Whether this effect is due to specific blocking of adhesion (integrin)
molecules needed for cell activation, or other effects such as competition for antigen
receptors (the monoclonal antibody is a murine protein; therefore, antigenic in
itself) is not known at this time. [An interesting fact to note is that integrins are
needed for all cell to cell contact between leukocytes (Braakman et al. 1990; Klein
1990; and Vanky et al. 1990).]
In summary, preliminary evidence has been obtained that Ama-like material
is found in activated-normal and diseased cells (lipid-laden macrophages and
malignant T lymphocytes), with manifold more residues in the diseased than normal
cells. The Ama-containing components are of various molecular sizes, perhaps
indicating that the Ama epitope is found in more than one protein. On the other
hand, it must be proven that anti-AmaSyn is acting specifically, without cross
reactivity.

Significance
The anti-AmaSyn antibody (W. Kirsch and R. Wellerson et al. 1989; Ortho
Diagnostic Systems Clone #57D4B6G2B11) has been shown (Kirsch and Hunsaker
unpublished data) to bind to atherosclerotic plaque and fatty streaks but not to
normal endothelium (Table I). This has sparked interest in the possible use of this
antibody in screening for atherosclerosis and heart disease. Anti-AmaSyn antibody
also binds to a number of tumor cells and therefore might be valuable for studying
tumor pathogenesis and in providing tumor therapy.
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Table I. Tissues were incubated with anti-Amasyn antibody using indirect
immunohistochemical labeling techniques. This work was carried out in
conjunction with Kirsch and Hunsaker, Loma Linda University, Loma Linda, CA.
"SCM's" indicate smooth muscle cells.
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Table I
Immunocytochemical Screening of Various Tissues with Anti-Amasyn Antibody
(Immunofluorescence or Immunoperoxidase)
Tissue Origin

Gross Appearance

Ama-Reactivity

newborn baby
(still born)

normal aorta

none (aortas, coronaries)

74-yr. male
(head trauma death)

fatty streaks
calcified plaque
aorta

positive foam cells,
SMC’s, collagen,
endothelial cells

30-yr. male
coronary occlusion

fatty streaks
fibrous plaque
coronary artery

positive foam cells,
collagen, endothelial cells,
SMC’s

subhuman primate
on atherosclerotic diet

fatty streaks
fibrous plaque
aorta
carotid artery

positive foam cells,
collagen, SMC’s

control subhuman primate

normal

negative

atherosclerotic
rat aorta

fatty streaks

positive foam cells

atherosclerotic
rabbit aorta
(Watanabe Rabbit)

fatty streaks

positive foam cells

brain

normal

negative, nerve cells and glia

kidney

normal

negative

liver

fatty degeneration

liver cells with fatty
infiltrations, positive

heart muscle

infant

positive

lung

normal

negative

normal lens

normal

negative

cataract lens

cataract

positive lens protein
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The anti-AmaSyn antibody was developed by conjugating aminomalonic acid
(Ama) to a hapten. To more closely approximate the epitope that Ama would create
in a protein, this Ama was placed in peptide linkage by producing Noc-acetyl-Ama-Nethyl amide, which we will refer to as Ama monopeptide. This was bound to BSA by
a 6 aminohexanoic acid (16 atom) spacer, with the conjugation achieved by benzene
diisothiocyanate (see Figure 1.10). Forty-six of the 59 lysine residues of the BSA
amino acids is rare among unrelated proteins. Assuming a totally random addition of
amino acids in the generation of peptides, a seven amino acid peptide contains (20)7
or 1.28 x 109 possible variations. There also may be changes in the tertiary and
quaternary structures of peptides with the same sequence due to the action of
flanking and spatially near amino acids, thus increasing the possible epitope
variations. Theoretically then, the more amino acids in a peptide sequence that an
antibody can recognize, the less likely that antibody is to cross-react with another
epitope. Since this anti-AmaSyn antibody was derived to a synthetic epitope that
contained only one amino acid (Ama), a more specific antibody needed to be made
which reacted to a naturally occurring Ama-epitope.
Since Ama is a minor amino acid (the tissue containing the most Ama found
to date is foam cells with 4 Ama residues/ 1000 Gly residues) the number of proteins
that contain Ama is probably small. This decreases the number of cross-reacting
proteins, enhancing the feasibility of isolating specific proteins containing the Ama
epitope. These proteins can be isolated using the anti-AmaSyn antibody, then used
to make a theoretically more specific anti-Amanat antibody.
Characterization of the epitope can determine Ama content and binding
assays can be used to compare the epitope specificity of the anti-Amanat antibody to
that of the anti-AmaSyn antibody.
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Figure 1.10. BSA-Ama monopeptide.
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G. Experimental Plan

The eventual goal of this line of research is to study a novel mechanism for
the blocking of tumor metastasis in general and prostatic cancer metastasis in
particular. The problem that this addresses is the growing number of cases of
prostatic cancer in the increasingly aging male population. This cancer, like all
carcinomas, is not lethal unless it metastasizes, but there is no cure for the
metastatic disease. Unlike most other carcinomas, primary prostatic
adenocarcinoma can exist in men for up to 15 years without displaying any evidence
of disease or metastasis. Thus we know that if the cancer could be confined to the
prostate, curative therapy is feasible. In fact, if a therapeutic regimen capable of
blocking metastasis was safe, effective and inexpensive, it might be given
prophylactically to older males. Even though this regimen might not kill the
primary cancer, the patients receiving this treatment might be free of symptoms
associated with prostate cancer for many years.
The strategy most commonly involved in cancer therapy is the direct killing
of cancer cells by surgical excision, radiation or chemotherapy. Another strategy
involves blocking tumor growth factors (e.g., hormone therapy). These strategies
are often inadequate, especially in dealing with tumors that have already
metastasized. Surgery works well for most unmetastasized solid tumors.
Chemotherapy and radiation therapy are partially-specific and non-specific,
respectively, and therefore the dosage is limited to a range that may be less than
optimal for killing of the tumor due to side effects on normal tissues and cells.
Conventional radiation therapy is only useful against unmetastasized tumors,
whereas chemotherapy can be useful after metastasis. Hormonal therapy is useful
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in treatment of a handful of hormone-sensitive tumors, including prostatic
adenocarcinoma, even after they have metastasized. Unfortunately, prostatic
adenocarcinomas generally become unresponsive to hormone therapy within two
years of onset of treatment.
The strategy of blocking metastasis would address some of these
shortcomings in the traditional therapies. First, unlike chemotherapy and radiation
therapy, this strategy would theoretically provide a truly specific therapy. The
inherent specificity of a monoclonal antibody, combined with the uniqueness of the
epitope and its presumed importance as an adhesion molecule vital for metastasis,
make this an interesting approach to cancer treatment. Second, while it would not
at first replace surgery for primary prostatic cancer, this strategy might be used in
conjunction with surgery until absolute determination has been made that there is
no extracapsular spread of the tumor. It is also conceivable that this strategy of
blocking metastasis in patients with primary prostatic adenocarcinoma would be
sufficiently effective to eliminate the need for surgery in the majority of prostatic
cancer patients who have no symptoms. Third, this strategy could also be used as an
adjunct therapy with patients who have distant metastasis. While this would not
cure the disease, it could slow or stop its progression. It has been shown that not
only does the primary tumor produce metastasis, but also the secondary metastasis
sites themselves may produce additional metastasis (Liotta 1992). This allows for an
exponential increase in both the number of sites and the tumor burden associated
with the end-stage disease. By the use of a therapy which involves eliminating
further metastasis, the rapid increase in tumor load could be reduced and an
increase in both quality and length of life could be expected.

56
The research goal for this project is to undertake the initial step in the study
of blocking metastasis by a monoclonal antibody. The hypothesis is that a
monoclonal antibody can be produced which is specific for an anti-AmaSyn reactive
epitope on a human tumor cell line. The aims of this project are to:
Aim 1) Find a source for the naturally occurring Ama epitope using the anti
Ama syn antibody. This step is to be completed by screening cell lines with the antiAmasyn antibody using cellular ELISA and flow cytometry.
Aim 2) Immunopurify Ama epitope-bearing natural components by affinity
column chromatography, using a matrix-bound anti-AmaSyn. Malignant cells will be
detergent lysed and the lysate will be run on affinity column chromatography using
a matrix-bound murine antibody (anti-AmaSyn) produced to a synthetic peptide
bearing the Ama epitope.
Aim 3) Produce a new monoclonal antibody to the natural Ama containing
epitope(s) (anti-Amanat)- for each trial of immunization, four mice will be injected
and boosted with purified natural proteins containing the Ama epitope. Titers will
be determined by ELISA as described by Engvall and Perlmann (1972); the mouse
with the highest titer will provide the spleen for the cell fusion. The spleen will be
diced and cells teased out using a syringe and fine needle. Spleen cells will be fused
with NS-1 murine myeloma cells and selected in HAT medium. After allowing the
hybridomas to grow for a sufficient period, supernatant will be taken from them
and screened (using ELISA) for its ability to bind to purified proteins bearing the
Ama epitope as well as synthetic Ama conjugated to BSA.
Aim 4) Isolate these naturally occurring Ama epitope containing components
by immunoaffinity purification using the anti-Amanat antibody and to purify and
characterize the protein containing the greatest apparent Ama-epitope density. An
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affinity column will be made with anti-Amanat- Lysates of malignant cells will be
applied on this column and the bound proteins then will be eluted and the fractions
collected and tested using ELISA for binding to the anti-Amanat- Fractions will also
be run on gel electrophoresis to estimate size and number of the proteins in each
fraction. Proteins of interest will then be purified and further characterized for
glycosylation, pi and Ama content.
Aim 5) Determine the epitope specificity of the anti-Amanat and anti
Ama syn antibodies and compare them. This can be done by the following methods.
Immunohistochemistry
Briefly, fresh frozen tissue sections can be stained in a sandwich technique
with anti-Amanat and anti-AmaSyn antibodies as the first antibodies, then a
peroxidase labeled anti-IgG as the second antibody. After addition of appropriate
substrate, the tissue can be counterstained with eosin and viewed under a light
microscope. Tissue sections will be compared for reactivity patterns between antiAmanat and anti-AmaSyn antibodies. Analysis will include defining any antibody
specificity for diseased versus normal tissue.
Flow Cytometry
The anti-Amanat and anti-AmaSyn antibodies can be tested on flow cytometry
for binding to the surface of tumor cell lines. DNA index and cell cycle analysis
information can be obtained for these cells as an objective analysis of cellular
phenotype, which can be compared to previous reports. The binding of the antiAma antibodies can be correlated with cell cycle analysis to determine any association
of binding with cell cycle phase.
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Kinetics
The kinetics of the anti-Amanat and anti-AmaSyn antibodies can be
determined by a competitive ELISA. Briefly, the antibodies can be incubated with
various amounts of BSA-Ama or anti-Ama reactive antigen from anti-Amanat
immunoaffinity column, and the binding allowed to come to equilibrium. The
antigen-antibody mixture can then be added to wells previously coated with BSAAma for determination of amount of unbound antibody. This can be used to
determine the affinity constants of the antibodies.

Specificity Studies
An additivity test can also be performed to determine whether the antibodies
bind to the same epitope. This test may be accomplished by using a competitive
ELISA and comparing the results of the two antibodies added to a given ELISA well
with antigen versus each of those antibodies alone.
Conjugates close to, but different than, the BSA-Ama conjugates can be made
to further determine antibody specificity. This will help determine the exact nature
of the binding site for the anti-AmaSyn and anti-Amanat* Briefly, the BSA can be
mixed with an excess NHS ester cross linker, BS3, which binds to epsilon amine
groups on lysine of available N-terminus amines. The BSA can be separated from
the excess BS3 by column chromatography. Then the free amino acids can be added
to the BSA-BS3 molecule. Finally, the BSA-amino acid can be separated from the
free amino acid and end-blocked with a ethanolamine buffer. This product can be
tested by ELISA for its ability to bind anti-AmaSyn and anti-Amanab and compared
with BSA-Ama (monopeptide).
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Future Work
The ability of anti-Amanat to block tumor growth and metastasis can be
tested. Briefly, SCID (mutant severe combined immunodeficient) mice
reconstituted with human immune cells (SCID-hu) can be inoculated with tumor
cells from a human prostatic adenocarcinoma. The mice can be treated in one of
four ways 1) with anti-Amanat> 2) with warfarin, 3) with both agents, or 4) with
saline. Uninoculated SCID-hu mice can also be treated with anti-Amanat for a
control. The mice can be euthanized after 10 weeks, their tumors weighed, and
their lungs and livers examined for evidence of metastasis. The relative
effectiveness of the various treatments can be evaluated based on the rate of
metastasis, size of tumor, and side effects of the regimen. An alternative model to
SCID-hu mice is nude mice receiving a tail vein injection of tumor cells to simulate
metastasis.
This project can be designed to overcome the obstacle of effector function
and foreignness by the following methods. If the epitope is part of an adhesion
molecule vital for metastasis, the effector function problem could be addressed by
humanizing the antibody (thus allowing for true effector function including C’
mediated lysis), or by leaving the antibody in its murine form (thus only using the
antibody to physically block the adhesion molecules). Furthermore, the reaction to
the foreignness of the antibody could be minimized through the addition of
deoxyspergualin (Pai et al. 1990).

II. ISOLATION OF A SOURCE OF A NATURALLY OCCURRING
AMINOMALONIC ACID EPITOPE

Introduction
The anti-AmaSyn antibody has been shown to bind to atherosclerotic plaque
and fatty streaks, but not to normal endothelium (Table I). This has sparked
interest in the possible use of this antibody in screening for atherosclerosis and
heart disease. The anti-Amasyn antibody has also been shown to bind to a number
of tumor cells, and therefore also might play a role in tumor recognition or,
conceivably, therapy.
The anti-AmaSyn antibody was developed by using hapten-linked
aminomalonic acid (Ama) as a primary antigen. To more closely approximate the
naturally occurring Ama epitope found in a protein, Ama was placed in peptide
linkage by synthesizing Na-acetyl-Ama-N-ethylamide, referred to hereafter as Ama
monopeptide (see Figure 1.10). This Ama monopeptide was bound to BSA by a
6 aminohexanoic acid (16 atom) spacer, with the conjugation achieved by treatment
with benzene diisothiocyanate. An epitope density of 59 lysine residues of the BSA
was achieved in this Ama monopeptide adduct. BALB/C mice received injections of
this immunogen. Spleen lymphocytes from successfully immunized mice were
fused with SP2/0 murine myelomas using polyethylene glycol. Hybridomas were
screened with an enzyme linked immunosorbent assay (ELISA) using keyhole
limpet hemocyanin (KLH) linked Ama monopeptide.
In principle, monoclonal antibodies are very specific. In reality they can
cross-react with similar epitopes. This is in part related to the degree of uniqueness
of the epitope to which the antibodies react as can be seen by the following
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reasoning. Antibodies generally recognize a sequence of 7 amino acids in an epitope
(Sternberger 1986). An identical sequence of seven consecutive amino acids is rare
among unrelated proteins. Assuming a totally random sequence of amino acids in a
seven amino acid peptide, there are (20)7 or 1.28 x 109 possible primary sequence
variations. There also may be differences in the tertiary and quaternary structures
of peptides of a given sequence due to allosteric effects of flanking and spatially near
amino acids, further increasing the possible number of epitope variations. From a
theoretical standpoint, the more amino acids in a peptide sequence recognized by an
antibody, the less likely a monoclonal antibody is to cross-react with another
epitope. This anti-AmaSyn antibody was derived to a synthetic epitope that
contained one amino acid (Ama) and a spacer giving it the approximate length of a
six to seven amino acid peptide. The reactivity of the antibody proved to be specific
for the Ama (monopeptide) epitope. Since this single amino acid reactivity provides
a theoretically higher cross-reactivity, an antibody which reacted to a naturally
occurring Ama-epitope (about 7 amino acids) was needed for greater specificity.
Ama is a minor alpha amino acid constituent found in both eukaryotic and
prokaryotic organisms (Van Buskirk et al. 1984). Foam cells, the tissue possessing
the most Ama found to date, contain only 4-20 Ama residues per 1000 Gly residues
(Wheelan et al. 1989). This suggests that the number of proteins containing Ama is
small. Theoretically, this decreases the number of cross-reacting proteins,
enhancing the feasibility of isolation of specific proteins containing the Ama epitope.
These proteins can be isolated using the anti-AmaSyn antibody, which in turn can be
used as a primary antigen to generate antibody to naturally occurring Amacontaining peptides.
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Ama is present in some pathological tissues, and it has been speculated that
Ama may play a role in the pathology of those tissues. It would be useful to have a
specific antibody for Ama. Since Ama may be found in different epitopes, it would
not be expected that an antibody made to a single naturally occurring Ama epitope
would necessarily cross-react with another naturally occurring epitope also
containing Ama. Therefore, by making an antibody to a naturally occurring epitope,
one might be sacrificing a more broadly reacting (to the Ama epitope) antibody for
one more specific.
Once the value of a more specific antibody to a naturally occurring Ama was
realized, different tissues and cell lines were tested to determine whether they
possessed Ama-containing epitopes. This chapter describes the testing of the cell
lines. (Tissues tested were listed previously in Table I.)

Methods
The methods described in this section are detailed in Appendix B. Briefly,
K-562, L-1210, MOLT-4, A-427, BT-20, Caco-2, CEM-CM3, DU-145, and PC-3 cells
were tested for reactivity with the anti-AmaSyn antibody by one of three methods
(Table II). One method, the cellular ELISA (cELISA), involves modification of an
indirect ELISA to use whole cells as antigen and anti-AmaSyn as first antibody.
A second method, light microscopy, involves a similar two-step binding of
anti-Amasyn antibody to cells, followed by binding of a fluorescein labeled anti-IgG
second antibody. Analysis was conducted with fluorescent microscopy and graded on
a four tier system based on a semi-quantitative assessment of fluorescence
intensity.

63

Table II. The tissues of origin are contained in parenthesis for the carcinoma cell
lines. None of the cell lines tested displayed observable binding with anti-AmaSyn
using light microscopy. Cellular ELISA (cELISA) showed that several of the cell
lines (Caco-2, CEM and DU-145) displayed an optical density of at least 0.100 greater
than the background control. Flow cytometry indicated that the CEM and DU-145
cells had anti-AmaSyn reactive epitopes as expressed by a significant shift in the
intensity of fluorescence of the anti-Amasyn treated cells over the irrelevant
antibody control treated cells. An "*" indicates that the test was not performed.
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Table II

Immunocytochemical Screening of Cell Lines with Anti-AmaSyn

Cell lines
K-562 (leukemia)
L-1210 (leukemia)
MOLT-4 (leukemia)
A-427 (lung cancer)
BT-20 (breast tumor)
Caco-2 (colon cancer)
CEM-CM3 (leukemia)
DU-145 (prostate cancer)
PC-3 (prostate cancer)

cELISA

immunofluorescence
Light Microscope Flow Cytometry

*

*

*

*

*

*
*

*

*

*

+/+
+/-

*

*

*

*

*

+
+
+/-
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Flow cytometry was used as a third method and was accomplished with a
direct labeling of the cells using fluorescein conjugated anti-Amasyn antibody. The
amount of binding of the antibody was measured by the intensity of the
fluorescence emitted at 515 nm to 545 nm after an excitation at 488 nm. An
increase in this fluorescence over the fluorescence of cells only (autofluorescence),
or cells plus a FITC labeled isotype control, indicated specific binding of the antibody
to the cells.

Results
Nine different cell lines were tested for their reactivity with the anti-Amasyn
antibody (Table II). A colon carcinoma cell line (Caco-2), and a prostatic carcinoma
cell line (PC-3) tested weakly positive. An adult leukemia cell line (CEM-CM3), and
another prostatic cancer cell line (DU-145) tested strongly positive with anti-AmaSyn
antibody.
Flow cytometric analysis of DU-145 cells stained with anti-AmaSyn F(ab')2
fragments conjugated to FITC revealed a substantial positive shift in the intensity of
fluorescence over cells incubated with FITC labeled anti-keyhole limpet hemocyanin
antibody or no antibody (Figure 2.1).

Discussion
In an effort to find a suitable naturally occurring Ama epitope, various assays
were employed to screen cell lines. An indirect immunofluorescence assay with
detection by light microscopy was used initially but was eventually abandoned due to
its semi-quantitative values, partial subjectivity and limited sensitivity.
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Figure 2.1. Flow cytometric analysis of DU-145 cells stained with anti-AmaSyn.
2 x 106 DU-145 cells were incubated with 20 jxL FITC-labeled anti-AmaSyn in 80 nL
PBS (—), 20 p.L of FITC-labeled anti-KLH (IgG2a isotype control) in 80 pL PBS (• • •),
or 100 pL PBS (—). The cells were analyzed on a FACS.
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Cellular ELISA (cELISA), a modified indirect ELISA using whole cells as
antigen targets, is a more reliable test. This proved to be adequate as a "first pass"
screening test for presence of an anti-AmaSyn reactive epitope; however, the
possibility of false negatives was present due to cells becoming dislodged from the
wells during wash cycles. A commercially-available cellular adhesive (Cell-Tak)
designed to anchor cells to the well proved of little value since the anti-Amanat
antibody bound to the adhesive, causing the signal (specific binding of the antibody
to the epitope) to become lost in the noise (non-specific background staining).
Initially, cells were non-enzymatically detached to prevent critical epitope
degradation and then plated in a 96-well plate for the cELISA. A major drawback of
this method was the poor binding of the cells to the plate surface. This binding
problem was addressed by growing the cells directly in the plate even though a
fraction of cells were unavoidably aspirated during the wash step. This
disproportionate binding of the cells was further complicated by the fact that tested
cell lines grew at different rates, making a direct comparison of anti-AmaSyn binding
between them difficult. Despite these inadequacies, this test proved useful as a
screening tool to determine the anti-Amanat reactive cell lines for further study by
more sensitive and quantitative methods.
Flow cytometry screening was carried out using direct labeling, with two cell
lines, DU-145 and CEM-CM3, showing the best binding by the antibody. Since
previous work had suggested that the Ama epitope may play a role in metastasis by
being an important component of a tumor adhesion molecule, DU-145 (an
adenocarcinoma) was selected over CEM-CM3 (a T-cell leukemia line) for further
study.
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An extensive literature review indicated that the DU-145 cell line had several
features that made it a suitable choice for this study. First, since the eventual goal of
this line of research is to develop a means for blocking human metastatic disease,
the cell line studied should be of human origin. Furthermore, the cell line selected
must be able to grow in an animal model as well as in an in vitro system and the
disease should represent a challenging and unsolved clinical problem.
The DU-145 cell line is an extensively studied human prostate
adenocarcinoma grown easily in nude mice and in vitro (Mickey et al. 1977).
Prostate cancer is the second leading cause of cancer death in men, killing 33,000
every year. As men live longer, an even greater incidence of this disease is not
unlikely. The metastatic disease has no cure, and the primary disease has a good
prognosis only if caught early, which has proved difficult. Fortunately, the
pathophysiology of this disease is fairly well understood. Thus for the scope of this
research, prostate cancer provides an ideal model.
There are six human prostate cell lines which can be grown in vivo. Three
of these, DU-145, PC-3 and LNCaP, have been extensively studied. These three cell
lines all can be grown in vivo in nude mice. Of these, only LNCaP is a primary
carcinoma which behaves similarly to a primary prostate carcinoma in a human. It
is androgen sensitive and dependent. At first it would seem that this would be the
ideal line to work with. Indeed, for the understanding of the disease
pathophysiology, it may be the best model currently available.
However, it was felt that because an antibody to a metastatic phenotype was
desired, a cell line that was taken from a metastatic site would be more suitable.
DU-145 and PC-3 both display insensitivity to androgen (typical of the metastatic
phenotype), but PC-3 has an apparent advantage because of its ability to metastasize
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in vivo. This was not demonstrated in the DU-145 cell line when it was transplanted
ectopically in nude mice (Mickey et al. 1977), but, as Stephenson et al. (1992)
showed, ectopic placement of human prostate cancer cells does not permit the
metastatic phenotype, whereas orthotopic placement of the cancer produces a
metastatic spread. In any case, a metastatic model similar to that reported by
Shevrin et al. (1989) can be made by intravenous administration of the DU-145 cells
in nude mice, followed by examination of the surface of the lung for foci of
metastasis in three weeks. Therefore it seemed that either cell line would be
adequate for the scope of this study.
The final selection criteria included cell culture conditions and the apparent
amount of antigen on the cells. The DU-145 cells had a clear advantage because of
their ease of tissue culture passage. They can be passaged using trypsin or a nonenzymatic (EDTA based) method. The PC-3 cell line is passaged using trypsin and
collagenase, creating conditions that may alter surface antigens. (This fact may
explain why flow cytometric analysis of anti-Amanat incubated PC-3's failed to show
any large shift in fluorescence as compared with cells without antibody.)
Thus, since one of the goals of this study is to produce an antibody to an Ama
containing epitope, presumably on the cell membrane, and since alternate models
for inducing the metastatic phenotype are available for this line, the DU-145 cell line
was felt to be the best choice currently available for antigen purification.
The DU-145 cell line was derived from a prostatic carcinoma metastasis to the
brain of a 69-year-old white male who had been undergoing diethylstilbestrol (DES)
therapy (Mickey et al. 1977; Stone et al. 1978). The fact that this cell line was derived
from a brain metastasis removes many criticisms of cell lines derived from the
primary site which may contain normal cells and hyperplastic benign cells, as well as
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various clones of malignant cells. Without markers to separate such cells it is
impossible to accurately define the cell line. Since the derivation of this cell line was
from a brain metastasis, the only malignant cells present should be of prostatic
origin. Other tests to confirm prostatic origin included histologic comparison with
the primary carcinoma, confirmation of epithelial origin, and testing for the
production of prostatic acid phosphatase (Stone et al. 1978).
This line is generally considered hormone independent and hormone
insensitive (Stone et al. 1978; Tilley et al. 1990). Studies by Stone et al. (1978)
showed that the DU-145 cells grew equally well in medium containing either fetal
calf serum or bull serum. Since these sera differ significantly in their hormonal
make-up, it was reasoned that the DU-145 cells were hormone insensitive. Tilley et
al. (1990) reported that DU-145 cells contained no detectable levels of androgen
receptor (AR) protein and only small amounts of AR message, yet the study found
that the AR gene did not have any large deletions or rearrangements. However,
using a more sensitive test, Castagnetta et al. (1990) was able to show that DU-145
cells do contain both nuclear and cytoplasmic AR. This was confirmed by Sicca et al.
(1991). Thus it appears that DU-145 cells do contain androgen receptors although in
lower numbers than LNCaP cells (Castagnetta et al. 1990). The androgen
insensitive phenotype of the DU-145 cells may be due to a mutation in the gene
coding for the AR similar to that described by Brinkmann et al. (1991). The DES
therapy may have selected for cells that were hormone independent; therefore, it is
likely that this cell line depends on the androgen independent pathway for cell
growth as concluded by Kim et al. (1991).
DU-145 cells express the epidermal growth factor (EGF) receptor to which
both EGF and transforming growth factor alpha bind (Pai et al. 1991). Suramin,
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which blocks growth factor binding, inhibits DU-145 cell growth (Knabbe et al.
1991), suggesting a growth factor dependent phenotype. These cells also display
significant levels of high affinity transferrin receptor versus a negligible amount
detected in prostatic resections of patients with benign prostatic hypertrophy (Keer
et al. 1990). Increased amounts of both types of receptors have been associated with
cancer cells.
This cell line secretes a small amount of prostatic acid phosphatase but no
prostate-specific antigen (Stone et al. 1978). In a radioimmunoassay, we tested cell
conditioned media as well as cell lysate and confirmed that the DU-145 cells produce
no detectable PSA (less than the 0.15 ng per ml sensitivity of the test). This cell line
displays some plasminogen activator activity which has been associated with invasion
and metastasis (Keer et al. 1991). In fact, urokinase, a plasminogen activator
protease thought to play a role in invasiveness, is secreted by DU-145 cells in
significant amounts (Hoosein et al. 1991). Metaloproteinase, another protease
associated with tumor invasiveness, was not detected in DU-145 cells (Pajouh et al.
1991). In vivo invasion assays confirmed that DU-145 cells display a highly invasive
phenotype (Hoosein et al. 1991).
Karyotype analysis showed a near triploidy with several characteristic
chromosome markers, including three long acrocentric marker chromosomes,
several minute chromosomes, and a Y chromosome bearing a translocation (Stone
et al. 1978). The aneuploidy of this cell line is generally associated with a more
aggressive, metastatic potential than a diploid tumor in vivo (Fair 1992). It has a
defective retinoblastoma (Rb) gene with a stop codon in exon 21, yielding an
abnormal gene product (Rubin et al. 1991). Its p53 gene contains a mutation in a
highly conserved region (Issacs 1991).
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These general characteristics of the DU-145 cell line indicate a prostatic cell
line that has a definite metastatic phenotype. The proteins secreted by this cell line
and those found in or on this cell line not only aid in the understanding of the
disease process caused by this cell, but may also provide additional therapeutic
avenues with regard to the adhesion-blocking therapy proposed by this research.

III. THE PRODUCTION AND CHARACTERIZATION OF MONOCLONAL
ANTIBODIES TO A NATURAL AMINOMALONIC ACID EPITOPE

A. Antibody Production

Introduction
The actual protocol for producing monoclonal antibodies varies from lab to
lab, but the general theory for the procedure remains the same (see Figure 1.9).
First, an antigen source must be selected. The antigen can be anything from an
amino acid or peptide linked to a hapten-carrier to a whole cell preparation. Next,
the antibody producer is chosen. The murine system provides an excellent
selection as 1) there are many mouse fusion partners available, 2) all the necessary
isotyping antibodies are readily available, 3) it is a mammal with a well-studied
immune system, and 4) the parameters for maximum immune stimulation have
been well-defined. The designated antigen must be administered to the animal,
with booster doses spaced 2-3 weeks apart. The first few injections may be given
i.p. and subcutaneously (s.c.), with the final boost given i.v. 2-5 days before the cells
are harvested to ensure maximal stimulation of appropriate plasma cells. Cells are
then immortalized by one of several methods, including EBV transformation or
fusion with an immortal cell line. The fusion (hybridoma production) generally
involves taking plasma cells from the spleen and/or other lymphocyte-rich tissue
(e.g., lymph nodes) and fusing them with an immortalized mutant cell line, usually a
myeloma. A fusion can be accomplished by a variety of methods, including
electrofusion or chemical fusion with polyethylene glycol (Harlow and Lane 1988b).
The fusion partner cell line typically has been grown in 8-azaguanine which is
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incorporated into the DNA of all cells containing an intact purine salvage pathway,
mediated by the enzyme hypoxanthine ribosyl transferase (HPRT). The
incorporated azaguanine is toxic to the cells and thus selects for only the HPRT
negative mutants, a spontaneous mutation which occurs at a relatively high
frequency of 1 in 107 cells (Harlow and Lane 1988b). When these HPRT negative
mutants are fused with the wild type lymphocytes, three types of fusions may
occur: 1) a normal lymphocyte may fuse with another normal lymphocyte yielding a
fusion cell without immortal genes necessary for survival, 2) an HPRT negative
mutant cell may fuse with another mutant cell possessing the ability to live forever
in culture, but is eventually selected out when grown in aminopterin (which blocks
de novo purine and thymidine synthesis, leaving only cells with intact purine salvage
pathways capable of making DNA and therefore living), and 3) a normal lymphocyte
and an HPRT negative mutant cell fusion. This hybridoma is the desired fusion and
is the only one living after one week in the selective culture medium.
The next task is to screen the successful hybridomas for production of
specific antibody against the antigen of interest. This can be done by many
methods, but ELISA is the most commonly chosen method, due to its ease of use
and high sensitivity. Other factors that need to be considered when screening are
relative growth properties of the hybridomas as well as class of antibody produced.
Most antibodies produced are either IgM or IgG. IgG antibodies, in general, are
easier to purify and more specific than IgM, but subclass may be critical with regard
to effector function or other physical characteristics such as size and target tissue.
(Only some classes of antibody can cross the blood-brain barrier or placenta, or be
excreted, for example). The next step is to clone the selected hybridomas to
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ensure identity of all antibodies produced (monoclonal). This may be accomplished
by limiting dilution resulting in only one cell per culture plate well.
Once the clone has been grown in sufficient quantities (liters), usually in
serum-free or protein-free media, the antibody can be purified from the
supernatant. For IgG, this process can be as simple as running the supernatant
through a chromatography column containing beads with protein A, a protein from
Staphylococcus aureus which has an affinity for the junction of the Ch2 and Ch3
domains of IgG (Lancet et al. 1978). The antibody binds to the column while the
remaining supernatant proteins wash through. The antibody is then eluted and
lyophilized or frozen for storage.

Methods
The methods for antibody production and purification are described in detail
in Appendix B. Briefly, eight BALB/c mice were immunized with the DU-145 Ag
(defined as the distinct set of proteins specifically bound by the anti-Ama
immunoaffinity columns) from anti-AmaSyn immunoaffinity chromatography in
RIBI’s adjuvant i.p. and s.c. on days 1, 22, 43, and 64. On day 73, sera obtained from
the mice were tested for reactivity with the BSA-Ama (monopeptide) molecule by
ELISA. The mice producing antibodies with the highest and third from highest
reactivity with BSA-Ama were boosted with i.v. administration of DU-145 Ag on day
85 and killed on day 90. ( The second and fourth highest reactive antibody producers
were reserved for repeat fusion if needed.) Polyethylene glycol-induced fusion of
NS-1 mouse myeloma cells with mouse splenocytes was accomplished as described
by Harlow and Lane (1988b). The resultant hybridomas were selected in HAT
media, and screened by ELISA for reactivity to DU-145 Ag and BSA-Ama, and non-
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reactivity with BSA. Selected hybridomas were cloned and their supernatants
assayed for antibody isotype. An antibody from an IgG producing hybridoma clone
was purified using protein A affinity chromatography. Selected hybridomas were
stored at -195°C.

Results
The fusion efficiency, defined as the number of wells containing a hybridoma
divided by the total number of wells times 100%, was approximately 75%; however,
the fusion efficiency for the fast-growing, single-population-per-well hybridomas
was 16.8%. Only these latter hybridomas were screened for appropriate antibody
production. Ten days after the fusion, 169 hybridomas were screened by ELISA for
reactivity with the DU-145 Ag. ELISA-positive clones were defined as those
producing antibody into the supernatant which, when introduced as first antibody in
an indirect ELISA, produced an optical density at 410 nm of greater than 0.150. Of
the 41 DU-145 positive hybridomas, 14 remained positive when screened for
reactivity with BSA-Ama but not BSA. Twelve days after the fusion an additional 202
hybridomas were screened. Of this second screening, 20 hybridomas bound to the
DU-145 Ag and 4 of those bound to BSA-Ama but not BSA.
Of these 18 doubly-positive hybridomas, five stable hybridomas were
observed (Table III). The antibodies produced by these hybridomas were isotyped
as IgGi Kappa (hybridoma 22E6, 11B5, and 3D3) and IgM Kappa (hybridoma 22B8
and 10D11).
The hybridomas which produced antibodies displaying the highest reactivity
for the BSA-Ama molecule (22E6 and 23B8) from each antibody class (IgG and IgM,
respectively) were subcloned. Of 26 single population, fast growing subclones of
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Table III. When the cells were first weaned from HT media, some of them stopped
producing antibodies and were discarded. The clones producing antibodies with the
highest reactivity to both BSA-Ama and anti-AmaSyn antibody-reactive DU-145
antigen were subcloned (22E6 and 22B8).
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Table III

Isotypes of Anti-Ama Antibody Producing Hybridoma Clones

Clone

Isotype

Comments

22E6

IgGi Kappa

Best IgG; Subcloned

11B5

IgGi Kappa

Not subcloned

3D3

IgGi Kappa

Not subcloned

16D7

IgM Kappa

Discarded; best IgM; stopped producing Abs

22B8

IgM Kappa

Next best IgM; Subcloned

22B2

IgM Kappa

Discarded; stopped producing Abs

10D11

IgM Kappa

Not subcloned
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the IgGi-producing 22E6, 8 bound to BSA-Ama and 3 of those bound to DU-145 Ag.
One of these doubly-positive subclones stopped producing antibodies and was
discarded. Of 42 single population, fast growing subclones of IgM-producing 23B8,
screening by ELISA for BSA-Ama reactivity revealed 12 positives which also bound
to DU-145 Ag. The three IgM clones showing the greatest reactivity with the BSAAma and DU-145 Ag as well as the two doubly positive IgGi clones were stored at
-195°C.
The IgG subclone most reactive with BSA-Ama was cultured in liter
quantities in serum-free media for the purpose of antibody purification. This
purification was accomplished using protein A affinity chromatography (Figure 3.1).
The monoclonal nature of the antibody was confirmed by ion exchange
chromatography (Figure 3.2). While it is not generally possible to separate different
IgG fractions using ion exchange, with a linear gradient, it is likely that a polyclonal
antibody would produce an asymmetrical peak. The single symmetrical peak also
indicates a single population of whole antibody with no evidence of degradation.

Discussion
The antigen injection protocol for this study was altered to include more
booster injections than usual. This change was undertaken to address two concerns.
First, the anti-Ama reactive antigens were of unknown antigenicity. Since Ama had
been found in commonly occurring diseased states in different species, it was
theorized that the murine immune system might not recognize the Ama epitope as
foreign. (Indeed, of the eight mice injected, sera from four produced little
detectable binding to BSA-Ama.) Therefore a conservative regimen including more
injections was chosen.
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Figure 3.1. Protein A affinity chromatography of anti-Amanat- One liter of
supernatant from the 22E11 IgGi producing clone was applied to a protein A affinity
column at 0.3 ml per minute. The column was then washed to baseline at 2 ml per
minute with PBS (first absorbance peak) and then the bound antibody was eluted
with 0.1 M citrate buffer, pH 5.0 (second absorbance peak).
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Figure 3.2. Ion exchange chromatography of anti-Amanat- A 1 mg sample of antiAmanat was added to a Mono Q 5/5 anion exchange column. An increasing linear
gradient of NaCl in Tris buffer, pH 8.0, eluted all the bound antibody at a
concentration of about 0.3 M NaCl at a flow rate of 1.0 ml per minute. The
absorbance was measured at 280 at a sensitivity of 1.0 and charted against time. The
chart speed was 0.5 cm per minute.
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Second, an antibody with high specificity for the Ama epitope was desired.
More injections of antigen over a longer period should theoretically increase
specificity since the immune system first produces less specific IgM antibodies and
then responds over time with increasingly more specific IgG antibodies. In fact, of
18 hybridoma colonies isotyped, there were 11 IgG producers and 4 IgM producers
with 3 producing both types of antibodies which bound to DU-145 Ag, lending
support to this rationale. However, of the stable antibody producers, this ratio
dropped to 4 IgGi to 3 IgM. [Initial instability of hybridoma gene product is
common as they often destroy or inactivate genes from either of the two parental
cells (Coding 1983d). In the case of monoclonal antibody production, the only genes
whose stability is critical in living hybridomas are ones coding for antibody
production. Thus it is expected that some initially promising hybridomas may have
to be abandoned due to cell death or termination of antibody production.]
The fact that there were no overt signs of pathology observed in the mice,
both during the 90-day immunization period and at autopsy, suggests that this
antibody does not react with a public normal cell epitope in BALB/c mice. While this
is not conclusive evidence of non-reactivity, it is important to note that the
substantial reactivity of the sera from immune mice for BSA-Ama resulted in part
from known C' binding classes of antibodies as well as antibodies capable of inducing
antibody-dependent cellular cytotoxicity. This non-reactivity with normal tissue is
important if this antibody is to be used therapeutically.
One interesting point is that all the antibodies isotyped were either IgM or
IgGi. This correlates well with the isotypes observed from a fusion of plasma cells
generated by using BSA-Ama as a primary antigen (Kirsch et al. 1989). IgM
antibodies are the first class of antibodies secreted to a foreign antigen. IgGi
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antibodies, generated by constant region gene rearrangement known as class
switching, are also associated with complimentarity determining region
rearrangements compatible with increasing specificity (Nossal 1992). The
observation that all isotyped antibodies contained a kappa light chain is consistent
with the fact that 95% of murine antibodies have a kappa light chain (Benjamini and
Leskowitz 1988).
The antibodies were screened first for binding to the DU-145 Ag; those which
displayed significant binding were then tested for binding to BSA-Ama and BSA.
Those clones producing antibodies which bound to both DU-145 Ag and BSA-Ama,
but not to BSA, were selected. The first step of this two step screening method
allowed the determination of clones which produced antibodies to the native DU-145
Ag (from anti-AmaSyn immunoaffinity chromatography) containing the anti-AmaSyn
reactive epitope. The second step involved the elimination of all but the Ama
epitope-reactive antibodies by screening against BSA-Ama and BSA. This method
allowed selection of antibodies specific for the putative Ama epitope contained by
DU-145 cells.
Thirty-percent of the antibodies which reacted to the DU-145 Ag also reacted
to BSA-Ama. This high percentage indicates that one of the predominant epitopes
on the DU-145 antigen is the Ama epitope. It could be that this epitope was the
most foreign, and therefore the most immunogenic. This is consistent with the
possibility that the Ama epitope may be an “altered-self antigen, typical of cancer
cells. This altered state may be in part due to a cancer cell associated posttranslational modification yielding Ama.
This section shows the production of an antibody which binds to an anti
Amasyn reactive protein from DU-145 cells as well as BSA-Ama but not BSA. The
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characterization of the antibody is the topic of the remainder of this chapter. This
Ama reactive antibody can be used to isolate protein from the DU-145 cells for
characterization (Chapter IV).

B. Antibody Binding Kinetics

Introduction
The determination of true affinity constants of antigen-antibody complexes
by an indirect ELISA was pioneered by Friguet et al. in 1985. This method has
several advantages over more traditional methods of ascertaining the dissociation
constant, including speed of assay, availability of materials, low cost, low amounts of
antigen and antibody required, and most importantly, no requirement for labeling
of either the antigen or the antibody. This is important because binding of marker
molecules to antigen or antibody can alter its binding characteristics and invalidate
subsequent tests.

Method
The method described in this section is detailed in Appendix B. Basically, the
affinity constants for the binding of anti-Amasyn to BSA and anti-Amanat to the
DU-145 Ag from anti-Amanat (WMK-I) immunoaffinity chromatography were
determined by indirect ELISA. Briefly, the antibodies were incubated with various
amounts of antigen. The binding was allowed to come to equilibrium with an
18 hour incubation at 20°C. The antigen-antibody mixture was then added to wells
previously coated with antigen for determination of amount of unbound antibody.
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After an appropriate incubation period, a labeled second antibody was added,
followed by substrate addition, and the optical density was read.

Results
As shown by Friguet et al. (1985), an antibody concentration which is not
saturating is necessary for the determination of the true affinity constant. This
concentration was determined by an indirect ELISA measuring the binding of antiAmaSyn and anti-Amanat to BSA-Ama (monopeptide) coated plates (Figure 3.3).
From these data, concentrations of 1.1 X 10’9 M and 2.5 x 10'8 M respectively for
anti-AmaSyn and anti-Amanat antibodies were chosen for use in the competitive
assay. These concentrations are non-saturating and in a linear portion of the binding
curve, making them suitable for use in the competitive ELISA.
A /fd of 3 x lO-7 M of the binding of anti-AmaSyn to BSA-Ama was determined
(Figure 3.4) and an dissociation constant of 4 x lO-8 M for the binding of anti-Amanat
to the DU-145 Ag was calculated (Figure 3.5).

Discussion
In order to determine the true affinity constant for the antigen-antibody
reaction, both the antigen and antibody must be in the same phase. The traditional
ELISA method directly measures the interaction of antibody with immobilized
antigen thereby yielding only a relative affinity constant which cannot be
extrapolated to the true affinity constant (Friguet et al. 1985). In the competitive
binding assay described in this section, the antigen-antibody reaction is allowed to
come to equilibrium in liquid phase and the amount of unbound antibody is
measured with the traditional ELISA. This assay requires a non-saturating
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Figure 3.3. Determination of appropriate antibody concentrations for the
competitive ELISA measurement of antibody dissociation constants. ELISA was
performed as described in text with BSA-Ama as antigen and various concentrations
of anti-AmaSyn antibody and anti-Amanat antibody. The arrows correspond with the
concentration of antibody chosen for the competitive study. The concentrations are
1.1 x 10'9 M for the anti-AmaSyn antibody and 2.5 x lO-3 M for the anti-Amanat
antibody.
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Figure 3.4. Scatchard plot of anti-Amasyn binding to BSA-Ama. A competitive
ELISA was performed as described in text. BSA-Ama was incubated with antiAmasyn antibody for 12 hours and the amount free antibody determined by an
indirect ELISA. The dissociation constant of anti-Amasyn was determined to be
3 x 10-7 M.

Figure 3.5. Scatchard plot of anti-Amanat binding to DU-145 Ag. A competitive
ELISA was performed as described in text. DU-145 Ag was incubated with antiAmanat antibody for 12 hours and then the amount of free antibody was calculated
by an indirect ELISA. The dissociation constant of anti-Amanat was determined to be
4 x 10-8 M.
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concentration of antibody so that the concentration of free antibody will not be due
to excess antibody but directly related to the affinity constant. The absorbance is
thus directly proportional to the amount of free antibody so that,

L =A
io

(1)

Ao

where i is the amount of free antibody, i0 is the total amount of antibody, Aq is the
absorbance of antibody alone (representing peak absorbance) and A is the
absorbance produced by free antibody from the antigen-antibody mixture. This
equation will only be valid if no equilibrium adjustment in the liquid phase of the
antigen-antibody mixture occurs in the antigen coated wells.

Ag + Ab <—> Ag/Ab

(2)

By binding some of the free antibody, one can see that the reaction would be driven
to the left, freeing more antibody to bind to solid phase antigen and resulting in an
artificial inflation of the apparent amount of free antibody. To study whether any
significant equilibrium adjustment takes place, the antibody was incubated at 20°C
for 60 minutes in antigen coated wells in Immulon IV plates and transferred into a
second set of coated wells. This enabled the determination of the amount of f (free
antibody) by antigen. The optical density of the first and second set of wells
mentioned above are Ai(c) and A2(c), respectively.

f = AjJc) - A9(c)
Ai(c)

(3)
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Using this equation, it was determined that more than 95% of the free antibody
remained unbound, showing that there was no significant displacement in the
antigen-antibody equilibrium.
Therefore, since the validity of equation (1) has been proven, the
concentration of bound antibody (x) and free antigen (a) at equilibrium can be
calculated as follows:

(4)

x = io - i

a = ao - x

where ao is the total concentration of antigen, and i0 and i are the total and the free
antibody concentrations, respectively.
The Scatchard equation (Scatchard 1949) for determining the dissociation
constant can be written as follows:

X = L (io-x)
a Kd

(5)

From equation (1), x and a can be expressed as:

(6)

x = i0 x

Ao
a — 3o ■ i© x An - A

Ao
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Thus the Scatchard equation can be expressed as follows:

An
a© - i©x Aq ~ A

(7)
KD

Ao

Ao

Using data obtained from a modified ELISA, the dissociation constant can be derived
from this equation.
As can be seen from the Scatchard plots, the antibody binding renders a good
fit to a straight line with the extrapolation of that line to 0 ordinate close to 1 and a
kD of 3 x 10'7 M for anti-AmaSyn with BSA-Ama (Figure 3.4). The binding of antiAmanat to DU-145 Ag requires a relatively high concentration of antibody. Since this
competitive assay requires a higher concentration of antigen than antibody and since
only a limited amount of antigen was available, an approximation of the affinity
constant was obtained with several data points. The affinity constant of the binding
of anti-Amanat to the DU-145 Ag was determined to be 4 x lO-8 M (Figure 3.5).
These affinity constants are similar to those reported for other antibodies (ranging
from 10‘6 M to 10'10 M) and indicate a relatively high affinity of the antibodies for
their respective antigens (Coding 1983d). Other researchers have reported
dissociation constants of 2.1 x lO-8 M for antibody to y-aminobutyric acid (Seguela et
al. 1984), 1.29 x lO-8 M and 3.6 x 19‘9 M for two antibdies to the p2-subunit of E. coli
tryptophan synthase (Friguet et al. 1985), 1.8 x lO-8 M for an antibody to DNA
polymerase-p (Recupero et al. 1992) and 1.6 x 10‘8 M for an antibody to a
glycoprotein associated with malignant proliferation of mammary epithelial cells
(Imam et al. 1991).

96
C. Epitope Specificity--Additivity Studies

Introduction
Antibodies from the five hybridomas [22E6-4E11(WMK-I), 11B2, 3D3, 10D11,
23B8] were assayed to determine whether their respective antigenic binding sites
were unique to a given antibody or cross-reactive with another antibody. This was
carried out by means of the ELISA additivity test, first described in 1983 (Friguet et
al.). The advantages of this test include simplicity, sensitivity, speed and availability.
The principle is quite simple and involves the estimation of competition of the
different antibodies for an epitope. This requires that the antigen be saturated with
each antibody tested. ELISA-generated saturation curves can be used to determine
appropriate dilutions for each antibody. The antibodies can be tested by ELISA at
the given saturating concentrations with equal volumes of two antibodies. The
results are compared with those using one antibody at the same dilution. If there is
a greater optical density with two antibodies than with either antibody alone, this
suggests additivity, indicating the recognition of a unique epitope by each of the two
monoclonal antibodies. If the optical density of the two antibody clones is equal to
that for each clone individually, this suggests that the antibodies compete for the
same epitope on the antigen. This effect can be quantitated by the use of the
additivity index (AI):

AI = [( 2 Ai+2 / Ai + A2 ) -1] X 100

where Ai is the optical density of one clone and A2 is the optical density of another
and Ai+2 is the optical density of the two antibody clones together. With this index
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one can predict that if the antibodies bind to the same site, Ai+2 will be equal to the
mean value of Ai + A2 and AI will equal zero. If the antibodies bind to different
sites, Ai+2 will be equal to Ai + A2 and AI will equal 100.

Methods
The methods described in this section are detailed in Appendix B. Briefly, an
indirect ELISA was completed in which BSA-Ama or KLH-Ama was bound to an
Immulon IV, 96-well plate (Fisher Biotech, Pittsburgh, PA), each at a concentration
of 2 pg per test well. The antibodies tested were anti-Amasyn (Ortho Diagnostics
System Clone #57D4B6G2B11, Raritan, NJ) (diluted 1:5,000), 22E6-4E11(WMK-I)
(diluted 1:50), 11B2 (neat), 3D3 (neat), 10D11 (neat), and 23B8 (neat). The antiAmasyn and WMK-I antibodies were purified while the 11B2, 3D3, 10D11, and 23B8
were unpurified supernatants from their respective clones. The antigens were
bound in the plate overnight in 50 mM carbonate buffer (pH 9.6). The plate was
washed, blocked with 0.05% Tween-80 and 0.25% BSA, incubated 30 minutes and
washed again. Each of the monoclonal antibodies (used as the first antibody) was
added at the given concentrations. After incubation for one hour, the plate was
washed and an alkaline phosphatase labeled second antibody (a mixture of goat anti
mouse IgG 1:1,000 and goat anti-mouse IgM 1:2,000) was added and incubated for an
additional hour. After a final wash, substrate was added and the optical density of the
test wells was read at 410 nm, 15 minutes after adding substrate. All assays were
performed in duplicate.
A parallel assay was performed using the same procedure with the DU-145
Ag from WMK-I immunoaffinity chromatography (Chapter IV) tested against the
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anti-AmaSyn antibody (1.3 x 10'7 M) and the Anti-Amanat (WMK-I) antibody
(1.0 x lO-7 M). The optical density of the test wells was read after 60 minutes.

Results
In order to determine the saturating concentration of antibody necessary for
the additivity test, an indirect ELISA was performed. The ELISA-generated
saturation curves of antibody binding to BSA-Ama indicate that the anti-AmaSyn
antibody (Figure 3.6) was saturated by a dilution of 1:5,000 (2.7 x 10-9 M) while the
anti-Amanat antibody (WMK-I) (Figure 3.7) was saturated by a dilution of 1:50
(2 x 10'7 M). Similar saturation curves were seen by the interaction of various
concentrations of these anti-Ama antibodies with bound KLH-Ama (Figure 3.8).
The saturating concentrations of the anti-AmaSyn and anti-Amanat antibodies
were used in the additivity test. The other antibodies tested were from frozen
hybridoma conditioned media and used neat. The total protein concentration of the
media containing these unpurified antibodies was 200 |!g/ml. All of the antibodies
were partially additive (Table IV) with anti-AmaSyn. The IgM antibodies (10D11 and
23B8) were also partially additive with all antibodies; the three IgG antibodies
(22E6-4E11 (WMK-I), 11B2, 3D3) were not additive with each other.
The DU-145 Ag assay revealed an additivity index (AI) of 57 for the antiAmaSyn and anti-Amanat antibodies. This value is more than the AI of 36 shown for
these two antibodies with the BSA-Ama additivity assay.

Discussion
The reason that the additivity test requires a saturating concentration of
antibody can be most easily explained by showing the theoretical results of a
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Figure 3.6. Saturation binding of anti-AmaSyn to BSA-Ama. An indirect ELISA was
performed using BSA-Ama as antigen and serial dilutions of anti-AmaSyn as primary
antibody. The results indicated a saturation binding of the antibody down to a
dilution of about 1:10,000 (1.3 x 10'8 M) with half binding at about 1:20,000
(6.5 x 10'9 M). The results of two ELISA assays are overlaid.

Figure 3.7. Saturation binding of anti-Amanat to BSA-Ama. An indirect ELISA was
performed using BSA-Ama as antigen and serial dilutions of anti-Amanat (WMK-I) as
primary antibody. The results indicated a saturation binding of the antibody down to
a dilution of about 1:100 (1.0 x 10-7 M). The three curves are the result of different
incubation times with substrate as indicated.
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Figure 3.8. Saturation binding of anti-Ama antibodies to KLH-Ama. An indirect
ELISA was performed using KLH-Ama as antigen and serial dilutions of anti-AmaSyn
or anti-Amanat as primary antibody. The results indicated a saturation binding of the
antibody down to a dilution of about 1:10,000 (1.3 x 10'8 M) for anti-AmaSyn (A) or
1:100 (1.0 x 10’7 M) anti-Amanat (WMK-I) (B), indicating similar binding affinities of
the antibodies for BSA-Ama and KLH-Ama.
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Table IV. The Additivity Index for the binding of the anti-Ama antibodies to
BSA-Ama. This test was accomplished by an indirect ELISA in which one or two
antibodies were incubated in BSA-Ama coated wells. The binding was determined
by the addition of a second enzyme linked antibody and substrate.
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Additivity Index of Anti-Ama Antibodies
Antibody
Clones
Anti-Ama
WMK-I
11B2
3D3
10D11
23B8

Anti-Ama WMK-I
36
PA
PA
PA
PA
PA

N
N
PA
PA

A = Additive (AI = 80-100)
N « Not additive (AI *= 0-20)
PA = Partially additive (AI = 20-80)

11B2

3D3

10D11

23B8

57
3

77
12
3

74
53
40
38

54
52
54
77
30

N
PA
PA

PA
PA

AI =

PA

1+2 _ J

Aj + A2

X100
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non-saturating concentration. For ease of argument, say there are 10 proteins, each
containing antibody binding sites. If two antibodies of type X and two of type Y
were added, the same amount of antibody binding would occur if the antibodies
both bound to the same epitope or to different epitopes. However, if 10 antibodies
of each type were added, a doubling of antibody binding would occur if the
antibodies bound to different epitopes rather than the same.
The anti-AmaSyn antibody displayed saturation binding with BSA-Ama at a
much lower concentration than the anti-Amanat antibody. This result correlates well
with the observed affinity constant of the anti-AmaSyn antibody for BSA-Ama.
Due to the small amount of the DU-145 Ag available, the saturating concentrations
were chosen by testing the binding of the antibodies at relatively high concentration
and then binding them at half that concentration. Saturation was evidenced by the
identical apparent amount of antibody binding at the two different concentrations.
Concentrations of antibody for the DU-145 Ag additivity test were 1.3 x 10‘7 M for
anti-AmaSyn and 1.0 x 10-7 M for anti-AmanatThe results of the BSA-Ama additivity study indicate that there were no
totally additive antibodies made to this antigen. This would be expected as these
antibodies were screened for their ability to bind only to the Ama epitope. Total
additivity would have suggested the recognition of two distinct epitopes. The most
obvious explanation of the non-additivity of the three IgG antibodies is that they
recognize identical epitopes. Yet, their binding sites may merely overlap in the
primary sequence of the antigen, or may be so close in the tertiary structure that
the antibodies sterically compete with each other. In any case, the conclusion
inferred from this non-additivity is that the antibodies recognize at least the same
region of the antigen, if not the same epitope.
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The partially additive antibodies are more difficult to explain. Perhaps the
partial additivity is due to overlapping epitopes or spatially near epitopes that are
limited by steric hindrance. Closer examination of the putative epitope may lead to
an understanding of why these antibodies display partial additivity. The antibodies
bind to BSA-Ama and not to BSA; therefore the epitope must involve the binding of
Ama to BSA. Theoretically, this could be at the junction of the spacer and BSA, on
the spacer itself, or on the Ama monopeptide end of the conjugate (see Figure 1.10).
The anti-Ama syn antibody was tested by ELISA with the BSA conjugated with a
6-amino hexanoic acid spacer used for the original BSA-Ama conjugate. The results
indicated no cross-reactivity with this molecule, which was expected because this
hydrophobic spacer is not a strong antigen. In contrast, the acetyl-Ama-ethylamide
group is strongly immunogenic and allows for hydrogen bonding and ionic
interactions, thought to be the basis for antibody binding (Klein 1990). Thus it is
likely that the different antibodies are each recognizing overlapping portions of this
epitope. This may or may not involve the proximity of the end group to another
part of the BSA molecule or to another end group. However, since only 46 of 59
lysine residues were bound by the conjugate, and BSA is a rather large molecule
(approximately 66 kD; Sigma 1993), it is unlikely that two of the end groups would
be spatially near.
Also, if the end group is in a tertiary position close to charged groups on
another part of the BSA molecule, the end group might be attracted to, or repulsed
by such groups. This may cause the end group to fold over and form an epitope not
found on native BSA. In the unlikely event that this folding is a random occurrence,
the end group on one BSA might bind to different amino acid groups than an end
group linked to the same site on another BSA. Therefore, any one antibody
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recognizing the end group plus an additional sequence of amino acids would not
bind strongly. In fact, even if the association of the end group with a portion of the
BSA is not random but rather dictated by a charged region of the BSA, for example,
it is unlikely that there would be a similarly charged region spatially near all of the
46 sites to which the monopeptide adduct is bound. So it remains most likely that
the antibodies recognize the end group differently.
The different concentrations of the antibodies used in the additivity test
should be addressed. It might seem that because a small amount of anti-AmaSyn
was used, not all of the Ama-containing sites on the BSA were bound and therefore
any other Ama-reactive antibody would be additive with anti-AmaSyn- However, a
concentration of anti-AmaSyn was used which saturated the BSA-Ama, as shown by
ELISA in Figure 3.6. Also, since antibodies of IgG and IgM class were studied, the
second antibody used was a mixture of anti-IgG and anti-IgM. This second antibody
solution was used throughout to control for non-specific binding not only to BSAAma, but also to the antibody of the class to which it is not directed. A control
showed that no binding of the second antibody solution to BSA-Ama occurred.
An alternative approach to cognitive validation of the additivity study is to
determine the theoretical optical density of the two antibodies combined. If there
were no additivity, indicating binding to the same epitope, this should be equivalent
to the sum of the optical densities of half the amount of each bound antibody in the
wells containing antibody alone. (Obviously, addition of half the amount of antibody
would not necessarily result in half the amount of binding, as indicated in Figure 3.6.
In fact, the concentration of antibody binding would be difficult to determine
directly in an ELISA, but since the optical density is directly proportional to the
amount of bound antibody, this can be approximated by taking half of the optical
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density.) If, on the other hand, the antibody demonstrates complete additivity, the
theoretical optical density would be equal to the sum of the optical densities of the
two individual antibodies.
From the results in Table IV, it is evident that the optical density of the two
antibodies combined is more than the sum of half of their individual optical
densities, indicating partial additivity. In addition to the partial additivity observed
between anti-AmaSyn antibody and anti-Amanat antibody for the BSA-Ama antigen,
there is an additivity of the two antibodies for the DU-145 antigens (from an antiAmanat antibody immunoaffinity column), with an AI of 57. This is higher than the
AI of 36 shown by these two antibodies for the BSA-Ama epitope. This can be
explained by the greater variety of epitopes that the natural protein might have
which may contain Ama, compared to the BSA-Ama conjugate, and also by the
assumption that these epitope(s) in the natural protein may contain more than one
amino acid. The anti-AmaSyn theoretically should bind only to the Ama assumed to
be included in the epitope. However, since the anti-Amanat antibody was obtained
by immunization with the DU-145 Ag, it may bind additionally to amino acids
surrounding Ama. This larger binding area would increase the additivity. The lack
of total additivity indicates an overlap of binding sites for the two antibodies, which
would be expected if the epitope contained an Ama to which both antibodies bound.

D. Epitope Specificity—BSA*Amino Acid Conjugations

Introduction
Conjugates close to but different than the original BSA-Ama conjugate (Koch
et al.) were produced for use in binding assays in an attempt to determine the

109
nature of the binding sites for the anti-AmaSyn and anti-Amanat antibodies. These
molecules were produced by a modification of a conjugation method described by
Pierce (1991). Bis(sulfosuccinimidyl) suberate (BS3) is a water soluble
N-hydroxysuccinimide (NHS) ester homobifunctional cross linker which principally
binds to primary amines. Since alpha-amines are seldom available on a protein, the
reaction with side chains becomes important. The net resultis significant binding with
only epsilon amine groups on lysine and available N-terminus amines (Pierce 1991).
The conjugation is accomplished by the acylation reaction of the BS3 cross
linker (Figure 3.9). A competing reaction is the hydrolysis of the BS3, which
increases at a higher pH and in more dilute protein solutions. It is important,
therefore, that the reaction be completed quickly, with relatively high protein
concentrations at a neutral pH. The need to react the BS3 quickly causes some
problems. The quickest method would entail the addition of the BSA, BS3 and
amino acids. The resultant conjugations would include BSA bound to BSA, BSA
bound to amino acid, and amino acid bound to amino acid. The latter conjugation
might be most predominant, since primary amines are the principle targets of the
BS3. However, since the only conjugates suitable for the purpose of this study are
the BSA-amino acid conjugates, some procedural expeditiousness had to be
sacrificed for assurance of product identity.
The method chosen required the initial addition of an excess of BS3 to a
solution containing BSA. This excess of cross-linker assures binding of all the
available lysines, and decreases the amount of BSA bound to BSA. After an
appropriate incubation period (to allow acylation of the epsilon-amines of lysine),
the BSA-BS3 was separated from the excess BS3 by size exclusion chromatography.
(This separation can be accomplished in approximately 10 minutes.) The various
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Figure 3.9. Acylation reaction of BS3 conjugation.
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amino acids (Glu, Asp, Gly and Ama) were added in excess to the BSA-BS3 conjugate.
After another incubation period, any unreacted BS3 molecules on the BSA were
blocked with a vast excess of primary amine-containing buffers such as Tris or
ethanolamine. Finally, the unbound amino acids and blocking buffer were
separated from the BSA-amino acid conjugates by size exclusion column
chromatography.
This technique yields a product which contains epitopes similar to the
original BSA-Ama (monopeptide) molecule. Antibodies can be tested for their
affinity to these altered epitopes, and comparisons of the antibody binding affinities
can yield clues about the specificity of the antibodies for the Ama (monopeptide)
epitope.

Methods
Conjugation with BS3
The methods described in this section are detailed in Appendix B. Briefly, a
350 molar excess of lyophilized BS3 was added to a neutral pH solution containing
BSA at a concentration of 2 mg per ml. The 350 molar excess corresponds to a
concentration of 10 BS3 cross-linkers for every available lysine. After a 30-minute
incubation at 20°C on a rocker, the BSA was separated from unbound BS3 by size
exclusion column chromatography using a UV detector measuring absorbance at
254 nm. A 350 molar excess of free amino acids (Gly, Ama, Asp, Glu) or modified
amino acids (Ama monopeptide, ethyl ester of Ama monopeptide) was added to the
BSA-BS3 conjugate and the mixture incubated at 20°C on a rocker. Any BS3
molecule on the BSA which remained unreacted (by hydrolysis or with amino acid),
was end-blocked by the addition of 0.1 M ethanolamine. As a control, a fraction of
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BS3 bound BSA was not reacted with amino acid but was reacted with either
ethanolamine or Iris during the end-blocking procedure. The resulting BSA-amino
acid (or BSA-Tris) conjugate was separated from the free amino acid and
ethanolamine (or excess Tris) by size exclusion column chromatography. This
conjugate was then vacuum concentrated and used in indirect ELISA.
Indirect ELISA
The methods described in this section are detailed in Appendix B. Briefly,
the BSA-amino acid conjugates were added to an Immulon IV plate (Fisher Biotech,
Pittsburgh, PA) in 50 mM carbonate buffer, pH 9.6. The plates were then incubated
at 37°C for 30 minutes followed by a 16-hour incubation at 4°C. After three washes
with 0.05% Tween-80 in PBS, the plates were blocked with blocking buffer
containing 0.25% BSA and 0.05% Tween-80 in PBS for 30 minutes at 20°C.
Alternatively, the antigens were acid treated with 1.17 M HC1 in blocking buffer and
incubation at 37°C for 1 hour. The plates were then washed as before and the first
antibody, diluted in blocking buffer, was added. After an incubation of 60 minutes at
20°C, the plates were washed as before and an alkaline phosphatase labeled second
antibody, diluted in blocking buffer, was added. After another incubation of
60 minutes at 20°C, the plates were washed and substrate added. The optical density
of the plates was read at 410 nm after an additional incubation.

Results
Separation of the BSA conjugates on a size exclusion column results in a
typical two peak elution profile (Figure 3.10). The first peak contains the BSA and
anything bound to it while the second peak contains smaller molecules which are
chromatographed. Figure 3.10 A displays the separation of the BSA BS3 conjugate
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(first peak) from the excess BS3 (second peak). The remaining peaks (B-D) are the
separations of the BS3-conjugated BSA-amino acids (first peaks) from the excess
amino acids, which do not absorb strongly at 254 nm but are in the vicinity of the
second peak.
These conjugates were then tested by ELISA to determine the specificity of
the binding of anti-Ama antibodies to the various BSA-amino acid conjugates. Figure
3.11 shows the results of several ELISA using the anti-Amasyn and anti-Amanat
antibodies at different concentrations which had been added to the various BSAamino acid conjugates. These results show remarkable specificity of both of the
anti-Ama antibodies for the BSA-Ama (monopeptide). There is cross-reactivity of
both antibodies with certain of the similar epitopes at high concentrations of
antibody (Figure 3.12), but not at lower concentrations.
As additional evidence that the antibodies were specific for the Ama epitope,
an ELISA was performed in which the conjugates and the DU-145 Ag were treated
with acid, which facilitates the decarboxylation of Ama. Thus, if the Ama were an
essential component of the epitope, one would expect that a physical alteration of
Ama would cause a change in the binding pattern of an anti-Ama antibody. An
ELISA was performed in which the antigens (BSA-Ama, BSA-Tris, or the semipurified DU-145 antigen from anti-Amanat immunoaffinity column
chromatography) were treated with acid and compared with untreated epitopes.
The results suggest that the anti-Ama antibody-reactive epitope on BSA-Ama does
not bind antibody as effectively when treated with acid (Figure 3.13). The BSA-Tris
cross-reacting epitope has no such acid-lability and was spared any apparent change
in antibody binding after acid treatment. The DU-145 antigen showed a 7-fold
decrease in anti-Amanat binding after acid treatment.
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Figure 3.11. ELISA of BSA-amino acid conjugates and anti-Ama antibodies (low
antibody concentration). An indirect ELISA was performed with the BSA conjugates
BSA-Tris, BSA-Glu, BSA-Asp, BSA-Gly, BSA-Ama (K) (original Ama monopeptide
conjugate), BSA-Ama (N) (BS3 Ama monopeptide conjugation), BSA-Ama (R) (BS3
ethyl ester of Ama monopeptide conjugation), BSA-Ama (F) (BS3 ethyl ester of Ama
monopeptide conjugation), BSA-Ama (F) (BS3 Ama free amino acid conjugation) and
BSA-Eth (BSA ethanolamine) as antigens. Anti-Amasyn (2.6 x 10'9 M) (A) and antiAmanat (1 x 10"7 M) (B) were added as primary antibodies. The three bars in (A)
denote triplicate tests under identical conditions indicating the good reproducibility
of the test.
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Figure 3.12. ELISA of BSA-amino acid conjugates and anti-Amasyn antibody (high
antibody concentration). An indirect ELISA was performed with the BSA
conjugates BSA-Tris, BSA-Glu, BSA-Asp, BSA-Gly, BSA-Ama (K) (original Ama
monopeptide conjugate), BSA-Ama (N) (BS3 Ama monopeptide conjugation), BSAAma (R) (BS3 ethyl ester of Ama monopeptide conjugation), BSA-Ama (F) (BS3 ethyl
ester of Ama monopeptide conjugation), BSA-Ama (F) (BS3 Ama free amino acid
conjugation) and BSA-Eth (BSA ethanolamine) as antigens. Anti-AmaSyn (1.3 x lO7
M) was added as primary antibody.
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Figure 3.13. Ama-epitope affinity by anti-Ama antibodies decreases after acid
treatment of antigen. An indirect ELISA was performed with BSA-Ama, BSA-Tris
and DU-145 Ag as antigen and anti-Amasyn (1.3 x lO'7 M for BSA-Tris and DU-145 Ag
and 2.6 x 10*9 M for BSA-Ama) (A) or anti-Amanat (1-0 x lO-7 M) (B) added as primary
antibody. The antigens were treated with 1.17 M HC1 in a blocking buffer for 1 hour
at 37°C (crosshatched) or treated with blocking buffer alone for 1 hour at 37°C
(solid). The statistics were generated from a paired T-test.
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Discussion
The result of these conjugations was the production of molecules that
resemble the original BSA-Ama molecule with some important distinctions
(Figure 3.14). The conjugation of BSA with the ethyl ester of Ama-N-ethylamide
produced an epitope that differed from the original BSA-Ama in that the free
carboxylic acid was substituted with an ethyl ester (-COO-CH2-CH2OH). The
conjugation of the saponified ethyl ester of Ama-N-ethylamide produced an epitope
identical to the original BSA-Ama monopeptide distal to the cross-linker. That is, the
ethyl ester was saponified to form a carboxylic acid. The conjugations with free
amino acids produced molecules in which the C-terminal end of the "monopeptide"
had no peptide linkage, equivalent to N-terminal amino acids. In addition, the size
of the spacer for the original BSA-Ama was 17 atoms long, while the spacer for the
BS3 conjugates was 7 carbons long. This shorter spacer should not have a
substantial effect on the binding of the antibodies unless the binding site is in a
"valley" on the BSA molecule, causing steric hindrances to come into play. This
possibility is made more remote by the fact that the spacer is attached to the epsilon
amine of lysine residues, making an even longer spacer (an additional 5 atoms
further from the carbon backbone of BSA). Since both conjugations were done by
binding of spacer to epsilon amine groups of available lysine residues in BSA, the
epitope densities should be similar. In addition, the fact that both the anti-Ama
antibodies bind to the BS3-conjugated BSA-Ama monopeptide in as great or greater
apparent quantities than when binding to the original BSA-Ama monopeptide
conjugation (containing a 17 atom spacer) lends credence to the hypothesis that the
antibodies are not reactive with the cross-linker or, at least, not to the part of the
cross-linker that varies between the two conjugates (Figure 3.14). The observed
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Figure 3.14. Two-dimensional structures of BSA-amino acid epitopes. The
structures of the epitopes are shown for the original conjugation of BSA-Ama
monopeptide (A); or the BS3 conjugations of BSA-Ama BSA-Ama (free amino acid)
(B); BSA-Gly (C); BSA-Tris (D); BSA-ethyl ester of Ama monopeptide (E); or
BSA-Ama monopeptide (F).
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decrease in binding of the anti-Ama antibodies to the original BSA-Ama
monopeptide conjugate may be due to the lability of the Ama epitope over time
(Van Buskirk et al. 1984), since there is no reason to believe that there was a
significant increase in epitope density for the BS3 conjugates. Both conjugations
were to the lysine groups of BSA, and the original conjugation of Ama
(monopeptide) with 46 of 59 lysines on the BSA approaches the number of lysines
available. Thus it could be assumed that any change in binding of antibodies to the
conjugates would be due to the change in epitope shape and not epitope density.
The only structural change in epitope is a change from an amino acid in
peptide linkage, as would occur inside a protein (original BSA-Ama linkage and
BS3-conjugated Ama monopeptide), to an amino acid constructed as it would occur in
the carboxy terminus of a protein (BS3 free amino acid conjugates). Therefore, the
results of the ELISA tests would indicate specificity of the antibody for intra-protein
Ama but not carboxy terminus Ama. It would also indicate that there is little cross
reactivity with any carboxy terminal percarboxylated amino acids. It is evident that
the anti-Amasyn antibody does not cross-react with Ama-like amino acids containing
similar positive charges and carboxylic acid side groups.
The results of the ELISA assay for the specificity of the two anti-Ama
antibodies demonstrate that at a concentration of 2.6 x 10’9 M there was virtually no
binding of the anti-AmaSyn antibody to any of the BSA-amino acid conjugates except
the BSA-Ama (monopeptide) conjugates (Figure 3.11). This indicates that even
though the epitopes may be similar both in shape and charge (with free carboxyl
groups), the anti-AmaSyn antibody is specific for only the Ama (monopeptide)
epitope.
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The binding of anti-Amanat to the various BSA-amino acid conjugates was
accomplished at an antibody concentration of 1 x 10'7 M (Figure 3.11). In contrast to
the anti-AmaSyn antibody, the anti-Amanat seems to be less sensitive yet just as
specific for the BSA-Ama (monopeptide) conjugate. Since the anti-AmaSyn antibody
was produced by using BSA-Ama as the antigen, the increased sensitivity of this
antibody for BSA-Ama is expected.
The binding of anti-Amasyn to the various BSA-amino acid conjugates at an
antibody concentration of 1.3 x lO7 M indicates a decrease in specificity
(Figure 3.12). It is interesting to note that the anti-Amasyn reactivity of
BS3-conjugated BSA-Tris (used to block the unreacted BS3 molecules) was not
significantly different from BS3 conjugated BSA-Gly or BS3-conjugated BSA-Ama
(free amino acid) at this antibody concentration. A similar trend (with less cross
reactivity) was observed in the binding of the anti-AmaSyn to the various BSA-amino
acid conjugates at an antibody concentration of 1.3 x lO-8 M (data not shown).
As suggested by Lane and Kowprowski (1982), the cross-reactivity of a
monoclonal antibody may be due to a structural similarity between two antigens or
due to a multispecific combining site. This cross-reactivity at high antibody
concentrations may be due to an epitope that mimics the internal Ama in a protein.
The BSA-Gly contains a similar free carboxyl group attached directly to its alpha
carbon; the BSA-Tris contains three methyl alcohol groups attached to the
equivalent of an alpha carbon. While BSA-Tris does not have a carboxyl group, the
electronegativity offered by the three hydroxyl groups may afford the antibody
three weakly binding epitopes rather than one strongly binding one. As shown in
Figure 3.13, the epitope generated by these three conjugates is similar, while the
epitopes generated by the less immunoreactive BSA-Asp (free amino acid) and
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BSA-Glu (free amino acid) are more dissimilar.
To further ascertain whether the specificity of the antibodies was due to the
anti-Ama epitope, the conjugates were treated with acid. This acid treatment
promotes the decarboxylation of the Ama to Gly (Wheelan et al. 1989). Figure 3.13
illustrates the results of an ELISA comparing acid treated antigens to untreated
antigens. There is a two-fold decrease in the binding of the antibody to the
BSA-Ama (monopeptide) epitope with no decrease in the binding to the BSA-Tris
epitope. Thus, the decrease in binding can be presumed to be due to the acidlability of the Ama epitope and not due to a total denaturing of the epitope. There is
a two-fold decrease in the binding of the anti-AmaSyn antibody to the acid treated
DU-145 antigen, indicating a possible acid lability of the epitope to which the
antibody binds. This lends credence to the theory that the epitope contains Ama.
The same trend of decreased binding to acid treated antigens is evidenced
with the anti-Amanat antibody. The seven-fold decrease in antibody binding to the
acid treated DU-145 antigen suggests that the antibody reacts with an acid labile
epitope. This, along with the fact that anti-AmaSyn binds to this epitope, suggests
that the epitope may contain Ama, and that Ama in the epitope is, in fact, necessary
for the high affinity binding of the antibody. The fact that the binding of the
antibodies to acid treated BSA-Ama is not decreased to the same extent as it is in the
binding of the anti-Amanat antibody to the DU-145 antigen suggests that there may
be multiple acid labile amino acids in the anti-Ama reactive epitope(s) of the DU-145
antigen. This model supports the theory that this protein may be an adhesion
molecule, because two spatially near carboxylic acids (or similar side groups) are
needed to bind a divalent cation, necessary for adhesion molecule binding to ligand.
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Furthermore, these two carboxylic acids could be provided by two spatially near
aminomalonic acids.

E. Cell and Tissue Binding Studies

Introduction
In order for an antibody to be of value therapeutically, it must bind to its
target with a higher affinity than it does to normal tissues. This selective targeting is
also necessary if the antibody is to be used for diagnostic tests. This section will
detail tests designed to determine 1) if anti-Ama antibodies bind to the human
prostatic adenocarcinoma cell line, DU-145; and 2) if the anti-Ama antibodies bind to
selected normal tissues including prostate. This section will demonstrate that the
anti-Ama antibodies bind to a subpopulation of DU-145 cells, yet do not bind to
normal prostate tissue, other selected normal secretory epithelial tissues, or other
selected normal tissues.

Methods
Immunohistochemistry
The methods described in this section are detailed in Appendix B. Briefly,
fresh breast, cervix, skin and muscle tissues from normal primate, as well as
human prostate tissues from a normal and a benign prostatic hyperplasia biopsy,
were rapidly frozen in supercooled isopentane (-195°C) and 4 to 10 |im sections of
tissue were sectioned and assayed for reactivity with the two anti-Ama antibodies.
Additionally, microscope slides of DU-145 cells (human prostate cancer) were
prepared by cyto-centrifugation and then frozen. Non-specific binding to the
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tissue-coated and cell-coated slides was blocked by addition of sera from the same
species as the source of the second antibody. The sections were incubated with
diluted primary antibody (anti-Amasyn 1-3 x 10’8 M; anti-Amanat 1 x 10-8 M) or PBS
(control), followed by addition of a biotinylated second antibody. A mixture of avidin
and biotinylated peroxidase was added. Addition of diaminobenzidine hydrochloride
resulted in a dark brown color appearing on antibody-bound tissues. The tissues
were then counter-stained with eosin and viewed under a light microscope. All tests
were performed at least in duplicate.
Flow cytometry
DU-145 cells were indirectly stained with anti-Ama antibodies and FITClabeled anti-IgG, then analyzed with a FACScan flow cytometer as described in
Chapter III. DU-145 cell cycle analysis was accomplished by creating a permeable
cell membrane, then staining DNA with propidium iodide as described in Appendix
B. A combined approach of surface and DNA staining was accomplished by
performing indirect surface staining, followed by DNA staining.

Results
Immunohistochemistry
The anti-Ama antibodies did not specifically stain any of the normal tissues.
The hyperplastic benign prostate sections were not bound by anti-AmaSyn or antiAmanat (Table V). The breast and skin sections showed some staining of the
superficial fat layer. The staining was very light in intensity and non-specific, as
evidenced by the staining of sections not labeled with primary antibody. The
epithelium in the skin and breast sections did not stain. Study of the stained breast
sections indicated that the antibodies did not bind to the glandular tissue either.
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Table V. Fresh frozen normal and diseased tissue sections were tested by
immunohistochemical techniques for reactiveity with the anti-Ama antibodies.
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Table V

Immunohistochemistry of Selected Tissues with Anti-Ama Antibodies

Tissue Source
Normal Tissues
Skin (Macaque)
Cervix (Macaque)
Breast (Macaque)
Muscle (Macaque)
Prostate (Human)
Diseased Tissue
DU-145 cells (prostate cancer)

anti-Amasyn

anti-Amanat

++
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Analysis of the anti-Ama antibody-treated muscle and cervix sections indicated no
specific antibody binding. The DU-145 cells were not stained by treatment with
anti-AmaSyn. However, the intense staining of the DU-145 cells with the antiAmanat antibody indicated a strong binding of antibody to these cells.
Flow cytometry
Flow cytometric analysis indicated that both anti-Ama antibodies bound to
DU-145 cells (Figure 3.15 and Figure 3.16). These antibodies, however, did not bind
to all DU-145 cells in the test group, indicating a dichotomous population. The antiAmanat antibody-bound cells displayed a higher mean channel shift (indicating
greater sensitivity/affinity) than the anti-AmaSyn antibody. Those cells having a
fluorescence intensity greater than the autofluorescence peak (cells only) were
considered to be bound by FITC-labeled second antibody. The percentage of cells
displaying a similar increase in fluorescence intensity when treated with second
antibody alone (non-specific binding) was subtracted from the percentage of
primary anti-Ama antibody- and secondary antibody-labeled cells to give the specific
binding. Cells treated with an irrelevant antibody (cells plus non-immune mouse
serum plus second antibody) did not show any specific binding. Multiple assays
confirmed that the percent specific staining of PI negative gated cells (live cells) was
approximately 20% for anti-AmaSyn and 35% for anti-AmanatAnalysis of DU-145 cells (DNA index = 1.4) relative to diploid human
lymphocytes (DNA index = 1.0) indicated that this cell line contains aneuploid cell
subpopulations. This finding is in agreement with a modal chromosome number of
64 (range 46-143) (Stone et al. 1978) and a reported DNA index of 1.42 (Keer et al.
1991). Heteroploidy of the DU-145 cell line was observed with a distinct presence of
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Figure 3.15. Flow cytometric analysis of anti-Amasyn stained DU-145 cells. 107
DU-145 ce’ls were incubated with 20 [i\ (2 mg/ml) anti-AmaSyn in 80 |il PBS, washed
and then incubated with a FITC-conjugated anti-IgG. The cells were subsequently
analyzed on a FACS. The histogram shown displays the number of events
(correlated to the number of cells) against the intensity of FITC fluorescence
(related to the amount of antibody bound).
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Figure 3.16. Flow cytometric analysis of anti-Amanat stained DU-145 cells. 107
DU-145 cells were incubated with 20 (il (1.5 mg/ml) anti-Amanatin 80 |il PBS,
washed and then incubated with a FITC-conjugated anti-IgG. The cells were
subsequently analyzed on a FACS. The histogram shown displays the number of
events (correlated to the number of cells) against the intensity of FITC fluorescence
(related to the amount of antibody bound).
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a near-tetraploid aneuploid population containing approximately 10% of the total
cell number, as reported by Keer et al. (1991).
To better understand the dichotomy of anti-Ama binding populations in the
DU-145 cells, an assay was designed to simultaneously allow measurement of DNA
content (PI) and anti-Ama surface binding (FITC) (Figure 3.17 and Figure 3.18). By
gating on individual populations, valuable interpretive data was obtained. For
instance, all the cells which did not bind antibody appeared to be in the Gq/Gi phase
of the cell cycle, while those binding antibody were spread throughout the cell cycle.
Gating on the different phases of the cell cycle revealed a pattern of growth cycle
associated with increasing green fluorescence (indicating antibody binding) with
Gq/Gi < S < G2/M. Conversely, by gating on the population of anti-Ama antibodybound cells (associated with increased FITC-related fluorescence), a substantial
difference was seen in the increased amount of cells in the G2/M phase over the
ungated or FITC-negative gated populations.

Discussion
Immunohistochemistry
The tissues selected for this test were chosen not only to represent a wide
variety of different tissues, but to depict tissues similar to the prostate as well.
Since DU-145 cells are human in origin, and fresh human tissue was hard to obtain,
it was decided to test tissues from a primate (macaque). Tissues from this primate
species included muscle, cervix (growth of cervical lining is under hormonal
control), breast (containing secretory mammary glands) and skin (which contains a
variety of normal tissues, including epithelium, fat, blood vessels, connective tissue,
secretory glands, etc.). A number of different types of human prostate tissue was
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Figure 3.17. Cell cycle analysis of DU-145 cells with anti-AmaSyn surface staining.
107 DU-145 cells were incubated with 20 ^1 (2 mg/ml) anti-AmaSyn in 80 |il PBS,
washed and then incubated with a FITC-conjugated anti-IgG. After another wash,
propidium iodide was added to the cells. The cells were subsequently analyzed on a
FACS. The histogram shown displays the number of events (correlated to the
number of cells) relative to the intensity of propidium iodide fluorescence (related
to the amount of DNA and thus to the cell cycle phase) (A) or the intensity of FITC
fluorescence (related to the amount of antibody bound) (B and C). Histograms B and
C are gaited on Gq/Gi and G2/M, respectively. The increase in fluorescence intensity
observed from B to C indicates a cell cycle-dependent expression of an anti-Ama
reactive cell surface molecule.
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Figure 3.18. Cell cycle analysis of DU-145 cells with anti-Amanat surface staining.
107 DU-145 cells were incubated with 20 ^il (2 mg/ml) anti-Amanat in 80 (il PBS,
washed and then incubated with a FITC-conjugated anti-IgG. After another wash,
propidium iodide was added to the cells. The cells were subsequently analyzed on a
FACS. The histogram shown displays the number of events (correlated to the
number of cells) relative to the intensity of propidium iodide fluorescence (related
to the amount of DNA and thus to the cell cycle phase) (A) or the intensity of FITC
fluorescence (related to the amount of antibody bound) (B and C). Histograms B and
C are gaited on Gq/Gi and G2/M, respectively. The increase in fluorescence intensity
observed from B to C indicates a cell cycle-dependent expression of an anti-Ama
reactive cell surface molecule.
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also obtained enabling the direct testing of normal human prostate, human
hyperplastic benign prostate, and human prostatic adenocarcinoma (DU-145 cells).
Neither of the anti-Ama antibodies bound specifically to any of the tested
normal macaque tissues in detectable amounts (Table V). These tissues, while not
of human origin, are similar in many ways. (Many of the monoclonal antibodies
provided for in vitro diagnostics for human systems work equally well with lower
primates, as do many drugs, indicating similar cell antigens and receptors. Thus, it
was felt that these tissues provided sufficiently similar epitopes to screen for cross
reactivity of the antibodies with selected normal tissues.)
The anti-Ama antibodies did not bind to sections of hyperplastic benign
human prostate or surrounding normal prostate. The anti-AmaSyn antibody did not
bind to the DU-145 cells in detectable amounts in this assay. The anti-Amanat
treated DU-145 cells, on the other hand, stained intensely.
There may be several reasons why the anti-AmaSyn antibody reacts with the
DU-145 cells when studied by flow cytometry but not with immunohistochemistry
staining. The most obvious is that the fixing procedure for the
immunohistochemistry sections, which utilizes acetone, may have damaged the
anti-Amasyn-reactive epitope on these cells.
Furthermore, the antibody concentration was 250-fold less in the
immunohistochemistry assay than in the flow cytometry assay. This was due to the
fact that the incubation time used for fixed immunohistochemistry sections was
much longer than that used for live, metabolizing cells (flow cytometry), as well as
the comparative ease of dislodging non-specific antibody staining from a single cell
suspension versus a bound tissue with all of its surface irregularities.
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A third explanation is that flow cytometry allows the analysis of millions of
cells individually facilitating the detection of a small population of stained cells that
may have been missed in the tissue staining test. It may be that the DU-145 cells
used in the immunohistochemistry sections did not contain any of the anti-Amareactive subpopulation observed in flow cytometry. This is unlikely, however,
because the anti-Amanat antibody reacted strongly with the DU-145 cells in this test.
Thus it remains likely that the fragile Ama epitope may have been altered, but the
anti-Amanat was still able to bind due to its recognition of surrounding amino acids.
If this is the case, the anti-Amanat antibody used in immunohistochemistry would
decrease the possibility of false negative results for the Ama epitope seen with the
anti-AmasynIn summary, the anti-AmaSyn antibody binds to human prostatic cancer cells.
It does not bind to benign human hyperplastic or normal prostate, nor does it bind
to equivalent tissue cells in lower primates or a variety of other selected normal
tissues. While the specificity of this antibody cannot be positively determined by a
diagnosis of exclusion, this test allows detection of antibody cross-reactivity with
normal prostate tissues and other normal secretory epithelial tissues. In passive
tumor immunotherapy, the non-reactivity of antibody with normal tissues is as
important as the specific binding of antibody to cancerous tissues. So while this list
of non-binding tissues does not prove the specificity of the antibody for the
cancerous prostate, its lack of cross-reactivity does leave open the possibility of
therapeutic use for this antibody.
Flow Cytometry
This study indicates that the anti-AmaSyn and anti-Amanat antibodies both
bind to intact DU-145 cells. As might be expected, the anti-Amanat antibody
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(generated by injections of DU-145 proteins) bound cells have a higher mean
channel fluorescence number than the anti-AmaSyn bound cells, possibly due to a
higher affinity of the anti-Amanat antibody for the putative “Ama-epitope” on the
DU-145 cell. In addition, the percentage of cells bound by the anti-Amanat antibody
is greater than those bound by the anti-AmaSyn antibody. Neither antibody binds
specifically to more than about one-third of the cell population. This variation of
binding within a cell line is common, especially when the antibody binds to an
activation marker or other temporally varying epitope.
To discern whether the expression of the anti-Ama antibody-binding cellular
protein is associated with stages in the cell cycle, an assay was devised in which
simultaneous staining of the cell surface with anti-Ama antibodies and DNA with PI
could be accomplished. This allowed cell cycle-associated changes in binding of
antibody to be observed. It was found that while both anti-Ama antibodies bound to
cells throughout the cell cycle, they displayed a predilection for cells in the G2/M
phase. Furthermore, virtually all of the antibody-negative cells were contained in
the Gq/Gi phase.
A study by Keer et al. (1991) described a similar cell cycle-dependent increase
in urokinase expression in DU-145 cells as well as PC-3 cells. Urokinase, a 54 kD
plasminogen activator, has been associated with tumor cell invasion and metastasis
(Dano et al. 1985). Since DU-145 cells in the G2M phase are more likely to contain
urokinase and bind to anti-Ama antibodies, this suggests that a population of actively
dividing cells would contain more of these markers than a quiescent population. It
follows that the population of actively dividing cells which contain an increased
expression of urokinase may have a concomitant augmented metastatic potential.
This population of DU-145 cells containing a supposed high metastatic potential
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possesses an associated augmentation of anti-Ama antibody binding, suggesting an
increase in cellular wAma-epitope” density. Thus the fact that this “Ama-epitope”
expression is apparently increased on these arguably higher metastatic potential
cells is consistent with the concept that this “Ama-epitope” may be associated with
metastasis.

F. Overall Discussion of Specificity Studies
Monoclonal antibodies are directed against specific epitopes. The degree of
similarity between epitopes dictates the amount of cross-reactivity of an antibody
(which is directed toward one epitope) reacting with a similar epitope. The ideal
antibody would not react with any epitope other than the one that induced it. The
low cross-reactivity of the anti-Amanat antibody with other epitopes may be
explained as follows.
First, there is a minute amount of Ama found only in certain tissues. This
minor amino acid has been found in quantities of up to 20 Ama per 1000 Gly
(Wheelan et al. 1989). Thus there simply are not very many proteins containing
Ama for recognition by the anti-Amanat antibody.
Second, anti-Amanat antibody is a monoclonal preparation produced by a
twice cloned hybridoma, a single population of cells that all produce identical
antibody. (The monoclonal nature of this antibody has been confirmed by ion
exchange chromatography.) Because it is monoclonal, each individual anti-Amanat
antibody has identical binding characteristics, decreasing the diversity of specificity
seen with polyclonal antibody preparations.
Third, the anti-Amanat antibody should theoretically be more specific than
the anti-AmaSyn antibody due to the epitope to which it was made. The anti-AmaSyn
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antibody was directed toward an epitope comprised of one amino acid, while the
anti-Amanat antibody was made in response to a group of anti-AmaSyn antibodyreactive proteins from the DU-145 cell line. The anti-Amanat antibodies should then
bind to an epitope containing approximately seven specific amino acids (including
Ama), increasing the theoretical specificity for this epitope by the anti-Amanat over
the anti-AmaSyn antibody by an order of 109. In other words, while both anti-Ama
antibodies may bind equally well to this DU-145 Ag, the anti-AmaSyn is much more
likely to bind to another Ama containing-epitope than the anti-Amanat antibody.
This can be seen in the considerably more sensitive binding of the anti-AmaSyn
antibody to BSA-Ama, than the binding of anti-Amanat to BSA-Ama. In fact, the
reason for any binding of the anti-Amanat antibody to this synthetic epitope may be
because it was screened for binding to the BSA-Ama epitope in addition to the
DU-145 Ag.
Fourth, while there are epitopes that may mimic the anti-Amanat antibodyreactive site, the sensitivity of the antibody for those epitopes should decrease in
direct proportion to the amount of variance of that epitope from the "true epitope."
Since Ama is most likely due to a post-translational modification, it is quite likely
that an unmodified protein (containing no Ama) would have a relevant epitope
much different than the same modified protein (containing Ama). This is because
the change from a neutral Ser or Gly to a positively charged Ama does more than
impact the primary amino acid sequence. This change alters the charge of the
epitope and may cause a concomitant modification of its tertiary structure. Since
antibody binding is dictated by electrostatic forces and tertiary structure of an
epitope, any alteration in these parameters can cause an alteration in antibody
binding.
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Theoretically, an epitope which binds the anti-Amanat antibody need not
contain Ama. The occurrence of such non-specific binding of antibody can be
addressed using an acid treated, anti-Amanat antibody-reactive protein. Since Ama is
acid labile, a decrease in binding after acid treatment may be associated with
decarboxylation of Ama (or another acid labile amino acid) and a concomitant
decrease in specificity of the antibody. Indeed this was demonstrated by acid testing
both the DU-145 protein fraction that bound with the antibodies, and BSA-Ama. In
addition, an attempt was made to test the antibodies with various other proteins that
contain epitopes thought to be similar to the "Ama epitope." This included proteins
such as activated prothrombin (which contains Gla), as well as several positively
charged molecules (dextran sulfate, poly L-glutamate, and avidin succinyl). None of
these proteins showed significant specific binding of the anti-Amanat <>r anti-AmaSyn
antibodies.
The next logical step in determining specificity of the antibody is to epitope
map a protein that displays significant specific binding of the antibody. For the
DU-145 prostate cell line, this protein has been partially characterized but has not
yet been sequenced.

IV. ANTIGEN PURIFICATION AND CHARACTERIZATION

Introduction
In order to determine the nature of the protein(s) containing the Ama
epitope in the DU-145 cells, the cells were lysed and the anti-Ama reactive proteins
were selected by an immunoaffinity column containing either anti-AmaSyn or antiAmanat antibodies. The apparent molecular weight of these immunopurified
proteins was then determined by gel electrophoresis. These proteins were
separated using gel filtration column chromatography to determine which protein
fraction had the highest reactivity with the anti-AmaSyn or anti-Amanat antibodies as
tested using indirect ELISA. The size exclusion fractions with the highest antibody
activities were taken and the protein of interest was purified using ion exchange
chromatography. This protein was then partially characterized for pi, glycosylation
pattern, apparent molecular weight and indirect Ama content analysis.

Methods
Immunoaffinity Chromatography
The anti-Amanat immunoaffinity column was made as described in
Appendix B. DU-145 cells were detergent lysed and the lysate was applied to the
immunoaffinity column. Bound protein was eluted in 100 mM diethylamine,
pH 11.0.
Polyacrylamide Gel Electrophoresis
The methods described in this section are detailed in Appendix B. Briefly,
native and SDS PAGE of the DU-145 Ag was accomplished on a PhastSystem
(Pharmacia, Uppsala, Sweden) gel electrophoresis unit. The gels were stained with
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either a comassie blue stain or the more sensitive silver stain. Characterization of
molecular weights of the proteins was accomplished with the aid of a transmissive
scanner (X-ray Scanner Corp., Torrence, CA), a Sun Sparc 2 station computer and
Bio-Image analysis software.
Gel Filtration Chromatography
The methods described in this section are detailed in Appendix B. Briefly,
proteins were separated based on size by gel filtration chromatography.
Concentrated proteins from anti-Amanat (WMK-I) or anti-AmaSyn immunoaffinity
chromatography were added to a Superose 6 column and separated in an
ammonium bicarbonate buffer at 0.3 ml per minute. Fractions of 3 ml each were
collected and assayed with ELISA for reactivity with both anti-Ama antibodies.
Indirect ELISA
The methods described in this section are detailed in Appendix B. Briefly,
fractions were bound in an Immunlon IV plate (Fisher Biotech, Pittsburgh, PA) in
50 mM carbonate buffer, pH 9.6, for 16 hours. The plate was then blocked with
0.05% tween-20 and 0.25% BSA in PBS for 30 minutes. An incubation with antiAma antibody for 60 minutes was followed by addition of an alkaline phosphataselabeled anti-IgG. The plate was washed three times between each step. After
addition of substrate, the optical density of the wells was read at 410 nm.
Ion Exchange Chromatography
The methods described in this section are detailed in Appendix B. Briefly,
the gel filtration fractions containing the highest reactivity with the anti-Ama
antibodies in the indirect ELISA were further purified using anion exchange
chromatography. Fractions were vacuum concentrated, re-solubilized in a histadine
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buffer, pH 5.5, and added to a Mono Q 5/5 anion exchange column. The bound
protein was eluted at a concentration of 0.75 M NaCl.
Isoelectrofocusing
The methods described in this section are detailed in Appendix B. Briefly, a
sample of the purified protein from ion exchange chromatography was diluted and
assayed for isoelectric point determination. The sample was added on both ends of a
Pharmacia 8/25 mini gel along with proteins of known pi. A program was run
which set up an electric gradient across the gel. This caused a migration of the
proteins to a point at which they became neutral (their isoelectric point). The gel
was then stained using a standard silver staining technique. The pi of the protein
was determined by measuring the distance which the proteins of known pi traveled
from the anode and plotting that distance against the pi. The unknown pi could
then be determined by measuring the distance of the protein band from the
cathode and extrapolating the pi from the graph.
Glycosylation pattern determination
The methods described in this section are detailed in Appendix B. Briefly,
protein from the WMK-I immunoaffinity column (DU-145 Ag) as well as purified
protein from ion exchange chromatography were assayed for glycosylation pattern
determination. The proteins were immobilized on Pro-Blott membrane (Applied
Biosystems, Foster City, CA) and incubated with the biotinylated lectins Con A,
Psium sativum agglutinin, Ricinus communis agglutinin I (RCA 120), peanut
agglutinin (PNA), wheat germ agglutinin (WGA), and Dolichos biflorus agglutinin
(DBA). Then the proteins were incubated with an avidin biotin-peroxidase mixture.
The bound peroxidase was developed by addition of diaminobenzidine
hydrochloride for 1 to 3 minutes.
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Results
Typical chromatographs of the DU-145 lysate on the anti-Amanat (Figure 4.1)
and anti-Amasyn (Figure 4.2) immunoaffinity column show a significant amount of
specific binding of proteins to the respective columns. The first peak in the
chromatographs displays the removal of unbound protein at neutral pH and the
second peak indicates the elution of the bound protein at pH 11. Similar elution
profiles are obtained with both the anti-AmaSyn or anti-Amanat immunoaffinity
columns. The anti-Amanat immunoaffinity chromatograph has a characteristic
"camel back" profile indicating the presence of two different binding affinities
contained by the pool of eluted proteins. The first part of the second peak is a
relatively loosely bound protein; the second part of the peak is a more tightly bound
protein (at pH 11). Anti-AmaSyn immunoaffinity chromatography (IAC) bound
significantly more protein per number of lysed cells than anti-Amanat IAC, yielding
approximately 1-2 mg per 109 DU-145 cells versus 0.5 mg per 109 DU-145 cells for
the anti-Amanat IAC.
SDS gel electrophoresis of an eluate from the anti-AmaSyn immunoaffinity
column reveals the presence of eight proteins (Figure 4.3). These protein bands
correlate well with the number and size of the gel filtration chromatograph peaks of
the eluates from the anti-AmaSyn (Figure 4.4) and anti-Amanat (Figure 4.5)
immunoaffinity columns. The relative reactivity of the fractions with the anti-Ama
antibodies are overlaid on each chromatograph.
Ion exchange column chromatography separation of an anti-Ama antibodyreactive protein fraction from size exclusion chromatography yielded several
distinct protein peaks. The protein of interest is revealed in a symmetrical peak
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Figure 4.1. Anti-AmaSyn immunoaffinity chromatograph of DU-145 Ag. Soluble
protein from detergent lysed DU-145 cells was applied to an anti-AmaSyn
immunoaffinity column as described in text. The absorbance of the eluted proteins
was measured at 280 nm and charted versus time. The chart speed was 0.05 cm per
minute. The first peak correlates with the removal of the non-bound protein and
detergent from the column with PBS and the second peak with the elution of bound
protein at a pH of 11.0.
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Figure 4.2. Anti-Amanat immunoaffinity chromatograph of DU-145 Ag. Soluble
protein from detergent lysed DU-145 cells was pumped through an anti-Amanat
immunoaffinity column as described in text. The absorbance of the eluted proteins
was measured at 280 nm and charted versus time. The chart speed was 0.05 cm per
minute. The first peak correlates with the removal of the non-bound protein and
detergent from the column with PBS and the second peak with the elution of bound
protein at a pH of 11.0.
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Figure 4.3. SDS-PAGE of DU-145 Ag from anti-AmaSyn immunoaffinity column.
Proteins from anti-AmaSyn immunoaffinity column as well as molecular weight
standards were boiled in an SDS and mercaptoethanol containing solution. Lanes
two through six contain molecular weight standards. Lane one contains the proteins
from the DU-145 cells. The gel was stained with a comassie blue staining procedure.
The optical density of the bands, as well as their apparent molecular weights were
determined by computer analysis.
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Figure 4.4. Gel filtration chromatography of DU-145 Ag from anti-AmaSyn
immunoaffinity column. A Superose 6 containing column was used to fractionate
the DU-145 Ag proteins by size. The flow rate of the 150 mM ammonium
bicarbonate buffer pumped on the column was 0.3 ml per minute and the chart
speed was 0.05 cm per minute. Approximately 0.75 mg of DU-145 sample was
injected in 2 ml of buffer. The absorbance was detected at 280 nm and charted
against time. The sensitivity was set at 1 AUFS.
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Figure 4.5. Gel filtration chromatography of DU-145 Ag from anti-Amanat
immunoaffinity column. A Superose 6 containing column was used to fractionate
the DU-145 Ag proteins by size. The flow rate of the 150 mM ammonium
bicarbonate buffer pumped on the column was 0.3 ml per minute and the chart
speed was 0.05 cm per minute. Approximately 0.75 mg of DU-145 sample was
injected in 2 ml of buffer. The relative absorbance was detected at 280 nm and
charted against time. The sensitivity correlated to a full scale deflection of 1.0
(absorbance units). The results of an indirect ELISA of the fractions against antiAma are overlaid on the chromatograph. The relative absorbance at 410 nm
obtained by the ELISA test of the various chromatography fractions is on the Y axis.
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that elutes at a Cl* concentration of about 0.8 M (Figure 4.6). This purified protein
was then partially characterized. The apparent molecular weight of the protein is
200 kD (Figure 4.5) and the pi of the protein is approximately 4.2 (Figure 4.7). The
glycosylation pattern of the protein is shown in Table VI and compared to that of
DU-145 eluate taken from the anti-Amanat immunoaffinity column. The purified
protein contains binding sites for WGA, whereas the DU-145 Ag contains binding
sites for WGA, Con A, DBA, RCA 120, and Psiwn sativum agglutinin.

Discussion
There were several technical difficulties associated with the isolation of this
DU-145 cell protein. To maximize the number of cells lysed, cells were grown until
late log phase or until they were confluent. Unfortunately, this strategy produced
cells which were less likely to be in the G2/M phase of the cell cycle associated with
an increased binding of the anti-Ama antibodies. The net result may have been less
DU-145 Ag purified.
Because the quantity of antigen found in the cells was relatively small, tens of
billions of cells were grown and lysed for antigen purification. The properties of this
cell line dictated that it be grown attached to a surface. These constraints instituted
the need to store lysed material and semi-purified protein. Prolonged storage of the
DU-145 Ag at 4°C appears to be unsatisfactory, possibly due to the instability of the
Ama epitope in a liquid aqueous environment. The avidity of the anti-Ama
antibodies for the DU-145 Ag was virtually abolished after six months at 4°C. This
problem has been overcome by antigen storage at -20°C which has proven
sufficient for retaining antigen reactivity for at least one year.
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Figure 4.6. Ion exchange chromatography of a 200 kD anti-Ama antibody-reactive
protein. The absorbance was detected at 280 nm and plotted against time. The
chart speed was 1 cm per minute and the flow rate through the column was 2 ml
per minute. The two buffers used in this assay were a histidine buffer, pH 5.5
(buffer A) and the same histadine buffer containing 1 M NaCl (buffer B). An
undetermined amount of protein from a gel filtration fraction containing a high antiAma antibody reactivity was diluted in 1 ml of buffer A and injected on a Mono Q 5/5
anion exchange column. The concentration of buffer B can be seen as the straight
line that starts a gradient increasing from 0% buffer B to 100% buffer B over 10
minutes. The protein separation profile shows two peaks, one early and one which
starts to elute at about 60% buffer B with peak elution at 78% buffer B.
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Figure 4.7. Isoelectrofocusing of a 200 kD anti-Ama antibody-reactive protein. This
graph shows the distance of control protein bands to the anode plotted against their
known pi. The standards used were amyloglucosidase (pi 3.6), trypsin inhibitor (pi
4.6), beta-lactoglobin (pi 5.1), carbonic anhydrase (pi 5.9) and trypsinogen (pi 9.3).
The distance of the 200 kD anti-Ama antibody-reactive protein from the anode was
measured and used to determine its pi of 4.7.
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Table VI
1. Lectin abbreviations are as follows: concanavalin A (Con-A), Psiwm sativum
agglutinin (PSA), Ricinus communis agglutinin 120 (RCA 120), peanut agglutinin
(PNA), wheat germ agglutinin (WGA), and Dolichos biflorus agglutinin (DBA).
2. DU-145 Ag is the set of seven different proteins from DU-145 cell lysate that
specifically bound to the anti-Amanat antibody (WMK-I) immunoaffinity column.
3. The purified protein is the protein taken from the gel filtration fraction
containing the highest reactivity with the anti-Ama antibodies and purified by ion
exchange chromatography.
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Table VI

Glycosylation Pattern of Anti-Ama Antibody-Reactive Proteins from DU-145 Cells

Lectin1 DU-145 Ag2
Con-A

++

PSA

++

WGA

+++

DBA

+++

RCA 120

+++

PNA

+

Purified Protein3
+/-

Lectin Binding Specificity
a-linked Man or a-linked Glc
mannose and glucose

++

GlcNAc
GalNAc

+/-

oligosaccharides ending in Gal
galactosyl end groups

170
Since only minute quantities of antigen were available for purification and
characterization, a system of purification was needed which could work with small
amounts of protein. By far the most efficient way of purifying individual proteins
from a large population of different proteins is affinity chromatography which often
yields 1000 to 10,000 fold purifications in one step (Thomas and McNamee 1990).
The technique described here also allows the use of non-ionic detergents such as
Triton X (a polyoxyethylene derivative) to lyse the cells. Many proteins are more
stable in non-ionic detergents than other detergents; however, these non-ionic
detergents generally form large micelles incompatible with gel filtration (Thomas
and McNamee 1990). Additionally, Triton X absorbs at 280 nm, the absorption
wavelength most commonly employed in protein detection. Affinity
chromatography allows the binding of the protein in the detergent followed by
buffer exchange to a detergent-free buffer prior to protein elution.
To decrease the non-specific binding, washes of the protein-bound column
were achieved with both detergent buffers (to decrease hydrophobic interactions)
and ionic buffers (to decrease electrostatic interactions) as outlined by Jack (1991)
and Thomas and McNamee (1990). Because of the acid lability of Ama, elution of the
immunoaffinity column was attained under alkaline rather than acidic conditions.
The double peak associated with the elution of the DU-145 Ag from the antiAmanat IAC indicates the presence of two distinct classes of proteins in the eluateone class containing a somewhat higher binding affinity than the other for the
column. This variability of antibody binding is further depicted by the fact that after
gel filtration of the proteins which bound to the anti-Ama antibody IAC, only one of
the seven proteins indicated specific binding to both of the anti-Ama antibodies.
This may be due to non-specific binding of the proteins to the IAC, since the
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covalent attachment of the antibodies to the solid column matrix may alter the
specificity of the antibodies (Friguet et al. 1985). The discrepancy in yields of the
two anti-Ama IAC columns may be either due to a decreased amount of available
anti-Amanat binding sites in the anti-Amanat IAC column or a lower specificity of the
anti-Amasyn antibody. The latter possibility fits nicely with the concept of increased
specificity of an antibody made to a naturally occurring antibody over one derived by
injection of an antigen containing a synthetic epitope comprised of one amino acid
linked to a spacer.
Due to the small amounts of antigen eluted using IAC, mini gels (which can
detect as little as 0.5 ng protein) were utilized. (Large agarose gels, on the other
hand, may require substantially more protein for detection.) Thus the use of IAC
and mini gels helped maximize the amount of purified protein and minimize the
loss of protein during analysis.
Unfortunately, the LAC proved not to be a one-step purification method but
yielded a set of seven distinct proteins. These proteins were separated by gel
filtration and their reactivity with anti-Ama antibodies quantified by ELISA.
Samples from both anti-AmaSyn and anti-Amanat IAC produced similar elution
profiles on gel filtration. The anti-Ama antibodies both reacted most strongly with a
fraction containing a peak absorbance correlating with an apparent molecular weight
of 200 kD. The peak absorbance of this fraction was several times smaller than the
peak absorbance of the fraction correlating with an apparent molecular weight of
63 kD. Thus, not only does this fraction contain the protein with the highest
antibody reactivity to the anti-Ama antibodies, but the apparent protein amount
tested in ELISA was at least two-fold less than several other tested fractions,
indicating a specificity of anti-Ama antibody binding for this protein.

172
The protein found to display the highest reactivity with the anti-Ama
antibodies was observed in complementary gel filtration fractions of DU-145 cell
eluate from anti-AmaSyn and anti-Amanat immunoaffinity chromatography
(Figures 4.4 and 4.5). The analogous elution profiles of DU-145 proteins from the
two immunoaffinity columns shows the similarity of binding specificities of the two
antibodies. However, the anti-AmaSyn binds less specifically to eluted proteins than
the anti-Amanat- The binding of anti-Amanat is associated with only one protein
peak indicating an increased specificity of the anti-Amanat antibody at the tested
antibody concentrations (about 10"7 M). The amount of bound antibody appears not
to be dependent on the amount of protein, since the protein exhibiting the most
binding with both anti-Ama antibodies came from a 200 kD fraction displaying little
absorbance (associated with less protein). The binding of the anti-AmaSyn to the
other fractions could be due to non-specific binding or it may bind to other Amacontaining proteins not recognized by anti-AmanatSince baseline separation of the proteins was not obtained, further
purification of the proteins was required. The two most commonly employed highresolution chromatography techniques are reverse phase chromatography and ion
exchange chromatography.
Repeated attempts at reverse phase separation of the protein from the gel
filtration fraction containing the highest reactivity with the anti-Ama antibodies
failed to work. That is, the antigen appeared not to bind at all to the column, as
evidenced by an initial peak immediately after injection, followed by a return to
baseline for the duration of the experiment. Alternatively, some protein may have
bound so tightly that it did not become eluted. This is perplexing, because protein
binding in a reverse phase column is based on protein hydrophobicity and all
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proteins are made up of a relatively hydrophobic carbon backbone. The protein
may, however, contain charged groups such as Ama which may mask the
hydrophobic backbone with a hydrophilic exterior. This outer layer of
hydrophilicity may have trouble binding to the hydrophobic matrix of the reverse
phase column.
It was decided, therefore, to purify the anti-Ama antibody-reactive antigen by
ion exchange. While the resolution of ion exchange is not quite as good as reverse
phase, its separation method does not involve the use of solvents as harsh as reverse
phase; therefore, 80% of proteins retain their normal activity (Thomas and
McNamee 1990). This anti-Ama antibody-reactive protein has a relatively low pi of
4.8. This is associated with a net negative charge on the protein which enables it to
bind to a positively charged solid matrix as in anion exchange chromatography. This
technique is so named because an anion, typically Cl', is added in increasing
concentrations until it displaces the protein bound to the positively charged matrix.
By decreasing the pH of the buffer, one can decrease the amount of negative
charges associated with the protein. The quantity of negative charges was such that
even at pH 5.5, 0.75 M Cl' was needed to elute the protein.
The limited quantity of sample obtained by this purification method made
accurate ELISA testing difficult. However, ion exchange chromatography of serial
fractions from gel filtration, along with their previously recorded anti-Ama antibody
reactivity, showed that the only protein which remained throughout the series of
anti-Ama antibody-reactive fractions was one which eluted in a symmetrical peak at
a Cl' concentration of 0.75-0.8 M.
The purity of this peak can be characterized in many ways. However, as was
eloquently described by Mohan (1991), while many tests may be used to assess the
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purity of the sample, these tests only provide examples of the failure to detect any
contaminating species. Therefore, a standard of a single band on SDS PAGE has
emerged by which purity is measured. The test used for purity in this study offers
an even more rigorous definition by starting with a partially pure protein in a
defined narrow molecular weight range and then separating the contaminating
groups by charge. The symmetry of the peak does not provide any evidence of
another contaminating protein.
This protein was further characterized by lectin binding studies to determine
its glycosylation pattern. Glycoproteins are carbohydrate-rich proteins located both
intracellularly and on the cell surface and can be secretory or structural. Cell surface
glycoproteins can undergo modification in association with normal cell
differentiation, proliferation, and adhesion as well as under pathological conditions
(e.g., neoplastic disease) (Chan and Wong 1991; Howard et al. 1981; Newman et al.
1979; and Zieske and Bernstein 1982).
Lectins can be categorized, based on their carbohydrate binding specificity,
into five groups: 1) glucose/ mannose (Glu/Man) binding lectins;
2) TV-acetylglucosamine (GlcNAc) binding lectins; 3) N-acetylgalactosamine/ galactose
(GalNAc/Gal) binding lectins; 4) L-fucose binding lectins; and 5) sialic acid binding
lectins. Recent literature suggests that there is no sialic acid in prostatic tissue and
that any L-fucose moieties are confined to the golgi apparatus (Chan and Wong
1991). Representative lectins from the remaining categories were employed in this
study.
The DU-145 Ag displayed lectin binding associated with the following
carbohydrate groups: Glu/Man (Con A and Psium sativum agglutinin binding),
GlcNAc (WGA binding), GalNAc (DBA binding), and Gal (RCA I and PNA binding)
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(Table VI). The purified protein from ion exchange showed significant binding by
only WGA, indicating a potential N-acetylglucosamine in this protein. These binding
specificities are compatible with reported lectin staining patterns of prostate
epithelial cells (Bischof and Aumuller 1982; Chan and Wong 1991) which suggest that
Man, GlcNAc and Gal are the common sugar residues found in prostatic epithelia of
several mammalian species including humans.
Since glycoproteins are generally either secretory proteins (such as prostatespecific antigen and prostatic acid phosphatase) or structural proteins (such as
adhesion molecules), tests were performed to identify the class of molecule to
which this glycoprotein might belong. An ELISA of DU-145 cell conditioned media
was performed which showed no evidence of anti-Ama antibody reactivity. Flow
cytometry and immunohistochemistry, on the other hand, indicated binding of antiAma antibodies to DU-145 cell surface, suggesting that the glycoprotein may be a
structural molecule found in the cell membrane.
Further characterization of this protein may detail its amino acid sequence in
addition to confirming the presence of Ama. From the sequence data, a similar or
identical protein may be matched, providing clues to the function of this protein.
In summary, the protein containing the highest binding to the anti-Ama
antibodies was partially characterized as a 200 kD glycoprotein containing a
N-acetylglucosamine-associated WGA binding site, with a pi of 4.8. Indirect evidence
was also given in Chapter III which indicated that due to its acid lability, this protein
may contain Ama.

V. OVERVIEW AND CONCLUSIONS

Overview of Project Goals
The hypothesis of this research is that a monoclonal antibody, with specificity
for an anti-AmaSyn-reactive epitope found in a human tumor cell line, could be
produced. This project was undertaken to produce a theoretically more specific
antibody to an Ama-containing epitope. The anti-AmaSyn antibody was elicited by
immunization with of a synthetic Ama epitope. This method proved useful for the
production of a first-generation anti-Ama antibody; however, to overcome
theoretical specificity problems associated with the use of 1) an epitope containing
only one amino acid and a spacer, and 2) a synthetic epitope that may not contain the
three-dimensional shape of a native Ama-containing protein, a second-generation
monoclonal antibody was produced with the use of a naturally occurring, antiAmaSyn antibody-reactive protein as the primary antigen.
The aims of the research were to identify a natural source of anti-AmaSyn
antibody-reactive protein (DU-145 Ag), extract that protein for immunization,
produce a monoclonal antibody (anti-Amanat) reactive with both the DU-145 Ag and
a synthetic Ama epitope, characterize and compare the binding of the two anti-Ama
antibodies and, finally, characterize the naturally occurring anti-Ama antibodyreactive protein.

Overview of Project Findings
The chosen source of the naturally occurring Ama protein was a human
prostate cancer cell line demonstrating relatively strong anti-AmaSyn antibody
binding as measured by flow cytometry.
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The anti-Ama reactive antigen was extracted from lysed DU-145 cells by
immunoaffinity chromatography and used to immunize mice. Immunized plasma
cells from the mice were fused with a murine myeloma cell line, and the resultant
hybridoma was screened for production of antibodies to the DU-145 Ag as well as a
synthetic Ama epitope, BSA-Ama (monopeptide). Based on these criteria, an IgGi
antibody-producing clone was selected for antibody (anti-Amanat) purification and
characterization.
The anti-Amanat antibody and the anti-AmaSyn antibody apparently compete
for a similar site on BSA-Ama and DU-145 Ag. That is, at a saturating concentration
of antibody, they display evidence of increased binding with both antibodies present
than with either antibody alone. This additivity, however, is less than what is
expected for the recognition of two distinct epitopes, suggesting an overlapping of
the recognized portions of the proteins. Furthermore, both antibodies recognize
BSA-Ama but not BSA, further suggesting that the epitopes recognized by these
two generations of anti-Ama antibodies are not totally unique.
The antibodies were tested for reactivity against synthetic epitopes designed
to be similar to the BSA-Ama (monopeptide) epitope. This test showed that the
antibodies were specific for only the BSA-Ama epitope at low antibody
concentrations with an increasing cross-reactivity with other epitopes seen at higher
antibody concentrations. The similarity of the individual synthetic epitopes to the
Ama monopeptide epitope seems to be directly proportional to their cross-reactivity
at high antibody concentrations.
The antibodies were also tested for their binding to various cells and tissues.
Flow cytometry studies indicated that both of the anti-Ama antibodies bound to
DU-145 cells. This binding was associated with the cell cycle phase, with increasing
numbers of cells in the G2/M phase binding the antibodies. These cells are the
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actively dividing cells which may be associated with a metastatic phenotype (Keer et
al. 1991). Immunohistochemistry studies provided no evidence of specific antibody
binding to normal tissue sections; however, similarly prepared prostate cancer
(DU-145) cells displayed strong binding of anti-Amanat antibody.
Anti-Ama reactive proteins from lysed DU-145 cells were extracted by antiAma immunoaffinity chromatography. There were seven distinct proteins which
bound to the immunoaffinity column. These proteins ranged in size from about
12 kD to about 200 kD. The anti-Ama antibodies bound most strongly to a protein
with an apparent molecular weight of 200 kD. This protein was purified and
partially characterized. It was shown to be an acidic protein with a pi of 4.7. It was
also shown to be a glycoprotein with a WGA binding site indicating the presence of
GlcNAc.

Significance of Findings
These findings indicate that an anti-Ama antibody-reactive protein is found on
the surface of DU-145 cells. The function of this protein is unknown; however, it
may be involved in adhesion. Ama contains a malonic acid moiety which has been
shown to bind Ca++. However, the single free carboxyl group in peptide-linked
Ama, unlike the two groups in Gla, does not bind Ca++ efficiently. To bind a Ca++
efficiently, this Ama theoretically would need to be spatially near another carboxylcontaining amino acid so that together they could form a Ca++ binding site. The
increased acid lability of the anti-Ama antibody-reactive epitope from the DU-145 Ag
over the lability of the synthetic BSA-Ama epitope suggests that there could be
more than one acid-labile amino acid in this tumor derived epitope. An epitope
containing two Ama would have the theoretical capability of binding Ca++ and
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explaining the increase in acid lability; however, the confirmation of such a
hypothesis can only come with further characterization of the protein.
In a preliminary investigation, the anti-Amanat antibody appeared to block
the growth of DU-145 cells in culture in a dose-dependent manner. This was not
associated with cell death, but rather seemed to be due to the decreased ability of
the cells to bind to the culture plate. This provides additional indirect evidence that
the anti-Ama antibodies may recognize an adhesion molecule.
This research indicates that the anti-Amanat antibody-reactive epitope is
found on prostatic cancer cells taken from a metastatic site (DU-145 cells), but not
with normal human prostate or benign hypertrophic prostate. The anti-Ama
antibodies did not react with normal tissues from a macaque. The difference in the
binding of the antibody to cancerous but not to normal prostate cells may lie in the
expression of metastasis-related adhesion molecules on the surface of the cancer
cells. To identify a correlation between antibody binding and metastatic phenotype,
dual parameter flow cytometric analysis was conducted. This test indicated that such
a relationship exists by showing that cells in the G2/M phase of the cell cycle-those
associated with a metastatic phenotype-preferentially bound the anti-Ama
antibodies.
The specificity of both of the anti-Ama antibodies for the synthetic Ama
epitope was shown to be high. Anti-Amanat is more sensitive than anti-AmaSyn for
the DU-145 cells, as shown by the decreased number of cells bound by anti-AmaSyn
in a flow cytometry assay and the absence of specific binding of anti-AmaSyn to
DU-145 cells in a immunohistochemistry test. This latter finding is interesting
because it suggests that, since the Ama epitope is not stable, the anti-AmaSyn is so
narrowly specific, it cannot be used to test fixed tissues.
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Anti-Amanat appears to be specific for one protein extracted from DU-145
lysate using an anti-Ama antibody immunoaffinity column. Anti-AmaSyn also binds
most strongly to that same protein fraction; however, it also reacts with other
protein fractions. The anti-AmaSyn antibody may be less specific than anti-Amanat
because the synthetic Ama epitope (comprised of only one amino acid and a spacer
conjugated to BSA) was used as the primary antigen for production of this antibody.
This indicates that the anti-Amasyn may be less specific than anti-AmanatIn summary, a monoclonal antibody, anti-Amanat. has been produced which
binds to a synthetic Ama epitope as well as a naturally occurring epitope believed to
contain Ama. This naturally occurring epitope is found on a protein extracted from
DU-145 cells. This epitope is apparently upregulated on actively dividing cells; these
cells may be associated with a metastatic phenotype. This epitope may be part of a
metastasis-associated adhesion molecule. If further research can show that this
epitope is involved in tumor cell metastasis, this antibody could be used to test
therapeutic strategies based on blocking tumor metastasis by binding to adhesion
molecules.

APPENDIX A
RELATED PROJECTS FOR FUTURE CONSIDERATION
Adhesion Molecule Related Disorders and Phenomenon

1. Autoimmunity
a) Autoimmune murine lupus nephritis (Wuthrich 1990)
b) Rheumatoid arthritis (Damle and Doyle 1990)
c) Adult Respiratory Distress Syndrome
d) Chronic Inflammation
2. Reperfusion Injury-Prevent entry of damaging WBC's
a) Post Myocardial Infarction
b) Post tourniquet
c) Transplant
d) Frostbite
3. Fertilization-adhesion of sperm to egg
4. Atherosclerosis-detection and therapy
5. Overproduction of adhesion molecules
a) Meningitis
b) Burns
6. Other diseases associated with adhesion molecules
a) AIDS-RGD sequence (Levesque et al. 1991)
b) Infections
c) Toxic shock (Karp et al. 1990)
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APPENDIX B
METHODS AND MATERIALS

A. Antibody Production
1. Murine Immunization Protocol
Purpose:
The purpose of this procedure is to immunize mice in a way that induces
antibody production to a specific epitope.
Principle:
The foreign protein should elicit an immune response. With a longer series of
injections, the antibody’ response may fa^or IgG over IgM. Since soluble antigens are less likely to
induce an immune response, and in fal may promote tolerance, the antigen is usually injected
with an adjuvant an oil in water emulsion containing immuno-enhancers. RESTs adjuvant has
several advantages over Freund’s including being gentler to the mouse as it does
not usually cause ascites or ulceration. This method is adapted from Harlow and
Lane (1988b), "Suggested immunization protocols for Ribi adjuvant system,"
Ribi ImmunoChem Research, Hamilton, MT, and "Reconstitution instruction:
MPL + TDM emulsion," Ribi ImmunoChem Research, Hamilton, MT.

Material:
adjuvant-RIBI's (Ribi Immunochem Research, Hamilton, MT)
0.5 mg monophosphoryl lipid A
0.5 mg synthetic trehalose dicorynomycolate
0.04 mg squalene (40 pi)
0.004 mg monooleate (Tween 80) (0.2%)
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injectable antigen
tuberculin syringes
22 G needles
6-week-old female BALB/c mice

Injection Times
Day 1

Perform immunization with adjuvant i.p. and subcutaneous (s.c.)

Day 22

Perfom first boost with adjuvant i.p. and s.c.

Day 43

Perfom second boost with adjuvant i.p. and s.c.

Day 64

Perfom third boost with adjuvant i.p. and s.c.

Day 74

Extract blood from the mice and assay for relevant antibody

Day 85

Perform final boost without adjuvant i.v.

Day 88-90

Perform fusion (see method A.2)

Method:
1.

Concentrated antigen should have a total protein content in the range of
50-250 fig/ml, or 250-100 |ig/ml if weakly immunogenic or non-purified.

2.

Place the adjuvant containing vial in a water bath at 40-45°C for 5-10 minutes.

3.

Inject antigen/saline solution (2 ml) directly into the vial through the rubber
stopper using a syringe fitted with a 21 gauge needle (leave the cap seal in
place).

4.

Vortex the vial vigorously for 2 to 3 minutes to form emulsion. (This can then
be stored up to 60 days at 4 °C or lyophilized.) Each vial contains 10 mouse
dose equivalents of 200 ^il each.
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5.

Mark the mice using dilute picric acid (this yellow stain binds to mouse hair
proteins for easy identification).

6.

Re-vortex bottle. Using a tuberculin syringe with a 22 gauge needle, inject
100 pJ i.p. (para-splenic) and s.c. (dorsal neck), or, alternatively for the final
boost, inject the antigen saline solution (without adjuvant) directly into the tail
vein.

2. Spleen Harvesting and Fusion Protocol
Purpose:
The purpose of this procedure is to create an immortal cell line (hybridoma)
which produces an antibody of interest.
Principle:
This method is adapted from Harlow and Lane (1988c). Briefly, cells from a
myeloma cell line are fused with spleen cells from an immunized animal.
Some of these fusions will retain genes from each of the parental cells. Those
containing both the genes for the antibody production (from the plasma cell of
the immunized animal) and the genes for immortality (from the myeloma cell)
can be selected.
Material:
immunized mice
sterile forceps
sterile scissors
sterile towels
sterile pipette tips
sterile petri dish
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sterile syringes
sterile needles
sterile 96 well culture plates
fusion partner cells (e.g., NS-1)

Reagents:
alcohol
polyethylene glycol 3000-3700 (PEG)
media with 20% PCS (see method A.3)
Method:
Week Before Fusion
1.

Propagate fusion partner cell line (SP2/0, NS-1 etc.) in 8-azaguanine-free
culture media for one week. Make sure there are adequate numbers of cells
for fusion.

2.

Prepare the PEG solution five days before the fusion. Add 5 ml of 2X DMEM
(from powder) to 5 mg of PEG to obtain approximately 10 ml PEG solution.
Place in 42°C water bath until all particulate matter has dissolved. Place in
incubator for several days until slightly alkaline.

3.

Boost mice i.v. 3-5 days prior to fusion.

Day of Fusion - Harvesting Spleen Cells
1.

Anesthetize mice using ether, then kill by cervical dislocation. Bathe whole
mouse in 70% ethanol. Using sterile instruments, carefully pull up skin using
forceps and snip an opening with the scissors. Make a diagonal cut through the
abdominal muscles over the spleen (left side) and spread incision open. Using
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a second set of sterile forceps, dissect spleen free of any vessels or tissue and
immediately place it in a sterile petri dish containing warm media.
2.

Using sterile syringes and needles, flush out the splenocytes by injecting
media repeatedly into the splenic tissue. Transfer the cells in the media to a
test tube and add fresh media to the spleen. To increase the cell yield, gently
tear the spleen apart using the needles, and then pool the released cells.

Day of Fusion - Cell washing
1.

Wash the splenocytes in media without serum. Centrifuge at 400 x g for
5 minutes. Repeat.

2.

Wash the myeloma cells in media without serum in a separate tube.
Centrifuge at 400 x g for 5 minutes.

3.

Enumerate splenocytes and myeloma cells and bring to a total number of 108
splenocytes and 107 myeloma cells. This is the number of cells required for
fusion using one complete vial of PEG.

4.

Discard the supernatant of both samples and resuspend the two cell pellets in
37°C medium without serum and combine the cell suspensions. Centrifuge
the cells at 800 x g and completely discard supernatant by blotting tube on
sterile absorbent paper.

Day of Fusion - Fusion
1.

Remove the 50% PEG from its container with a Pasteur pipette and slowly add
the PEG to the cell pellet while resuspending the cells by stirring with the end
of the pipette. Add the PEG slowly over 1 minute. Continue stirring for an
additional minute.
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2.

Fill a 10-ml pipette with 10 ml of medium without serum (prewarmed to
37°C). Add 1.0 ml to the cell suspension over the next minute while
continuing to stir with the end of the 10-ml pipette. Then add the remaining
9.0 ml over the next 2 minutes while stirring. Centrifuge the cells at 400 x g
for 5 minutes.

3.

Remove the supernatant and resuspend the cells in 10 ml of medium
supplemented with 20% FCS (prewarmed to 37°C), with 1% oxaloacetate,
pyruvate and insulin (OPI), 2% HAT, and 5% hybridoma cloning factor (HCF)
(see method A.3).

4.

Dispense 100 pi of the cells into the wells of 96-well culture plates using a
multiple pipettor. Place at 37°C in a humidified incubator containing 8% CO2.

5

Clones should be visible by light microscopy by approximately four days after
fusion. In 96-well plates, the clones tend to grow along the edges of the wells.
It is important that screening be done and cells transferred before they
become overcrowded and deplete the media of essential nutrients.

3. Culture of Hybridomas
Purpose:
The purpose of this procedure is to successfully culture hybridoma cells.
Principle:
The method described is adapted from Harlow and Lane (1988c). The principle
for the selection of the hybridomas is as follows. The aminopterin blocks
de novo purine and pyrimidine synthesis in the unfused myeloma cells which
have been selected for a mutant (non-functional) hypoxanthine-guanine
phosphoribosyl transferase (HPRT) gene whose product performs one of the
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essential steps in the salvage pathway. The fused cells receive a normal gene
from the plasma cells and thus can grow in this media. The unfused plasma
cells do not survive in long term culture.
Material:
sterile media filters
sterile laminar flow work space
37°C humidified CO2 incubator
Reagents:
Media
Amount

Ingredient

Use

70 ml

Delbucco's modification of Eagles media media

20 ml

PCS

growth factors

1 ml

penicillin and streptomycin

antibiotics

1 ml

Glu

nutrient

1 ml

OPI1’2

growth factors

5 ml

HCF2

growth factor

2 ml

hypoxanthine, aminopterin
and thymadine (HAT)3

selection of
hybridoma

!Add oxaloacetate first to acidify media, then add insulin. Insulin has a low pi,
therefore it dissolves more readily at low pH.
2For low density cultures (fusion and cloning).
3For 1 week after fusion to ensure the death of all unfused myeloma cells. After
that, add hypoxanthine and aminopterin to the media for several weeks to
ensure substrate for the purine salvage pathway, as well as thymidine. This is
necessary until the concentration of aminopterin is negligible. After that the
media may consist entirely of the first four ingredients.
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Method:
1.

Warm all media ingredients to 37°C in the morning . When the ingredients are
warm, spray media containing bottles and flask containing cell culture
thoroughly with alcohol before placing under sterile hood. Add some DMEM
(about 20 ml) then add remaining ingredients (1 ml penicillin/streptomycin,
1 ml Glu, 20 ml Fetal Calf Serum, 5 ml HCF, 1 ml OPI, 2 ml HAT) and fill to
100 ml with DMEM. Wipe sterile work area with 70% ethanol.

2.

Add media to cultures as needed. As the cells multiply, transfer hybridomas
from 96-well plates to 24-, then 6-well plates to T-25, T-75 and T-150 flasks for
subcloning (see method A.4) and finally to a 1 L spinner flask for antibody
purification (see method A.5). Only selected clones (see method E.3) should be
cultured in this fashion. All selected clones should be frozen for safe storage as
soon as there are sufficient hybridoma cells (see method B.4).

4. Cloning of Hybridomas
Purpose:
The purpose of this procedure is to select, purify and expand a single clone
producing the desired monoclonal antibody.
Principle:
The method described here is adapted from Coding (1983d). Briefly, the
hybridoma cells are diluted to a concentration of one cell per 200 pi. Because of
the Poisson distribution, different wells will contain two, one or no cells
(Coding 1983d). In the final stages of cloning, the only wells of interest are
those that contain exactly one cell (monoclonal).
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Material:
sterile 10 ml tubes
sterile 96-well culture plates
multipipettor
sterile laminar flow work space
37°C humidified CO2 incubator
Reagents:
DMEM
HAT media
Method:
1.

Perform a cell count on hybridomas using the traditional cell count method
outlined in method F.l.

2.

Using serial dilutions in DMEM of no more than 1:10, bring the concentration
of the hybridomas to 5 cells/ml. Bring up final volume to at least 30-50 ml
(enough for 3-5 96-well plates). The last two dilutions should be made in HAT
media (20% FCS and 5% HCF).

3.

Dispense 100 pi of the diluted hybridomas into each well of 96-well culture
plates and place in a humidified 37°C incubator containing 8% CO2.

4.

After two days, check clones for growth. There will be many wells with no
cells, some with one clone and some with two. Mark those with one clone only
and screen the fastest growing of these for specific antibody production by
ELISA (see method D.3).

5.

Transfer the selected clones to 24-well plates changing to HT media.
Determine the isotype of any antibody found in the supernatants using ELISA
(see method E.3).
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6.

Transfer selected clones to 6-well plates, then T-25 flask, and finally T-75 flask.

7.

Freeze cells (see method B.4) for later use.

8.

Culture appropriate clones in serum-free media containing additives such as
Nutridoma (Boehringer Mannheim Biochemicals, Indianapolis, IN) in spinner
flasks to provide a large quantity of antibody for purification (see method A.5).
The use of serum-free media is designed to ensure all antibodies purified from
the supernatant are from the hybridoma.

5. Purification of Antibody-Protein A
Purpose:
The purpose of this method is to purify IgG from cloned hybridomas (e.g..
WMK-I).
Principle:
This method is based on the suggested method for affinity chromatography
purification of IgG by Pharmacia LKB (Instructions: Protein A Sepharose. Pharmacia
LKB Biotechnology, Piscataway, NJ). This procedure involves a binding of IgG
antibody by protein A (a Staphylococcal protein thought to aid the organism in the
evasion of the human immune system). This protein, when linked to a solid
matrix can be used to selectively bind IgG from the supernatant of hybridoma cells.
The addition of a low pH buffer will elute this antibody.
Material:
FPLC system
protein A column
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Reagents:
1M Tris-HCl, pH 8.0
0.1 M Tris /HC1.14 M NaCl, pH 8.0
0.01 M Tris /HC1.15 M NaCl, pH 8.0
0.1M Citrate/NaOH , pH 5.0
0.1M Citrate/NaOH, pH 3.0

Method:
1.

Harvest supernatant from spinner flasks by centrifugation for 15 minutes at
3000 x g and add azide to 0.02%. Add 1/20 volume of 1 M Tris, pH 8.0,
containing 0.02% azide.

2.

Filter the stabilized supernatant.

3.

Equilibrate the column with 100 mM Tris buffer, pH 8.0, containing 0.14 M
NaCl and 0.02% azide.

4.

Add half of the supernatant (approximately 500 ml) at 2 column volumes (cv)
per hour and the second half at 1 cv/hour.

5.

Wash column with 10 mM Tris, pH 8.0, containing 0.15 M NaCl and 0.02%
azide.

6.

Elute with 100 mM Citrate, pH 5.0, containing 0.02% azide.

7.

Neutralize fractions with 1/10 volume 1.0 M Tris, pH 8.0.

8.

Regenerate column with 100 mM Citrate, pH 3.0.

9.

Re-equilibrate and store column in 100 mM Tris buffer, pH 8.0, containing
0.14 M NaCl and 0.02% azide.

10.

Buffer exchange and concentrate final product by ultrafiltration (method C.3).
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B. Cell Culture
1. Culture of CEM Cells
Purpose:
The purpose of this procedure is to culture CEM cells for identification and
purification of Ama epitope-containing proteins.
Principle:
This procedure is adapted from cell culture conditions specified by American
Type Culture Collection (ATCC), and Freshney (1986). The method involves
adding nutrients for cell growth, buffering, monitoring and adjusting the pH of
the media, removing spent media containing toxic by-products (e.g., products
of Glu metabolism) and adjusting cell concentration to desired densities for
appropriate growth.
Material:
culture flasks
37°C humidified CO2 incubator
sterile laminar flow work area
Reagents:
Media
Amount

Unit

1

L

10

ml

penicillin/streptomycin Antibiotic

10

ml

Glu

Nutrient

25

ml

HEPES

Buffer

30

ml

FCS

(for spinner flask)

50

ml

FCS

(for Stock culture)

Ingredient

Use

RPMI

Media

194
Method:
Spinner Flask
1.

Warm all media ingredients to 37°C and autoclave spinner flask. When the
ingredients are warm, spray media containing bottles and tubes, spinner flask
and flask containing stock culture thoroughly with alcohol before placing under
sterile hood.

2.

Add RPMI (about 400 ml) then add remaining ingredients (10 ml
penicillin/streptomycin, 10 ml Glu, 25 ml HEPES, 30 ml PCS).

3.

Add cells from stock culture flask to spinner flask and fill to 1 L with RPMI.

4.

Place spinner flask in 37°C humidified incubator containing 5% CO2 in air.

Stock Culture
1.

Combine and filter 1 L RPMI, 10 ml penicillin/streptomycin, 10 ml Glu, 25 ml
HEPES, 50 ml PCS). Keep at 4°C until used.

2.

Warm prepared media to 37°C. Count and perform viability test on cells to
determine appropriate density of seeding.

3.

When the media is warm, spray media-containing bottle and stock culture flask
thoroughly with alcohol before placing under sterile hood.

4.

Aspirate predetermined amount of stock culture and use to inoculate spinner
flask or discard and add fresh media.

5.

Place flask back in 37°C humidified CO2 incubator and wash work area with
70% ethanol.
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2. Culture of DU-145 Human Prostate Carcinoma Cells
Purpose:
The purpose of this procedure is to culture DU-145 cells for identification and
purification of Ama epitope-containing proteins.
Principle:
This procedure is adapted from cell culture conditions specified by ATCC and
Freshney (1986). The method involves adding nutrients for cell growth,
buffering, monitoring and adjusting the pH of the media, removing spent
media containing toxic by-products (e.g., products of Glu metabolism) and
adjusting cell concentration to desired densities for appropriate growth.
Material:
sterile media filters
sterile laminar flow hood
37°C humidified CO2 incubator
Reagents:
Media: DMEM with 10% FCS
Amount

Unit

500

Ingredient

Use

ml

DMEM

Media

5

ml

Penicillin/streptomycin Antibiotic

10

ml

Glu

Nutrient

50

ml

FCS

Growth factors

HESS without Ca++ or Mg++.
cell dissociation buffer, and/or
trypsin
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Method:
1.

Media: Retrieve DMEM from refrigerator and P/S, Glu and PCS from freezer.
Thaw frozen ingredients. Filter ingredients in a low protein binding 500 ml
filter in a sterile environment (under the hood). Make sure the glutamine is
fully dissolved prior to filtering as it tends to precipitate. Add about 300 ml
DMEM, then add other ingredients (5 ml Penicillin/streptomycin, 10 ml Glu,
and 50 ml PCS) and remaining DMEM. Keep at 4°C until it is used.

2.

Set-up: Warm prepared media to 37°C using incubator or water bath. Count
and perform viability test on cells to determine split ratio. When the media is
warm, spray media-containing bottle and culture flask thoroughly with alcohol
before placing under sterile hood.

3.

Cell Split: Aspirate media and discard. Pipette 10 ml (per T-150 flask) HBSS
without Ca++ or Mg++. Rinse, aspirate and discard HBSS. Pipette 8 ml cell
dissociation buffer (Sigma, St. Louis, MO) or 0.04 g EDTA in 500 ml HBSS,
recap flask and place in 37°C incubator for 10 minutes. Take flasks out of
incubator and sharply rap edge of flask against the palm of your hand to
dislodge cells. Respray with alcohol and place under hood. Add 5 ml complete
media to the flask to neutralize. Enumerate and perform viability test on cells
to determine split ratio. Aspirate predetermined amount of stock culture to
inoculate roller bottle or T-150 flasks. Add fresh media (total of 15 ml for T-150
flasks and 180 ml for roller bottles). Place flask back into CO2 incubator
(8% CO2 for DMEM). Place roller bottle on roller rack in walk-in incubator at
37°C.
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3. Culture of PC-3 Human Prostate Carcinoma Cells
Purpose:
The purpose of this procedure is to culture PC-3 cells for identification and
purification of Ama epitope-containing proteins.
Principle:
This procedure is adapted from cell culture conditions specified by ATCC, and
Freshney (1986). The method involves adding nutrients for cell growth,
buffering, monitoring and adjusting the pH of the media, removing spent
media containing toxic by-products (e.g., products of Glu metabolism) and
adjusting cell concentration to desired densities for appropriate growth.
Material:
sterile media filters
sterile laminar flow hood
37°C humidified CO2 incubator
Reagents:
media: Ham’s F-12 with 7% FCS
Amount

Unit

500

Ingredient

Use

ml

Ham’s F-12

Media

5

ml

Penicillin/streptomycin Antibiotic

5

ml

Glu

Nutrient

35

ml

FCS

Growth factors

HESS without Ca++ or Mg++
trypsin/collagenase solution
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Method:
1.

Media: Filter Ham's F-12 media, penicillin, streptomycin, Glu, and FCS in a
sterile environment. Make sure the glutamine is fully dissolved prior to
filtering as it tends to precipitate. Keep at 4°C until it is used.

2.

Set-up: Warm prepared media to 37°C. Count and perform viability test on
cells to determine appropriate seeding density. When the media is warm,
spray media containing bottle and culture flask thoroughly with alcohol before
placing under sterile hood.

3.

Cell Split: Aspirate media from culture flask and discard. Pipette 10 ml (per
T-150 flask) HBSS without Ca++ or Mg++ into culture flask. Rinse, aspirate and
discard HBSS. Pipette 10 ml trypsin/collagenase solution, recap flask and place
in 37°C incubator for 10-15 minutes. Take flasks out of incubator and sharply
rap edge of flask to dislodge cells. Respray with alcohol and place under hood.
Add 5 ml media to the flask. Cells are now ready for studies or subculturing
To subculture, add fresh media (total of 15 ml for T-150 flasks) and place flask
back in CO2 incubator.

4. Freezing Cell Lines and Hybridomas
Purpose:
The purpose of this procedure is to provide a back-up source of the cell lines
and hybridomas in case of contamination, cell line mutation or cell line death.
Principle:
The method described here is adapted from Hay (1986). This method allows
safe storage of cells for decades in a -195°C environment, these cells can
subsequently be thawed and grown in culture. The cryoprotective agent
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(DMSO) enables the cell membrane to withstand the freezing without being
punctured by ice crystals.
Material:
disposable sterile cryogenic vials
freeze container
sterile hood
centrifuge
-70°C freezer
-195°C freezer
Reagents:
freeze media
94% PCS
6% DMSO
PBS
Method:
1.
2.

Perform a cell count using the method outlined in method F.l.
Centrifuge cells gently at 400 x g and discard supernatant. Resuspend cells
gently in sterile PBS then centrifuge at 400 x g and discard supernatant.

3.

Resuspend cells in cold 94% PCS and 6% DMSO bringing them up to
5 x 106 cells/ml in 1 ml aliquots in freezer vials (Coming, Corning, NY). DMSO
is toxic to metabolizing cells so as soon as the cells are resuspended in it,
freeze them.

4.

Label the freezer vials with number, cell type, date and initials and place in a
freeze container at room temperature. Place the freeze container in the -24°C
freezer overnight. This cools the cells at the even rate of 1°C per minute.
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5.

After 24 hours, place the freezer vials in a -195°C liquid nitrogen freezer.
Store the freeze container at room temperature and add fresh isopropyl
alcohol after 5 uses.

C. Antigen Purification
1. Lysis of DU-145 Human Prostate Carcinoma Cells
Purpose:
The purpose of this procedure is to provide a pool of proteins from which the
Ama epitope-containing proteins can be isolated.
Principle:
This method is adapted from Coding (1983b). The principle is based on the
fact that Triton X-100, a non-ionic detergent, physically destroys the integrity
of the cell membrane. It also acts to free and stabilize membrane bound
proteins. The procedure is carried out at 4°C and protease inhibitors are added
to inhibit enzymatic cleaving of native proteins.
Material:
DU-145 cells
Reagents:
PBS (4°C)
lysis buffer (4°C)
0.5% Triton X-100 (membrane detergent)
0.1 % PMSF (protease inhibitor)
0.02% Azide (antibiotic)
PBS (buffer)
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Method:
1.

Culture cells until late log phase. Decant media and add Triton X-100 lysis
buffer directly to T-150 flask or roller bottle at 2 x 107 cells/ml (about 10 ml for
T-150 flasks and 30 ml for roller bottles). One pi PMSF per ml lysis buffer
must be added fresh as this protease inhibitor has a short half life. Keep flasks
at 4°C for 45 minutes, lightly mixing them intermittently during this time.
For roller bottles, roll bottle at 100-120 rpm at 4°C for about 15 minute then
roll occasionally for next 30 minute.

2.

Centrifuge lysate 15 minutes at approximately 4000 x g, 4°C. Transfer
supernatant to a 50 ml freezer vial and keep cold, or freeze supernatant if it is
to be used later than 12 hours hence.

2. Immunoaffinity Chromatography
Purpose:
The purpose of this procedure is to immunopurify proteins containing a
specific epitope (e.g., an Ama epitope-containing protein).
Principle:
This method is adapted from Coding (1983a). The antibodies are bound to a
solid matrix which is then packed into a column. Proteins flowing past these
antibodies will be bound if they have the appropriate epitope. After the
sample has been applied to the column, one column volume of lysis buffer is
pumped through at a slow rate to help solubilize any remaining membrane
lipoproteins bound to the epitope containing membrane proteins. Another
two column volumes of lysis buffer are pumped through at the maximum
rate to flush all remaining lipoproteins. The column is then reversed (so that
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there is a shorter distance from the end of the column to the UV light detector)
and flushed with PBS. Then the bound proteins are eluted with a buffer
containing diethylamine, pH 11.0. The high pH decreases the ability of the
antibody to bind. (The use of a low pH buffer also would cause antigen elution;
however, since Ama is acid labile, a high pH buffer was chosen.)
Material:
FPLC system
centrifuge
Reagents:
diethylamine buffer
diethylamine 100 mM
NaCl 0.15 M
azide 0.02%
pH 11.0 (add HC1)
lysis buffer (4°C)
0.5% Triton X-100 (membrane detergent)
0.1% PMSF (protease inhibitor)
0.02% azide (antibiotic)
in PBS (buffer)
PBS 10 mM
phosphate buffer 100 mM pH 6.8
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Method:
Immunoaffinity Chromatography-Protocol for Column Preparation
1.

Couple anti-Ama antibody (mAb-AmaSyn) to Actigel ALD (Sterogene) at a
concentration of 2 mg Ab/ml of gel (as described in "Coupling Chemistry of
Acitgel-ALD/Acitgel-ALD Superflow," Sterogene Bioseparations, Inc., Arcadia,
CA).

2.

Buffer exchange antibody extensively with 0.1 M phosphate buffer, pH 7.0, by
ultrafiltration.

3.

Wash gel 3 times with phosphate buffer and drain.

4.

Add 10 ml antibody solution to 10 ml drained gel. Adjust concentration to 0.1 M
NaCNBHa and agitate 4 hours.

5.

Wash gel with 10 volumes of 0.5 M NaCl.

6.

Agitate gel in 0.1 M ethanolamine, pH 7.0, containing 0.1 M NaCNBHs for
2 hours to block unreacted sites.

7.

Wash gel with 0.5 M NaCl and store in PBS with Azide.

8.

Pack 8 ml of gel into a Pharmacia XK 16/20 column or 20 ml into a XK 26/20
column.

Immunoaffinity Chromatography-Protocol for Column Use
1.

Degas all buffers before they are applied to the column otherwise the pressure
drop in the column will cause the dissolved gasses to come out of solution and
introduce bubbles into the column.

2.

Thaw lysate and add PMSF fresh. Centrifuge lysate 4000 x g and save
supernatant containing cellular proteins.

3.

Turn on UV lamp two hours prior to elution.
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4.

Precycle column with 2 column volumes of diethylamine, then wash with PBS
at 2 ml per minute. This is necessary to eliminate any antibody that has
become dissociated from the matrix and any residual bound antigen from
previous uses. Equilibrate column with 2-3 column volumes of lysis buffer at
2 ml per minute.

5.

Apply lysate at <1 column volume per hour. Wash column first with lysis
buffer at low rate for 1 column volume then at maximum rate for 2 column
volumes. Insert a flush line in place of the column and flush pumps A and B
with PBS and diethylamine respectively. Zero the chart recorder. Reverse
column and wash with PBS to baseline.

6.

Elute with 0.1 M diethylamine, pH 11.0 and collect fractions. Neutralize
fractions with 1 M phosphate buffer, pH 6.8 immediately.

7.

After the elution is complete, re-equilibrate column to neutral pH with
100 mM phosphate buffer.

8.

Store column in PBS containing 0.02% azide at 4°C.

9.

Buffer exchange fractions and concentrate by ultrafiltration.

3. Ultrafiltration Concentration of DU-145 Eluate from Immunoaffinity
Chromatography
Purpose:
The purpose of this procedure is to provide a more concentrated source of the
Ama epitope-containing protein for further studies.
Principle:
The sample protein is concentrated by a size limiting membrane (filter) so that
the diethylamine buffer and salt passes through the membrane and is
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discarded while the protein remains behind. Various filters can be used but
caution should be taken to chose a filter with a pore size at least an order of
magnitude smaller than the desired protein since the given pore size is an
"average" pore size and thus there may be a small percentage of larger size
pores.

Material:
DU-145 eluate from immunoaffinity chromatography
concentrator
YM-3 membranes
stir plates
positive air pressure
Reagents:
PBS

Method:
1.

Place the YM-3 membrane with its smooth surface down in a beaker of
pyrogen free water at room temperature for 10 minutes to elute the azide.
Repeat once.

2.

Assemble concentrator and add sample. Place concentrator on stir plate
(preferably at 4°C) and stir at a moderate speed (not enough to disrupt or foam
proteins but enough to keep them from clogging the membrane). Apply
100 K pascals positive air pressure. For preservation of membrane function,
do not expose dialysis membrane to amines (e.g., diethylamine) for prolonged
periods of time. Store in PBS if not to be used for several hours.
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3.

Refill concentrator with eluate as needed. Discard filtrate.

4.

For injection into mice, buffer exchange sample protein with 10 ml of sterile
PBS x 3.

4. Gel Filtration Chromatography
Purpose:
The purpose of this assay is to separate proteins by size.
Principle:
The size exclusion column is made up of beads with many indentations. These
pockets tend to trap smaller proteins slowing their progression through the
gel. Larger proteins, due to steric forces, are only affected by the larger
pockets and thus travel through the gel faster. Too large of a sample volume
will decrease the resolution of this method due to the different start times of
the sample on the column. This method is adapted from Simpson (1988b) and
the "Pharmacia FPLC system handbook #5, Theory and optimization."
Material:
FPLC system
Superose 6 column (100 ml volume)
Reagents:
PBS or
150 mM ammonium bicarbonate
sample protein
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Procedure:
1.

Precycle column with degassed 150 mM ammonium bicarbonate (if to be
vacuum concentrated) or PBS with 2 column volumes at or below maximum
flow rate of given column.

2.

Zero chart recorder.

3.

Prepare fraction collector.

4.

Continue to pump ammonium bicarbonate or PBS through the column as the
concentrated sample is loaded in loop (100 jil to 2 ml) or in superloop (up to
10 ml).

5.

Change the valve position so that the PBS is pumped through the loop. This
will load the sample onto the column.

6.

After approximately 3 loop volumes, when the sample has been loaded and the
loop thoroughly rinsed, change the valve position back to its original position.

7.

Collect fractions and chromatograph.

8.

Wash beyond the total column volume (until all proteins are out), then wash
for 2 cv more, and store column contents in PBS with 0.02% azide.

Note: Fractions can be evaluated for Ab staining using ELISA. They will need
to be concentrated for further purification (e.g., reverse phase or ion exchange
chromatography).

5. Reverse Phase Chromatography
Purpose:
The purpose of this procedure is the high resolution separation of proteins.
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Principle:
The proteins are separated based on differences in their hydrophobicity. This
is accomplished by using hydrophobic beads in the column. These beads bind
the hydrophobic part of the protein. The protein is eluted when an increasing
gradient of acetonitrile is added which competes with the protein for the
hydrophobic binding sites; proteins eluted first have the least hydrophobicity.
This harsh treatment may denature proteins. This method is adapted from
Simpson (1988b) and the "Pharmacia FPLC system handbook #5, Theory and
optimization."
Material:
FPLC system
Reverse phase column (ProRPC HR 5/2)
Reagents:
HPLC grade water
HPLC grade acetonitrile
trifluroacetic acid (TFA)
Method:
1.

Precycle column with HPLC grade water, then acetonitrile with 0.1% TFA
(buffer B)

2.

Wash pumps A and B with acetonitrile with 0.1% TFA then wash pump A with
water containing 0.1% TFA (buffer A).

3.

Clean out the FPLC tubing and reverse phase column for this very sensitive
assay with an increasing concentration of acetonitrile. Flush with HPLC grade
water.

4.

Dilute the sample in buffer A
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5.

Centrifuge sample for 10 minutes at maximum in microfuge.

9.

Set up fraction collector.
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Load sample by pumping it through column at 0.01 ml per minute for
15 minutes then at 0.5 ml per minute for 2 minutes with buffer A.

11.

Separate the bound proteins in the sample by adding an increasing gradient of
acetonitrile.

12.

Save appropriate fractions for analysis.

13.

Store column in methanol by pumping on 5 to 10 column volumes (for
HR 5/2, this is 2.5-5.0 ml) of 20% methanol at 0.7 ml per minute.

6. Ion Exchange Chromatography
Purpose:
The purpose of this procedure is the relatively high resolution separation of
proteins in their native state (versus denatured).
Principle:
The proteins are separated based on their relative charge. The column matrix
is either negatively charged (cation exchange) or positively charged (anion
exchange). In anion exchange, for example, proteins are dissolved in a buffer
of appropriate pH to ensure that the proteins are negatively charged. They are
then pumped through the column where they bind to the positively charged
beads. After loading the column in this fashion, an increasing concentration of
Cl' is pumped through the column, displacing those proteins that are less
positively charged first and progressively displacing the more positively
charged tighter bound proteins. The same general principle holds true for
cation exchange, using opposite charges. This method is adapted from
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Simpson (1988b) and the Pharmacia FPLC system handbook #5, Theory and
optimization.
Material:
FPLC system
Ion exchange column (e.g., Mono Q 5/5)
Reagents:
Buffer A
20 mM Tris

pH 7.5

20 mM Methylpiperazine

pH 4.5

20 mM Histadine

pH 5.5

Buffer B
Buffer A with 1 M NaCl
Method:
1.

Choose appropriate buffer based on pi of sample. Make 500 ml each of
buffers A and B. Degas the buffers.

2.

Wash pumps A and B with buffers A and B, respectively.

3.

Wash column at 1 ml/minute as follows:
Time

Buffer

Purnose

5 minute

buffer A

wash out methanol

20 minute

buffer B

wash out any bound protein

10 minute

buffer A

equilibrate column

4.

Dilute sample in Buffer A, mix and centrifuge.

5.

Inject sample into appropriate injection loop (e.g., 500 pi).

6.

Set up fraction collector and zero chart recorder.

7.

Load sample at 0.1 ml per minute for 5 minutes.
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8.

Add buffer A at 1 ml per minute and, after five minutes, begin to
incrementally add buffer B (creating a gradient) until there is 100% buffer B at
25 minutes. Hold the gradient there for 10-15 minutes to assure all previously
bound protein is eluted.

9.

To use again, wash the column with buffer A for 10 minutes at 1 ml per
minute. Then start at step #4.

10.

For storage, treat column as follows:
Purpose

Time

Buffer

Rate

10 minute

buffer B

2 ml/minute wash out any protein

10 minute

Water

2 ml/minute wash out buffer B

10 minute

20% ethanol 1 ml/minute storage

D. Antigen Characterization
1. SDS-Polyacrylamide Gel Electrophoresis
Purpose:
The purpose of this procedure is to determine the relative molecular weight
and quantity of a given protein sample.
Principle:
The principle is based on the fact that negatively charged proteins will move
toward a positive charge. An SDS and mercaptoethanol mixture is added to the
proteins which are then boiled. During this denaturing process, SDS binds to
the protein with approximately one SDS molecule for every two amino acids.
This gives the protein a strong net negative charge with a mass-to-charge ratio
which is virtually identical for all proteins. An electric gradient is produced in a
gel through which the protein must pass. The gel impedes progression of the
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larger proteins while the more maneuverable smaller proteins proceed at an
accelerated rate. By running samples of known molecular weight it is possible
to obtain an apparent molecular weight for a sample. The method described
below is adapted from Pharmacia PhastSystem Separation Technique File
No. 110: SDS-PAGE (1990), Pharmacia PhastGel Silver Kit Instruction Manual,
Pharmacia PhastSystem Separation Technique File No. 200 Fast Comassie
Staining, and Simpson (1988a).
Material:
Pharmacia PhastSystem
Hot plate
Beaker
Gel
Reagents:
2X Sample Buffer
2 mM EDTA
0.2% brome phenol blue
5% SDS
1% beta-mercaptoethanol
in 20 mM Tris-HCl, pH 8.0
Development Buffers:
Step

Buffer

Fix

30% ethanol and 10% acetic acid

Wash

30% ethanol

Stain

0.4% silver nitrate
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Destain

10% acetic acid

Storage

20% glycerol

Method (Pharmacia PhastSystem):
1.

Turn on PhastSystem unit to cool to 15°C.

2.

Mix sample protein and molecular weight markers with sample buffer 1:1 and
boil for five minutes.

3.

Centrifuge stained samples to remove any protein precipitate.

4.

Load 4 ml of sample onto appropriate polyacrylamide gel.

5.

Run appropriate separation program to produce an electrical gradient across
the gel.

6.

Move gel to the development chamber.

7.

Run appropriate development program. This will fix the gel, then stain, wash,
destain and finally preserve the gel for storage using the development buffers
described in the reagents section.

8.

Analyze with the aid of transmissive scanning for computer analysis.

2. Determination of pi by Isoelectrofocusing
Purpose:
The purpose of this procedure is to determine the pi of a sample.
Principle:
This procedure is based on the fact that a protein has a net charge. The pi
relating to this charge can be deduced by setting up a pH gradient on a gel and
allowing the protein to migrate through the gel until it no longer has a charge.
Thus a negatively charged protein will migrate toward a lower pH until the
hydrogen ion concentration neutralizes the charge of the protein.
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consequently eliminating further charge-mediated migration by that protein.
The distance traveled can be compared with that of standards of known pi to
deduce a pi for that protein. The method described here is adapted from
Pharmacia PhastSystem Separation Technique File No. 100: IEF and
Electrophorectic Titration Curve Analysis, Pharmacia PhastGel Silver Kit
Instruction Manual, Pharmacia PhastSystem Separation Technique File
No. 200 Fast Comassie Staining, and Simpson (1988a).
Material:
Pharmacia PhastSystem
polyacrylamide gel
Reagents:
Development Buffers:
Fix

20% trichloroacetic acid

Stain

0.02% PhastGel blue R
30% methanol
10% acetic acid
0.1% w/v CuS04
in deionized water

Wash

30% methanol and 10% acetic acid in deionized water

Destain

10% methanol and 10% acetic acid in deionized water

Method (Pharmacia PhastSystem):
1.

Turn on PhastSystem unit to cool to 15°C.

2.

Centrifuge stained samples to remove any protein precipitate.

3.

Load 4 ml of sample onto the comb.
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4.

Run appropriate separation program to set up a pH gradient along the gel.

5.

Apply sample to gel and allow program to run.

6.

Move gel to the development chamber.

7.

Run appropriate development program. This program will fix the gel, then
stain, wash, destain and finally preserve the gel for storage using the
development buffers described in the reagents section.

8.

Analyze on a light box to determine the distance sample protein band traveled
from the anode, and by comparing that with controls, determine the pi.

3. Characterization of Clycosylation Sites on Glycoproteins
Purpose:
The purpose of this procedure is to identify any glycosylation sites on the antiAma antibody-reactive DU-145 antigen to further characterize that protein.
Principle:
The ability of lectins to bind specific glycosylation groups have made them
fundamental to the analysis of glycoproteins. Since many cell surface markers
(including tumor markers) and many adhesion molecules (selectins) are
glycoproteins, it would be of interest to characterize the glycosylation pattern
of the DU-145 Ag. The biotinylation of the lectins allows for a very sensitive
assay designed to show glycosylation patterns of subnanomolar quantities of
sample. The ProBlott membrane allows for optimal capture of protein. This
method is based on the procedure described by Hsi et al. (1991).
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Material:
Biotinylated Lectin Sample Kit

Pierce, Rockford, IL

avidin and biotinylated horseradish peroxidase

Pierce, Rockford, IL

ProBlott Membrane
polyvinylpyrrolidone-360

Sigma Chemical Co., St. Louis, MO

Triton X-100

Sigma Chemical Co., St. Louis, MO

trifluroacetic acid (TFA)

Reagents:
1.

Blocking buffer (50 ml)
50 mM Tris-HCl
0.5 M NaCl
2% polyvinylpyrrolidone-360 (PVP-360)
pH 7.5

2.

Wash buffer (100 ml)
50 mM Tris-HCl
0.5 M NaCl
0.1% Triton X-100 (v/v)
pH 7.5

3.

Reaction buffer (200 ml)
50 mM Tris-HCl
0.5 M NaCl
pH 7.5

4.

Applied Biosystems, Foster City, CA

Methanol

217
5.

Development buffer (DAB) (make fresh for each use)
0.05% diaminobenzidine-HCl
0.03% of 30% H2O2
diluted in reaction buffer

Method:
1.

Prewet the ProBlott membrane with methanol, followed by water, and place it
on water-soaked thick filter paper. Be careful not to allow any air bubbles
between the membrane and filter paper.

2.

Add 2-4 |il of sample in intervals 1 cm apart, taking care to restrict the size of
the spot to 2-3 mm in diameter. The sample will be drawn through the
membrane by wicking action. Allow to air dry.

3.

Steps 3-9 are carried out in a 8.5 x 12 cm plastic box. Rewet the membrane
with methanol and then soak in 15 ml blocking buffer (50 mM Tris-HCl, 0.5 M
NaCl, and 2% PVP-360, pH 7.5) and place it on a shaker for 1 hour at room
temperature. This should saturate the binding sites. The PVP-360 not only
offers better blocking than BSA but also seems to facilitate lectin binding to
glycosylation groups (Hsi et al. 1991).

4.

Add 15 ml of biotinylated lectin solution diluted 10 pg/ml in blocking buffer,
and incubate for 2 hours.

5.

Rinse the membrane 3 times (10 minutes per rinse) with wash buffer (50 mM
Tris-HCl, 0.5 M NaCl, and 0.1% Triton X-100 (v/v), pH 7.5).

6.

Prepare the ABC reagent mixture by adding one drop each of Avidin “A” and
biotinylated horseradish peroxidase “B” to 5 ml of reaction buffer (50 mM Tris-
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HC1 and 0.5 M NaCl, pH 7.5). Incubate this for 30 minutes at room
temperature; then dilute to a total volume of 15 ml.
7.

Add the ABC reagent mixture to the membrane and gently shake the
membrane on an orbital mixer for 1 hour.

8.

Decant and rinse membrane with was buffer three times (10 minutes each
with gentle shaking prior to decanting).

9.

Develop the reaction by placing the membrane in DAB (0.05%
diaminobenzidine-HCl, 0.03% of 30% H2O2 in reaction buffer) for about
1-3 minutes until a brownish color appears.

10.

Rinse with water and allow to air dry.

E. Antigen-Antibody Studies
1. Flow Cytometric Analysis of Cells Using Monoclonal Antibodies
Purpose:
The purpose of this procedure is to determine whether antibodies will bind to
the surface of different cells, thus indicating the presence of a particular
epitope on those cells.

Principle:
This method is adapted from Coding (1983c). Briefly, antibody specific
epitopes on cell surfaces can be detected either directly (by conjugating a
fluorescent molecule to the antibody) or indirectly (by using a sandwich
technique in which the second antibody contains the fluorescent label). The
cells can be analyzed on a flow cytometer which projects a laser beam onto the
cells traveling through a laminar flow stream activating any bound fluorescent
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label. The FACS can detect the intensity of that fluorescence which is directly
proportional to the amount of bound antibody. Thus with appropriate controls
for non-specific binding, the relative amount of the epitope can be deduced.
Material:
FACS
12 x 100 mm polystyrene tubes
Reagents:
PBS
primary antibody (e.g., anti-Amanat or anti-AmaSyn)
labeled anti-primary antibody (e.g., FITC labeled goat-anti-mouse antibody)
propidium iodide (10 mg/dl)
Method:
1.

Set centrifuge temperature to 4°C.

2.

Harvest cells and perform a cell count. Centrifuge at 450 x g for 5 minutes.
Pour off supernatant and adjust cell concentration to 3 x 106 cells per ml.

3.

Aliquot 0.5 ml of the cell solution into plastic 12 x 75 mm tubes. Wash with
4 ml of cold PBS (first add 2 ml, vortex then add the other 2 ml and vortex).
Maintaining the cells at 4°C will minimize patching, capping and internalization
of membrane antigens-very important for this assay.

4.

Centrifuge at 450 x g for 5 minutes. Pour off the supernatant and blot.

5.

Add 100 ml of first antibody dilution (1:4 to 1:5) and vortex. Incubate for
30 minutes at 4°C with periodic mixing.

6.

Add 3 ml cold PBS, centrifuge and discard supernatant, then wash with 4 ml of
cold PBS (first add 2 ml, vortex then add the other 2 ml and vortex). Pour off
supernatant and blot.
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7.

Add 100 ml of labeled second antibody dilution (1:4 to 1:5) and vortex. Incubate
in the dark for 20 minutes at 4°C with periodic mixing.

8.

Add 3 ml cold PBS, centrifuge and discard supernatant; then wash with 4 ml of
cold PBS (first add 2 ml, vortex then add the other 2 ml and vortex). Pour off
supernatant and blot.

9.

Add 0.5 ml cold propidium iodide (PI) 10 mg/dl and incubate 15 minutes in the
dark at 4°C. Store on ice until ready for analysis.

2. Cellular ELISA for Ama Epitope
Purpose:
The purpose of this procedure is to determine if the Ama epitope is found on
the surface of cells.
Principle:
Cells containing an epitope on their surface to which the antibody binds can be
detected indirectly by using a sandwich technique in which the second
antibody contains an enzyme (e.g., alkaline phosphatase) and substrate is
added. The optical absorbance of the well is directly proportional to the
amount of bound antibody and thus, taking the controls into account, to the
amount of the epitope. This method is based on a procedure described by
Thomas and McNamee (1990).
Material:
ELISA plate reader
centrifuge
pipettes
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Reagents:
PBS
blocking buffer
2% BSA in 100 mM carbonate buffer, pH 9.6
primary antibody
labeled secondary antibody
substrate (para-nitorphenylphosphate 1 mg/ml)
Method:
1.

Pipette 300 pi of 2% BSA (for plate blocking) in 100 mM carbonate buffer
(pH 9.6) into 96-well plate. Incubate for at least one hour at room temp.

2.

Count cells and aliquot a sufficient amount for procedure into test tube.
Centrifuge 5 minute at 400 x g, 4°C, and discard supernatant. Resuspend in
PBS and repeat twice. Bring up to final volume of 5 x 105 cells/ml.

3.

Discard the BSA and dispense 100 pi of cell suspension (5 x 105) into wells of
round-bottom microtiter plates. Centrifuge 1 minute at 400 x g, 4°C, remove
supernatant by vacuum aspiration, and disrupt pellet by briefly shaking the
microtiter plate on the vortex mixer. Note: To avoid "splash over," it is
advisable to use a more time consuming method of cell resuspension. Take
the plate and gently tap it on its edge until resuspension is attained.

4.

Resuspend cells in 100 pi solutions containing anti-Ama (1:100 in PBS) or
control antibody (anti-CD 5,1:100 in PBS) in ice-cold PBS. Incubate one hour at
4°C, resuspending cells by gently shaking at 15-minute intervals.

5.

Centrifuge 1 minute at 400 x g, 4°C, remove supernatant by vacuum
aspiration, briefly vortex pellet, and resuspend in 200 ml ice-cold wash buffer.
Repeat twice.
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6.

Resuspend pellet in 100 pi of the second Ab (anti-IgG) diluted 1:1000 in PBS.
Incubate 1.0 hour at 4°C, resuspending cells by gently shaking at 15-minute
intervals.

7.

Centrifuge 1 minute at 400 x g, 4°C, remove supernatant by vacuum
aspiration, briefly vortex pellet, and resuspend in 200 ml ice-cold PBS. Repeat
three times.

8.

Add 100 pi substrate (alkaline phosphate) and place in dark at room
temperature.

9.

Read using microtiter plate reader at 30 minutes and 60 minutes.

3. ELISA
Purpose:
The purpose of this procedure is to determine whether an unknown
antibody is directed against a known antigen, or whether a known antibody is
directed against an unknown antigen.
Principle:
Proteins containing an epitope to which the antibody binds can be detected
indirectly by using a sandwich technique in which the second antibody contains
an enzyme (e.g., alkaline phosphatase) and substrate is added. The absorbance
of the well is directly proportional to the amount of bound antibody and thus,
taking the controls into account, to the amount of the epitope. The plate
reader performs a double blanking procedure for each well in which it not only
subtracts the absorbance of a well containing either no antigen or no primary
antibody, but also subtracts the absorbance at a different wavelength (490 nm)
at which alkaline phosphatase activated substrate is not absorbed. This second
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subtraction compensates for any smudges or scratches on individual wells that
could increase the absorbance. This method is adapted from Engvall and
Perlmann (1972).
Material:
Immulon IV 96-well plate
ELISA plate reader
pipettes
Reagents:
binding buffer-100 mM carbonate buffer (pH 9.6)
PBS
blocking buffer-0.05% Tween 80, 0.25% BSA, 0.02% azide in PBS
primary antibody
labeled secondary antibody
substrate (para-nitrophenylphosphate, 1 mg/ml)
Method:
1.

Pipette 50 pi antigen solution into 96-well plate.

2.

Add 50 pi 100 mM carbonate buffer (pH 9.6).

3.

Incubate overnight at 4°C.

4.

Wash plate with PBS 3 times and block with 315 pi plating buffer (0.05%
Tween 80, 0.25% BSA, 0.02% azide in PBS). Incubate for 30 minutes.

5.

Wash plate with PBS 3 times and add 100 pi (0.02 mg/ml) of first antibody.
Incubate for 60 minutes.

6.

Add 100 pi (1:1000) second Ab (anti-IgG). Incubate for 60 minutes at 37°C.
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7.

Wash plate with PBS 3 times; then add 100 pi substrate (alkaline phosphatase)
and place in the dark at room temperature.

8.

Read absorbance at 30 and 60 minutes at 410 nm on an ELISA plate reader.

4. Fresh Frozen Tissue Sections
Purpose:
This procedure is designed to prepare tissues for staining with various
antibodies in a way that will cause a minimal amount of epitope destruction.
Principle:
Flash freezing of the tissue will preserve the epitopes in a manner close to
the physiological state with minimal denaturation. The speed with which this
procedure can be carried out also ensures minimal activity of proteolytic
enzymes. This procedure is adapted from Mayer and Walker (1987).
Material:
liquid nitrogen (-195°C)
specimen molds
storage freezer (-70°C)
Reagents:
isopentane
tissue freeze media
Method:
1.

Harvest tissue from recently deceased animal or from recently performed
biopsy.

2.

Cool isopentane in liquid nitrogen (-70°C).

3.

Place a 2 cubic millimeter sample of tissue into a plastic specimen mold.
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4.

Cover the specimen with freeze compound and remove any bubbles.

5.

Drop the molded specimen into a double insulated container containing the
cooled isopentane; this will freeze in about 2 minutes.

6.

Store at -70°C until needed.

5. Sectioning and Mounting Frozen Tissue Sections
Purpose:
To cut previously frozen tissue sections and mount them on slides for
immunohistochemistry.
Principle:
The microtome makes uniform slices of tissue, from 2 pm to 20 pm, which
can be used in immunohistochemical analysis. This procedure is adapted
from Mayer and Walker (1987).
Material:
razor blades
charged microscope slides
refrigerant spray
tissue freezing medium
brush
microtome
Method:
1.

Place samples embedded in tissue freeze medium in microtome, toaBowthemto
equilibrate to the temperature at which the procedure will be accomplished

2.

Place approximately 1 ml of tissue freeze medium on sample base, positioning
sample block so that the long axis of the tissue is perpendicular to the blade.
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3.

Place a cold blade in the microtome blade holder.

4.

Cut any excess frozen tissue freeze medium from the tissue block and away
from the sides of the sample. This will decrease the compression of the tissue
which occurs during cutting.

5.

Place base containing sample in holder and adjust so that the plane of the
sample is perpendicular to the blade throughout.

6.

Cut several sections until they are uniform throughout the cut. Move the
blade to a sharper section.

7.

Cut while gently pulling section away from blade with brush. Keep section
flat. Pick up section with warm microscope slide which will immediately melt
the tissue freeze medium. Repeat, keeping sample and blade cool with
refrigerant spray.

8.

Upon completion, clean microtome, discard blade and place dry sections in
-70°C freezer.

6. Immunohistochemical Analysis of Tissue Sections
Purpose:
To identify tissue components to which a given antibody binds; for antibody
specificity testing.
Principle:
The tissue sections can be screened for reactivity with the anti-Ama antibodies.
This is carried out by a three step binding process. First, the primary antibody
is incubated with the tissue section followed by addition of a secondary
biotinylated antibody. The third binding step involves the addition of a mixture
of avidin and biotinylated peroxidase. The avidin binds the biotinylated antibody
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and biotinylated peroxidase. The bound enzyme then acts on the substrate to
produce a dark brownish color. Counterstaining of the section enables the
viewing of unstained portions of the tissue. This procedure is adapted from
Mayer and Walker (1987) and Pierce (ImmunoPure ABC Peroxidase Staining
Kits, Pierce, Rockford, IL).

Material:
microscope
tissue section cut and on slides
cover slip adhesive (e.g., Permount)
cover slip
Reagents:
primary antibody
peroxidase labeled secondary antibody or Avidin-Biotin kit
diaminobenzidine tetrahydrochloride (DAB)
clearing agent (d-Limonene)
100% alcohol
3% H2O2
PBS
hematoxylin
Method:
Dewax and Fix
1.

Dewax paraffin embedded sections by heating on hot plate for 10 seconds at
55°C (to melt wax) and then treat with xylene or safety buffer for 10 minutes.
In assays involving frozen sections, this step is omitted.
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2.

Rinse sections in 100% alcohol, then rinse sequentially in beakers containing
95% EtOH, 70% EtOH and a final rinse with running distilled water. If
assaying a frozen section, fix in acetone.

Block endogenous peroxidase (This step is omitted if using alkaline
phosphatase for secondary development.)
3.

Place sections in 0.3% H2O2 (v/v) diluted in methanol for 7-10 minutes for
paraffin embedded sections or 30 minutes for frozen sections. Do not use
buffers or antibodies containing azide.

4.

Block non-specific binding with 20-30% serum (preferably from same species
as second antibody) for 20 minutes.

5.

Aspirate (don't rinse).

Add First Antibody
6.

Apply first antibody for 30-60 minutes at known concentration. Dilute
antibodies can be applied for 12 to 24 hours to decrease non-specific binding.

7.

Wash thoroughly three times, 5 minutes each in PBS.

Add Second Antibody
8.

If using Avidin-Biotin kit, add one drop biotinylated antibody to 10 ml PBS.
Apply this to sections for 30 minutes. At this time, prepare Avidin-Biotin
Peroxidase stain by adding two drops of Reagent A (Avidin) to 10 ml PBS, mix
and immediately add two drops Reagent B (Biotin). Let stand at least
30 minutes.
If not using ABC kit, dilute peroxidase labeled second antibody (2 mg/ml) in
PBS (1:1000).

9.

Aspirate and wash thoroughly, 3 times for 5 minutes each.
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Add Stain
10. Add Avidin-Biotin Peroxidase stain for 30 minutes.
11. Aspirate and wash thoroughly, 3 times for 5 minutes each.
Add Substrate
12.

Dissolve 1 mg per ml of DAB in Tris buffer (pH 7.2) and activate by mixing an
equal volume of this DAB solution with 0.02% H2O2. Add this activated
substrate to tissue sections for 2-7 minutes.

13. Aspirate DAB solution and wash with PBS thoroughly, 3 times for 5 minutes
each.
Counterstain and View
14. Apply Hematoxylin (counterstain) to tissue sections for 10 seconds; then rinse
in running water. An alternative is to stain with Harris stain (regressive stain)
for two minutes and then dip 2-3 times in 1% acid alcohol.
15.

Dip tissue sections in alcohol, then in xylene or safety buffer (clearing agent).

16.

Dry slide and allow tissue sections to air dry.

17. Add a drop of Permount to a cover slip and turn tissue section over onto cover
slip. Squeeze out any bubbles.
18. View tissue section under microscope.

7. Conjugation of Amino Acids to BSA
Purpose:
The purpose of this procedure is to make conjugates close to but different
than the BSA-Ama (monopeptide) conjugates, to determine the exact nature of
the binding site for the anti-AmaSyn and anti-Amanat-

230

Principle:
The NHS ester binds to primary amine functions of epsilon amine groups on
lysine or available N-terminus amines. This enables binding to lysines on the
BSA and to the amine of the free amino acid. BS3 is a water soluble analog of
disuccinimidyl suberate. This method is adapted from the recommended
procedure ("Homobifunctional NHS-ester crosslinkers," Pierce, Rockford, IL).
Material:
FPLC system
size exclusion column (Sephadex G-25 S.F.)
BSA
free amino acids
Bis(sulfosuccinimidyl) suberate (BS3)
Reagents:
PBS
100 mM ammonium bicarbonate
50 mM Tris-HCl pH 7.5
Method:
1.

Warm the BS3 to room temperature before opening as it is hygroscopic and
hydrolyzable. Mix the BSA with a 10 molar excess NHS ester cross linker,
BS3. This binds to epsilon amine groups on lysine of available N-terminus
amines. Incubate for 30 minutes at 20°C on a rocker.

2.

Separate the BSA from the excess BS3 by size exclusion column
chromatography with PBS at 2 ml per minute (see method C.5). The
exclusion limit of 5,000 allows the 66,000 kD BSA to pass unimpeded through
the column while chromatographing the BS3.
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3.

Add the free amino acids to the BSA-BS3 fraction. Incubate for 30 minutes at
20°C on a rocker. Add 0.1 M ethanolamine to block unbound BS3 molecules
and incubate for another 30 minutes at 20°C on a rocker.

4.

Separate each BSA-amino acid from the free amino acid by size exclusion
chromatography. This may be accomplished with ammonium bicarbonate if
the fractions are to be vacuum concentrated.

5.

Speed vacuum fractions until dry.

8. DU-145 Detachment from Six-Well Culture Plates using the Anti-Amanat
antibody
Purpose:
The purpose of this procedure is to determine whether the anti-Amanat
antibody can detach the DU-145 cell from a culture plate. This would provide
evidence that the antibody may be directed against an adhesion molecule.
Principle:
The antibody binding to a cellular adhesion molecule should make it less easy
for the cell to bind and thus the number of cells attached to the surface of the
culture plate should be inversely proportional to the ability of the antibody to
bind a relevant adhesion molecule.
Material:
six-well culture plate
humidified, 5% CO2 incubator
sterile laminar flow hood
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Reagents:
growth media (see method B.2)
antibody (azide free)
Method:
1.

Detach growing DU-145 cells with a non-enzymatic solution (e.g., an EDTA
containing buffer). Plate out cells into a six-well plate. The cell concentration
should be less than 105 cells per ml.

2.

Add antibody at the appropriate time at various concentrations.

3.

Incubate in a humidified, 8% CO2 incubator.

4.

Observe cell concentration under a light microscope.

5.

After several days, decant media, trypsinize and enumerate attached cells (see
methods B.2 and G.l).

6.

Plot concentration of antibody against cell number.

F. Miscellaneous
1. Cell Count (Hemocytometer Method)
Purpose:
While estimates can be made of the stage of growth of a culture from its
appearance under the microscope, standardization of culture conditions and
proper quantitative experiments are difficult unless the cells are counted
before and after, and preferably during each experiment.
Principle:
The concentration of a cell suspension is determined by placing the cells in an
optically flat chamber (hemocytometer) and under a microscope. The cell
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number within a defined area is counted and the cell concentration is
calculated.
Material:
hemocytometer (Neubauer) with cover slide
cell counter
microscope
Reagents:
trypan blue (0.2%)
Method:
1.

Clean and dry the hemocytometer and cover slide with 70% ethyl alcohol and
absorbent paper. Place the cover slide on the hemocytometer carefully so
that the two V notches on each side of the chamber are partially covered.

2.

Add 10 ml of cell suspension into 390 ml 0.2% trypan blue and mix well. This
gives a 1:40 dilution of the cell suspension. Different dilutions should be made
if the cell concentration is too numerous or too few to count accurately.

3.

Immediately after mixing, transfer the diluted cell suspension (approximately
10 ml) to the edge of the hemocytometer chamber, fill the chamber slowly
from the V notch. The chamber fills by capillary action so it is important that
the cell suspension flow evenly into the chamber in one smooth delivery. Do
not overfill or underfill.

4.

Using the 10X objective on the microscope, observe the cells for proper
disbursement.

5.

Count the cells (non-viable cells stain blue while viable cells exclude dye and reflect
light) in the desired areas (the four 1 mm squares of the counting chamber).
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Calculations
Each square of the hemocytometer, with cover slide in place, represents a total
volume of 0.1 mm3 or lO-4 cm3. Because 1 cm3 is equivalent to 1 ml, the
subsequent cell concentration per ml (and the total number of cells) will be
determined using the following calculations:
cells per ml = the average count per square x dilution factor x volume
per square (= 104/ml)
total cells = cells per ml x the original volume of cell suspension
% cell viability = total viable cells / total cells (viable and nonviable cells)
x 100%

2. Total Protein Assay
Purpose:
The purpose of this procedure is to determine the total protein concentration
in solution.
Principle:
The principle of this method is based on the absorbance shift from 465 to
595 nm which occurs when the Comassie protein reagent binds to proteins in
an acidic solution. The charge of the protein is important as the number of dye
molecules bound to each protein molecule is approximately proportional to
the number of positive charges on the protein. This method is based on the
recommended procedure (Comassie Protein Assay Reagent Instructions,
Pierce, Rockford, IL).
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Material:
cuvettes
spectrophotometer
samples of known protein concentration
Reagents:
Comassie protein assay reagent
Method:
1.

Prepare a sample of a known protein concentration in the same diluent as the
protein sample whose concentration is to be determined. These standards
should cover the concentration range between 125 and 2000 pg/ml.

2.

Pipette 50 pi standard or unknown into a 16 x 100 mm test tube using sample
diluent as blank.

3.

Add 2.5 ml Comassie Blue G-250 (Pierce, Rockford, IL) and vortex. Wait
30 minutes.

4.

Zero the spectrophotometer using a cuvette with reagent only as a blank.

5.

Read absorbance of samples at 595 nm.

6.

Prepare a standard curve by plotting the average net absorbance at 595 nm for
each standard. Using the standard curve, determine the protein concentration
for each unknown protein sample.

3. DNA Cell Cycle Analysis by Flow Cytometry
Purpose:
The study of cell cycle kinetics is possible with the use of flow cytometric DNA
analysis. Quantitation of the proportion of cells in Gl, S, and G2 phases, as well
as the transition rates and characteristic phase lengths can be rapidly and easily
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performed using this technique. This technique allows observation on a
cellular level of genetic material, to detect the presence of aneuploid DNA in
peripheral blood or to estimate cell cycle kinetics.
Principle:
Propidium iodide will intercalate between base pairs of accessible genetic
material. Stimulation with an appropriate wavelength of light will cause
proportionate fluorescent emission. The total genetic material can be
quantified with a measurement of the total fluorescent emissions of each cell.
Material:
1.0 ml Eppendorf pipette
0.1 ml Eppendorf pipette
centrifuge
15 ml conical centrifuge tubes
12x75 sterile polystyrene test tubes
tuberculin syringes with 26G needles

Reagents:
PBS
NIM-PI solution
1. Weigh and combine the following in 100 ml of PBS:
a. 5 mg propidium iodide
b. 0.667 ml 30% BSA
c. 0.100 ml Nonidet P-40
NOTE: NIM-PI is good for three months when stored at 6-10°C in the
dark.
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2. Mix well to insure that all the PI has gone into solution.
3. Cover with aluminum foil and store at 4°C. (This solution is good for
three months from the date prepared).
Ribonuclease A (DNase free): 1% Solution
1. Measure an appropriate amount of the Ribonuclease A and dissolve
into IX PBS working solution to equal 1% w/v. (Example: 10 mg
Ribonuclease A /1 ml of PBS)
2. This should be prepared and used fresh.
Method:
1.

Label 12 x 75 mm polystyrene tubes.

2.

Pipette 1.0 ml of cells at a concentration of 2 x 106 cells/ml, into the test tubes.

3.

Centrifuge the cells at 400 x g for 5-10 minutes.

4.

Remove the supernatant by aspiration, leaving a dry cell button.

5.

Pipette 1.0 ml of NIM-PI solution to the cell button.

6.

Mix using a tuberculin syringe, with a 26G needle; aspirate a portion of the
liquid and dispense it out of the syringe allowing it to run down the side of the
tube. (Doing this will keep the amount of frothing to a minimum as well as aid
the perforation of the cell membranes).

7.

Repeat this mixing process with the syringe for a total of 3-5 times.

8.

Pipette 100 ml of the 1% RNase to the cell suspension and repeat the mixing
procedure as in steps 6 and 7 above.

9.

Cap the tubes and incubate in the dark at room temperature for 15 minutes.

10. After incubation the tubes are ready to be analyzed by flow cytometry.
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